New coolants, and preparations containing same
Patent Information
- Application Number
- EP2023701992
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-01-28
- Filing Date
- 2023-01-27
- Publication Date
- 2024-12-04
AI Technical Summary
Current physiological cooling agents, such as menthol, have disadvantages like strong odor, volatility, bitterness, and skin/mucous membrane irritation, limiting their use in cosmetics, nutrition, and pharmaceuticals, and fail to provide a long-lasting cooling sensation.
Development of new compounds represented by general formulas (I) to (VIII), which are physiological coolants with specific structural features, providing intense and long-lasting cooling effects while minimizing taste and irritation, suitable for various applications.
These compounds offer a strong, rapid, and long-lasting cooling sensation with reduced bitterness and irritation, making them suitable for use in cosmetics, nutrition, and pharmaceuticals, and overcoming the limitations of existing cooling agents.
Smart Images

Figure IMGF000004_0001 
Figure IMGF000005_0001 
Figure IMGF000006_0001
Abstract
Description
New refrigerants and preparations containing them Field of invention
[0001] The present invention is in the field of physiological cooling agents and relates to new representatives of this group, the use of these cooling agents, and articles and preparations comprising these cooling agents. Technological background
[0002] Physiological cooling agents are regularly used to create a cooling sensation on the skin or mucous membranes, for example, on the mucous membranes of the mouth, nose, and / or throat. However, no actual physical cooling, such as that which occurs during the evaporation of solvents, takes place. Both single components and mixtures can be used as physiological cooling agents. It is important to note that not all compounds that influence receptors in vitro that are (also) involved in mediating a physiological cooling effect actually produce such an effect in vivo on the skin or mucous membranes. In particular, such an effect will not always be identical.This means, for example, that the strength of the mediated physiological cooling effect and the course of the strength of the cooling effect over time cannot be inferred solely from the fact that a particular compound is an agonist of a receptor involved in mediating a cooling sensation.
[0003] TRP channels play an important role in the perception of temperature (hot-cold). TRP channels (transient receptor potential channels) are a large family of cellular ion channels that can be divided into seven subfamilies.
[0004] The cold menthol receptor TRPM8 (also known as cold membrane receptor (CMR1)) belongs to the family of "transient receptor potential ion channels", is specifically expressed in a special group of neurons and forms pores in the cell membrane (four units combine to form a tetramer) that selectively absorb Ca 2+The protein allows ions to pass through. It has six transmembrane domains and a cytoplasmic C- and N-terminus. Low temperatures (preferably 10 to 25 °C) stimulate this receptor, resulting in signal transduction that is interpreted by the nervous system as a sensation of cold.
[0005] Several TRP channels have been shown to play a role in growth control. Alterations in the expression of some of these channels can contribute to the development of cancer. For example, the expression of the TRPM8 gene is upregulated in prostate cancer. Accordingly, TRPM8 is also an attractive target for the treatment of prostate or bladder cancer. State of the art
[0006] Cooling compounds, such as menthol, have long played an important role in the flavor and fragrance industry to create an association with freshness and cleanliness.
[0007] The best-known physiologically active cooling agent is L-menthol. Menthol has been shown to act as a natural modulator of the TRPM8 receptor. Application of menthol activates TRPM8, thereby increasing calcium levels. 2+ This causes an influx of electrical signals into the cold-sensitive neurons. The resulting electrical signal is ultimately perceived as a sensation of cold.
[0008] However, menthol has some disadvantages, such as a strong odor, high volatility, and, in higher concentrations, a bitter and / or sharp taste, as well as skin irritation. Excessive menthol concentrations can also cause irritation and an anesthetic effect on the skin and mucous membranes.
[0009] Previously, researchers had sought strong cooling agents that did not have the adverse properties of L-menthol.
[0010] For example, lactic acid esters of menthol(en) were described according to DE 2608226 A1 and mixed carbonates with menthol(en) and polyols according to DE 4226043 A1 and menthon ketals according to EP 0507190 B1.
[0011] Furthermore, menthol derivatives with similar effects have been described in various publications.
[0012] Menthyl monoesters of diacids according to US 5,725,865 and US 5,843,466 are interesting naturally occurring alternatives, but cannot achieve the strength of the previously described cooling agents in sensory tests.
[0013] It has been found that the compounds L-menthanecarboxylic acid ZV-ethylamide ("WS-3") and, in particular, / \ / a-(L-menthanecarbonyl)glycine ethyl ester ("WS-5") are strong cooling agents. However, the latter, despite its strong effect, has the disadvantage of being susceptible to hydrolysis, thereby forming the corresponding free acid / \ / a-(L-menthanecarbonyl)glycine, which itself exhibits only a very weak cooling effect. Despite the detailed investigations described, a systematic prediction of the properties of potential cooling agents, especially their bitterness and / or other trigeminal effects, is neither possible nor has it been described. Thus, many molecules belonging to the class of menthanecarboxylic acid amides, while strongly cooling, often simultaneously exhibit pronounced bitter notes, such as the menthanecarboxylic acid N-(alkyloxyalkyl)amides according to JP 2004 059474 A2, or are additionally strongly irritating, such as the one also known as WS-5. N-[[5-Methyl-2-(1-methylethyl)cyclohexyl]carbonyl]glycine ethyl esters are designated according to US 2005 0222256 A1, so such compounds are not suitable for use in food preparations or the like.
[0014] / Va-(Menthanecarbonyl)alkyloxyalkylamides were described in JP 2004 059474 A2. While they have a strong cooling effect and high hydrolysis stability, they have the disadvantage of being very bitter and are therefore unsuitable for use in food or cosmetic products used for facial care.
[0015] Furthermore, menthyl glyoxylates and their hydrates have been described as cooling substances in JP 2005 343795 A2.
[0016] Overviews of the cooling agents produced and used to date are known to experts.
[0017] There are also isolated compounds structurally unrelated to menthol that cause significant TRPM8 modulation, such as the coolant WS-23 or the compounds listed in patent application WO 2007 019719 A1.
[0018] However, many of the TRPM8 modulators found so far have shortcomings in terms of potency, duration of action, skin / mucous membrane irritation, odor, taste, solubility, and volatility.
[0019] In WO 2010 026094 A1, individual compounds for the modulation of the TRPM8 receptor are disclosed.
[0020] Further compounds for modulating the TRPM8 receptor are also proposed in WO 2011 061330 A2.
[0021] Special coolants with carboxamide structure (I) are also known from WO 2012 061698 A1.
[0022] On the oral mucosa, many to all of the aforementioned conventional cooling substances known from the state of the art exhibit more or less identical cooling behavior. The cooling sensation they impart begins after about 0.5 minutes, but then, after a peak at 3 to 5 minutes, subsides relatively quickly. The cooling effect is clearly perceptible for a maximum of 30 minutes and, based on experience, is only minimally affected in intensity and duration by changes in dosage. which can be influenced. However, consumers desire a particularly long-lasting cooling effect, which is associated with a corresponding feeling of freshness and well-being for the user. Object of the invention
[0023] The primary objective of the present invention was therefore to identify new substances possessing a particular physiological cooling effect, preferably those that modulate the TRPM8 receptor (so-called modulators), which can be used as alternatives, preferably as more suitable agents, to previously known modulators. Such compounds should be particularly suitable for applications in the fields of cosmetics, nutrition, textiles, OTC products (e.g., burn ointments), pharmaceuticals (e.g., in the treatment of cancer or bladder weakness), or packaging. The compounds or mixtures of compounds to be specified should preferably have the weakest possible inherent taste, in particular be only slightly bitter or not bitter at all, and be as non-irritating as possible.
[0024] To solve the problem according to the invention, the focus was primarily on finding active ingredients that could provide a particularly long-lasting cooling sensation. Preferably, these active ingredients should also be able to provide particularly intense and / or rapid onset of cooling sensations. The cooling agents should be efficient, i.e., they should produce a high cooling effect or sensation even at low concentrations.
[0025] Another task was to compensate for off-flavors exhibited by many flavorings, especially sweeteners such as steviosides. This particularly concerns their bitter, astringent, and metallic aftertaste.
[0026] The problem is solved by the subject matter of the independent claims. Further aspects of the present invention will become apparent from the wording of the dependent claims, the following description, and the examples. Detailed description of the invention
[0027] The primary object of the present invention is achieved according to the invention by a physiological cooling agent selected from the group consisting of compounds represented by the general formulas (I) to (IV) (I) or the general formula (II) or the general formula (III) or the general formula (IV) where in formulas (I) to (IV) the remainders R1 and R2 can be the same or different and independently have the following meanings: R1 • H; or • a group Q; or • a possibly substituted linear or branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted acyl group -R(C=O)-; or • a possibly substituted cycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted heteroaryl group; R2 • H; or • a group Q; or • a possibly substituted linear or branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted acyl group R-(C=O)-; or • a possibly substituted cycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heterocycloalkyl group; or • is a possibly substituted heteroaryl group; or R1 and R2 together with the C atoms to which they are bonded form a conjugated or non-conjugated ring system; X • S; or • SO; or • SO2; or • NH; or • O; or • a possibly substituted linear or branched alkyl group • a possibly substituted linear or branched alkenyl group • a possibly substituted linear or branched alkylthio group; or • a possibly substituted cycloalkyl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted hetero-aryl group; Y • is a possibly substituted linear or branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted acyl group R-(C=O)-; or • a possibly substituted alkylaryl group; or • a possibly substituted alkyl heteroaryl group; Z • NH2; or • an NHRa group; or • an NRaRb group; or • a possibly substituted linear or branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted linear or branched alkoxy group; or • OH; or • a possibly substituted cycloalkyl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heteroaryl group; or • NH is and forms a heterocyclic ring with X; m is 0 or 1; and / or n is 0 or 1; with the proviso that if m = 0, Y is omitted; or if m = 1, Y occurs singly; or if n = 0, -(C=O)- is omitted; or if n = 1, -(C=O)- occurs singly; or if m = 0 and n = 0, Y is omitted and -(C=O)- is omitted; or if m = 1 and n = 1, Y occurs singly and -(C=O)- occurs singly; or if m = 0 and n = 1, Y is omitted and -(C=O)- occurs singly; or if m = 1 and n = 0, Y occurs singly and -(C=O)- is omitted; where the group Q is a residue selected from the group consisting of: halogen, -OA, -SA, -NBB, -CF3, -CN, -OCN, -SON, -NO, -NO2, -S(O)2A, -S(O)2OA, -OS(O)2A, - OS(O)2OA, -P(O)(OA) 2I-P(O)(OA)(OA), -C(O)A, -C(S)A, -C(NA)A, -C(O)OA, -C(S)OA, -C(O)NBB, -C(NA)NBB, -OC(O)A, -OC(S)A, -OC(O)OA, -O -NAC(O)OA, -NAC(S)OA, -NAC(O)NBB, -NAC(NA)A or -NAC(NA)NBB; where A selected is from the Group consisting of: hydrogen, optionally substituted linear or branched alkyl group, in particular optionally substituted Ci to Cw alkyl group, in particular optionally substituted Ci to Ce alkyl group, especially optionally substituted Ci, C2, C3 or C4 alkyl group, optionally substituted linear or branched alkoxy group, in particular optionally substituted Ci-Ce alkoxy group, especially optionally substituted Ci, C2, C3 or C4 alkoxy group, optionally substituted linear or branched alkylthio group, in particular optionally substituted Ci to Ce alkylthio group, especially optionally substituted Ci, C2, C3 or C4 alkylthio group, optionally substituted cycloalkyl group, optionally substituted aryl group, optionally substituted heterocycloalkyl group, optionally substituted heteroaryl group; and / or B means A or alternatively, two Bs together with the nitrogen atom to which they are bonded, meaning a four-, five-, six- or seven-membered heterocycloalkyl ring or heteroaryl ring, wherein the heterocycloalkyl ring or heteroaryl ring may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; the optionally substituted linear or branched alkyl group is an optionally substituted Ci to Cw alkyl group, in particular an optionally substituted Ci to Ce alkyl group, especially an optionally substituted Ci, C2, C3 or C4 alkyl group;the optionally substituted linear or branched alkenyl group is an optionally substituted Ci to Cw alkenyl group, in particular an optionally substituted Ci to Ce alkenyl group, especially an optionally substituted Ci, C2, C3 or C4 alkenyl group; the optionally substituted linear or branched alkynyl group is an optionally substituted Ci to Cw alkynyl group, in particular an optionally substituted Ci to Ce alkynyl group, especially an optionally substituted Ci, C2, C3 or C4 alkynyl group; the optionally substituted linear or branched alkoxy group is an optionally substituted Ci to Cw alkoxy group, in particular an optionally substituted Ci to Ce alkoxy group, especially an optionally substituted Ci, C2, C3 or C4 alkoxy group; the optionally substituted linear or branched alkylthio group is an optionally substituted Ci to Cw alkylthio group, in particular an optionally substituted Ci to Ce alkylthio group, especially an optionally substituted Ci, C2, C3 or C4 alkylthio group; in the acyl group R-(C=O)- the residue R stands for hydrogen or an optionally substituted linear or branched Ci to Cw alkyl group, in particular an optionally substituted Ci to Ce alkyl group, especially an optionally substituted Ci, C2, C3 or C4 acyl group; the optionally substituted cycloalkyl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered, monocyclic cycloalkyl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, cycloalkyl group;the optionally substituted aryl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered, monocyclic aryl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, aryl group; the optionally substituted heterocycloalkyl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered monocyclic heterocycloalkyl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, heterocycloalkyl group, wherein the heterocycloalkyl group may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;the optionally substituted heteroaryl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered monocyclic heteroaryl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, heteroaryl group, wherein the heteroaryl group may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; Ra • an optionally substituted linear or branched alkyl group, and / preferably an O1 to C3 alkyl group, preferably a methyl or group; or Rb • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted acyl group R-(C=O)-; or a cycloalkyl group, optionally substituted; or a ryl group, optionally substituted; or a heterocycloalkyl group, optionally substituted; or a heteroaryl group, optionally substituted; or Ra and Rb, as defined above, are linked together to form a saturated or unsaturated ring; wherein the substituents are each selected independently of each other; as well as their salts, preferably acid addition salts, with inorganic or organic acids.
[0028] The cooling agents according to the invention, represented by the general formulas (I) to (IV), can be present either in stereoisomerically pure form or as mixtures of different stereoisomers.
[0029] In a preferred embodiment according to the first aspect of the present invention, the refrigerant is a physiological coolant according to one of the general formulas (I) and (II), wherein X is selected from the group consisting of S, SO, NH and O. Even more preferred is a refrigerant according to the present invention, wherein in the general formulas (I) and (II) X represents S.
[0030] In an alternative preferred embodiment according to the first aspect of the present invention, the physiological cooling agent is one of the general formulas (III) and (IV), wherein X is selected from the group consisting of S, SO2, an optionally substituted linear or branched alkyl group, an optionally substituted cycloalkyl group and piperidinyl.
[0031] In a more preferred embodiment according to the first aspect of the present invention, the physiological cooling agent is selected from the group consisting of compounds represented by the general formula (V) or by the general formula (VI) where in formulas (V) and (VI) the remainders R1 and R2 can be the same or different and independently have the following meanings: R1 as defined for formulas (I) to (IV); R2 as defined for formulas (I) to (IV); Y • is a possibly substituted linear or branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted acyl group R-(C=O)-; or • a possibly substituted alkylaryl group; or • a possibly substituted alkyl heteroaryl group; Z • NH2; or • an NHRa group; or • an NRaRb group; or • a possibly substituted linear or branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted linear or branched alkoxy group; or • OH; or • a possibly substituted cycloalkyl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heteroaryl group; or • NH is and forms a heterocyclic ring with X; m is 0 or 1; with the proviso that if m = 0, Y is omitted; or if m = 1, Y occurs once; where the group Q is a residue selected from the group consisting of: halogen, -OA, -SA, -NBB, -CF3, -CN, -OCN, -SON, -NO, -NO2, -S(O)2A, -S(O)2OA, -OS(O)2A, -OS(O)2OA, -P(O)(OA) 2I -P(O)(OA)(OA), -C(O)A, -C(S)A, -C(NA)A, -C(O)OA, -C(S)OA, -C(O)NBB, -C(NA)NBB, -OC(O)A, -OC(S)A, -OC(O)OA, -OC(S)OA, -NAC(O)A, - NAC(S)A, -NAC(O)OA, -NAC(S)OA, -NAC(O)NBB, -NAC(NA)A or -NAC(NA)NBB; where A is selected from the group consisting of: hydrogen, optionally substituted linear or branched alkyl group, in particular optionally substituted Ci to Cw alkyl group, in particular optionally substituted Ci to Ce alkyl group, especially optionally substituted Ci, C2, C3 or C4 alkyl group, optionally substituted linear or branched alkoxy group, in particular optionally substituted Ci-Ce alkoxy group, especially optionally substituted Ci, C2, C3 or C4 alkoxy group, optionally substituted linear or branched alkylthio group, in particular optionally substituted Ci to Ce alkylthio group, especially optionally substituted Ci, C2, C3 or C4 alkylthio group, optionally substituted cycloalkyl group, optionally substituted aryl group, optionally substituted heterocycloalkyl group, optionally substituted heteroaryl group; and / or B means A or alternatively, two Bs together with the nitrogen atom to which they are bonded, meaning a four-, five-, six- or seven-membered heterocycloalkyl ring or heteroaryl ring, wherein the heterocycloalkyl ring or heteroaryl ring may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; the optionally substituted linear or branched alkyl group is an optionally substituted Ci to Cw alkyl group, in particular an optionally substituted Ci to Ce alkyl group, especially an optionally substituted Ci, C2, C3 or C4 alkyl group;the optionally substituted linear or branched alkenyl group is an optionally substituted Ci to Cw alkenyl group, in particular an optionally substituted Ci to Ce alkenyl group, especially an optionally substituted Ci, C2, C3 or C4 alkenyl group; the optionally substituted linear or branched alkynyl group is an optionally substituted Ci to Cw alkynyl group, in particular an optionally substituted Ci to Ce alkynyl group; in particular an optionally substituted Ci, C2, C3 or C4 alkynyl group; the optionally substituted linear or branched alkoxy group is an optionally substituted Ci to Cw alkoxy group, in particular an optionally substituted Ci to Ce alkoxy group, in particular an optionally substituted Ci, C2, C3 or C4 alkoxy group; the optionally substituted linear or branched alkylthio group is an optionally substituted Ci to Cw alkylthio group, in particular an optionally substituted Ci to Ce alkylthio group, in particular an optionally substituted Ci, C2, C3 or C4 alkylthio group;in the acyl group R-(C=O)- the residue R stands for hydrogen or an optionally substituted linear or branched Ci to Cw alkyl group, in particular an optionally substituted Ci to Ce alkyl group, especially an optionally substituted Ci, C2, C3 or C4 acyl group; the optionally substituted cycloalkyl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered, monocyclic cycloalkyl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, cycloalkyl group; the optionally substituted aryl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered, monocyclic aryl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic aryl group;the optionally substituted heterocycloalkyl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered monocyclic heterocycloalkyl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, heterocycloalkyl group, wherein the heterocycloalkyl group may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;the optionally substituted heteroaryl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered monocyclic heteroaryl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, heteroaryl group, wherein the heteroaryl group may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; Ra • an optionally substituted linear or branched alkyl group, and / preferably an O1 to C3 alkyl group, preferably a methyl or group; or Rb • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or an optionally substituted linear or branched alkoxy group; or an optionally substituted linear or branched alkylthio group; or • a possibly substituted acyl group R-(C=O)-; or • a possibly substituted cycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted heteroaryl group is / are; or • Ra and Rb, as defined above, are linked together to form a saturated or unsaturated ring; wherein the substituents are each selected independently of each other; and their salts, preferably acid addition salts, with inorganic or organic acids; or represented by the general formula (VII) or by the general formula (VIII) where in formulas (VII) and (VIII) the remainders R1 and R2 can be the same or different and independently have the following meanings: R1 as defined for formulas (I) to (IV); R2 as defined for formulas (I) to (IV); V • S; or • SO2; or • a possibly substituted linear or branched alkyl group; or • a possibly substituted cycloalkyl group; or • Piperidinyl is; Y • is a possibly substituted linear or branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted acyl group R-(C=O)-; • a possibly substituted alkylaryl group; or • a possibly substituted alkyl heteroaryl group; Z • NH2; or • an NHRa group; or • an NRaRb group; or • a possibly substituted linear or branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted linear or branched alkoxy group; or • OH; or • a possibly substituted cycloalkyl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heteroaryl group; or • NH is and forms a heterocyclic ring with X; m is 0 or 1; with the proviso that if m = 0, Y is omitted; or if m = 1, Y occurs singly; where the group Q is a residue selected from the group consisting of: halogen, -OA, -SA, -NBB, -CF3, -CN, -OCN, -SON, -NO, -NO2, -S(O)2A, -S(O)2OA, -OS(O)2A, - OS(O)2OA, -P(O)(OA) 2I -P(O)(OA)(OA), -C(O)A, -C(S)A, -C(NA)A, -C(O)OA, -C(S)OA, -C(O)NBB, -C(NA)NBB, -OC(O)A, -OC(S)A, -OC(O)OA, -OC(S)OA, -NAC(O)A, - NAC(S)A, -NAC(O)OA, -NAC(S)OA, -NAC(O)NBB, -NAC(NA)A or -NAC(NA)NBB; where A is selected from the group consisting of: hydrogen, optionally substituted linear or branched alkyl group, in particular optionally substituted Ci to Cw alkyl group, in particular optionally substituted Ci to Ce alkyl group, especially optionally substituted Ci, C2, C3 or C4 alkyl group, optionally substituted linear or branched alkoxy group, in particular optionally substituted Ci-Ce alkoxy group, especially optionally substituted Ci, C2, C3 or C4 alkoxy group, optionally substituted linear or branched alkylthio group, in particular optionally substituted Ci to Ce alkylthio group, especially optionally substituted Ci, C2, C3 or C4 alkylthio group, optionally substituted cycloalkyl group, optionally substituted aryl group, optionally substituted heterocycloalkyl group, optionally substituted heteroaryl group; and / or B means A or alternatively, two Bs together with the nitrogen atom to which they are bonded, meaning a four-, five-, six- or seven-membered heterocycloalkyl ring or heteroaryl ring, wherein the heterocycloalkyl ring or heteroaryl ring may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; the optionally substituted linear or branched alkyl group is an optionally substituted Ci to Cw alkyl group, in particular an optionally substituted Ci to Ce alkyl group, especially an optionally substituted Ci, C2, C3 or C4 alkyl group;the optionally substituted linear or branched alkenyl group is an optionally substituted Ci to Cw alkenyl group, in particular an optionally substituted Ci to Ce alkenyl group, especially an optionally substituted Ci, C2, C3 or C4 alkenyl group; the optionally substituted linear or branched alkynyl group is an optionally substituted Ci to Cw alkynyl group, in particular an optionally substituted Ci to Ce alkynyl group, especially an optionally substituted Ci, C2, C3 or C4 alkynyl group; the optionally substituted linear or branched alkoxy group is an optionally substituted Ci to Cw alkoxy group, in particular an optionally substituted Ci to Ce alkoxy group, especially an optionally substituted Ci, C2, C3 or C4 alkoxy group; the optionally substituted linear or branched alkylthio group is an optionally substituted Ci to Cw alkylthio group, in particular an optionally substituted Ci to Ce alkylthio group, especially an optionally substituted Ci, C2, C3 or C4 alkylthio group; in the acyl group R-(C=O)- the residue R stands for hydrogen or an optionally substituted linear or branched Ci to Cw alkyl group, in particular an optionally substituted Ci to Ce alkyl group, especially an optionally substituted Ci, C2, C3 or C4 acyl group; the optionally substituted cycloalkyl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered, monocyclic cycloalkyl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, cycloalkyl group;the optionally substituted aryl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered, monocyclic aryl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, aryl group; the optionally substituted heterocycloalkyl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered monocyclic heterocycloalkyl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, heterocycloalkyl group, wherein the heterocycloalkyl group may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;the optionally substituted heteroaryl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered monocyclic heteroaryl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, heteroaryl group, wherein the heteroaryl group may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; Ra • an optionally substituted linear or branched alkyl group, and / preferably an O1 to C3 alkyl group, preferably a methyl or group; or Rb • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted acyl group R-(C=O)-; or • a possibly substituted cycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted heteroaryl group is / are; • Ra and Rb, as defined above, are linked together to form a saturated or unsaturated ring; wherein the substituents are each selected independently of each other; as well as their salts, preferably acid addition salts, with inorganic or organic acids.
[0032] The cooling substances according to the invention, as defined in the general formulas (V) to (VIII), can be present either in stereoisomerically pure form or as mixtures of different stereoisomers.
[0033] In a more preferred embodiment according to the first aspect of the present invention, the physiological cooling agent is selected from the group consisting of compounds represented by the general formula (Va) or by the general formula (via) where in formulas (Va) and (Via) the remainders R1 and R2 can be the same or different and independently have the following meanings: R1 as defined for formulas (I) to (IV); R2 as defined for formulas (I) to (IV); or R1 and R2 together with the C atoms to which they are bonded form a conjugated or non-conjugated ring system; Y • is a possibly substituted branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted acyl group R-(C=O)-; or • a possibly substituted alkylaryl group; or • a possibly substituted alkyl heteroaryl group; Z • NH2; or in the • an NHRa group; or generally • an NRaRb group; or i nen • a possibly substituted linear or branched alkyl group; formula oder (Va) , ejne optionally substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted linear or branched alkoxy group; or • OH; or • a possibly substituted cycloalkyl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heteroaryl group; or • NH is and forms a heterocyclic ring with X; Z in the • NH2; or generally • an NHRa group or an NRaRb group, excluding -NH-phenyl and -N(CH3)-phenyl; or Formula • a possibly substituted linear or branched alkyl group; (Via) or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted linear or branched alkoxy group, excluding -OC2H5 and -C(CH3)3; or • a possibly substituted cycloalkyl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted aryl group; or • is a possibly substituted heteroaryl group; or is NH and forms a heterocyclic ring with X; m 1; where the group Q is a residue selected from the group consisting of: halogen, -OA, -SA, -NBB, -CF3, -CN, -OCN, -SON, -NO, -NO2, -S(O)2 a , -S(O)2OA, -OS(O)2 a , - OS(O)2OA, -P(O)(OA) 2I -P(O)(OA)(OA), -C(O)A, -C(S)A, -C(NA)A, -C(O)OA, -C(S)OA, -C(O)NBB, -C(NA)NBB, -OC(O)A, -OC(S)A, -OC(O)OA, -OC(S)OA, -NAC(O)A, - NAC(S)A, -NAC(O)OA, -NAC(S)OA, -NAC(O)NBB, -NAC(NA)A or -NAC(NA)NBB; where A is selected from the group consisting of: hydrogen, optionally substituted linear or branched alkyl group, in particular optionally substituted Ci to Cw alkyl group, in particular optionally substituted Ci to Ce alkyl group, especially optionally substituted Ci, C2, C3 or C4 alkyl group, optionally substituted linear or branched alkoxy group, in particular optionally substituted Ci-Ce alkoxy group, especially optionally substituted Ci, C2, C3 or C4 alkoxy group, optionally substituted linear or branched alkylthio group, in particular optionally substituted Ci to Ce alkylthio group, especially optionally substituted Ci, C2, C3 or C4 alkylthio group, optionally substituted cycloalkyl group, optionally substituted aryl group, optionally substituted heterocycloalkyl group, optionally substituted heteroaryl group; and / or B means A or alternatively, two Bs together with the nitrogen atom to which they are bonded, meaning a four-, five-, six- or seven-membered heterocycloalkyl ring or heteroaryl ring, wherein the heterocycloalkyl ring or heteroaryl ring may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; the optionally substituted linear or branched alkyl group is an optionally substituted Ci to Cw alkyl group, in particular an optionally substituted Ci to Ce alkyl group, especially an optionally substituted Ci, C2, C3 or C4 alkyl group;the optionally substituted linear or branched alkenyl group is an optionally substituted Ci to Cw alkenyl group, in particular an optionally substituted Ci to Ce alkenyl group, especially an optionally substituted Ci, C2, C3 or C4 alkenyl group; the optionally substituted linear or branched alkynyl group is an optionally substituted Ci to Cw alkynyl group, in particular an optionally substituted Ci to Ce alkynyl group, especially an optionally substituted Ci, C2, C3 or C4 alkynyl group; the optionally substituted linear or branched alkoxy group is an optionally substituted Ci to Cw alkoxy group, in particular an optionally substituted Ci to Ce alkoxy group, especially an optionally substituted Ci, C2, C3 or C4 alkoxy group; the optionally substituted linear or branched alkylthio group is an optionally substituted Ci to Cw alkylthio group, in particular an optionally substituted Ci to Ce alkylthio group, especially an optionally substituted Ci, C2, C3 or C4 alkylthio group;in the acyl group R-(C=O)- the residue R stands for hydrogen or an optionally substituted linear or branched Ci to Cw alkyl group, in particular an optionally substituted Ci to Ce alkyl group, especially an optionally substituted Ci, C2, C3 or C4 acyl group; the optionally substituted cycloalkyl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered, monocyclic cycloalkyl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, cycloalkyl group; the optionally substituted aryl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered, monocyclic aryl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic aryl group;the optionally substituted heterocycloalkyl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered monocyclic heterocycloalkyl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, heterocycloalkyl group, wherein the heterocycloalkyl group may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;the optionally substituted heteroaryl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered monocyclic heteroaryl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, heteroaryl group, wherein the heteroaryl group may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; Ra • an optionally substituted linear or branched alkyl group, and / preferably an O1 to C3 alkyl group, preferably a methyl or group; or Rb • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted acyl group R-(C=O)-; or • a possibly substituted cycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted heteroaryl group is / are; or • Ra and Rb, as defined above, are linked together to form a saturated or unsaturated ring; wherein the substituents are each selected independently of one another; and their salts, in particular acid addition salts, with inorganic or organic acids, wherein the cooling agents may be in stereoisomerically pure form or as mixtures of different stereoisomers; or represented by the general formula (Vila) or by the general formula (villa) (Villa) where in the formulas (Vila) and (Villa) the remainders R1 and R2 can be the same or different and independently have the following meanings: R1 as defined for formulas (I) to (IV); R2 as defined for formulas (I) to (IV); or R1 and R2 together with the C atoms to which they are bonded form a conjugated or non-conjugated ring system; V • S; or • SO2; or • a possibly substituted linear or branched alkyl group; or • a possibly substituted cycloalkyl group; or • Piperidinyl is; Y • is a possibly substituted branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted acyl group R-(C=O)- is; Z • NH2; or • an NHRa group; or • an NRaRb group; or • a possibly substituted linear or branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted linear or branched alkoxy group; or • OH; or • a possibly substituted cycloalkyl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heteroaryl group; or • NH is and together with the X forms a heterocyclic ring; m 1 ist; where Group Q is a residue selected from the group consisting of: Halogen, -OA, -SA, -NBB, -CF3, -CN, -OCN, -SON, -NO, -NO2, -S(O)2A, -S(O)2OA, -OS(O)2A, -OS(O)2OA, -OS(O)2A 2I -P(O)(OA)(OA), -C(O)A, -C(S)A, -C(NA)A, -C(O)OA, -C(S)OA, -C(O)NBB, -C(NA)NBB, -OC(O)A, -OC(S)A, -OC(O)OA, -O -NAC(O)OA, -NAC(S)OA, -NAC(O)NBB, -NAC(NA)A or -NAC(NA)NBB; where A selected is from the Group consisting of: hydrogen, optionally substituted linear or branched alkyl group, in particular optionally substituted Ci to Cw alkyl group, in particular optionally substituted Ci to Ce alkyl group, especially optionally substituted Ci, C2, C3 or C4 alkyl group, optionally substituted linear or branched alkoxy group, in particular optionally substituted Ci-Ce alkoxy group, especially optionally substituted Ci, C2, C3 or C4 alkoxy group, optionally substituted linear or branched alkylthio group, in particular optionally substituted Ci to Ce alkylthio group, especially optionally substituted Ci, C2, C3 or C4 alkylthio group, optionally substituted cycloalkyl group, optionally substituted aryl group, optionally substituted heterocycloalkyl group, optionally substituted heteroaryl group; and / or B means A or alternatively, two Bs together with the nitrogen atom to which they are bonded, meaning a four-, five-, six- or seven-membered heterocycloalkyl ring or heteroaryl ring, wherein the heterocycloalkyl ring or heteroaryl ring may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; the optionally substituted linear or branched alkyl group is an optionally substituted Ci to Cw alkyl group, in particular an optionally substituted Ci to Ce alkyl group, especially an optionally substituted Ci, C2, C3 or C4 alkyl group;the optionally substituted linear or branched alkenyl group is an optionally substituted Ci to Cw alkenyl group, in particular an optionally substituted Ci to Ce alkenyl group, especially an optionally substituted Ci, C2, C3 or C4 alkenyl group; the optionally substituted linear or branched alkynyl group is an optionally substituted Ci to Cw alkynyl group, in particular an optionally substituted Ci to Ce alkynyl group, especially an optionally substituted Ci, C2, C3 or C4 alkynyl group; the optionally substituted linear or branched alkoxy group is an optionally substituted Ci to Cw alkoxy group, in particular an optionally substituted Ci to Ce alkoxy group, especially an optionally substituted Ci, C2, C3 or C4 alkoxy group; the optionally substituted linear or branched alkylthio group is an optionally substituted Ci to Cw alkylthio group, in particular an optionally substituted Ci to Ce alkylthio group, especially an optionally substituted Ci, C2, C3 or C4 alkylthio group; in the acyl group R-(C=O)- the residue R stands for hydrogen or an optionally substituted linear or branched Ci to Cw alkyl group, in particular an optionally substituted Ci to Ce alkyl group, especially an optionally substituted Ci, C2, C3 or C4 acyl group; the optionally substituted cycloalkyl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered, monocyclic cycloalkyl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, cycloalkyl group;the optionally substituted aryl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered, monocyclic aryl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, aryl group; the optionally substituted heterocycloalkyl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered monocyclic heterocycloalkyl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, heterocycloalkyl group, wherein the heterocycloalkyl group may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;the optionally substituted heteroaryl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered monocyclic heteroaryl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, heteroaryl group, wherein the heteroaryl group may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; Ra • an optionally substituted linear or branched alkyl group; and / preferably an O1 to C3 alkyl group, preferably a methyl or group; or Rb • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted acyl group R-(C=O)-; or • a possibly substituted cycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted heteroaryl group is / are; or • Ra and Rb, as defined above, are linked together and form a saturated or unsaturated ring; wherein the substituents are each selected independently of each other; as well as their salts, in particular acid addition salts, with inorganic or organic acids, wherein the cooling agents may be in stereoisomerically pure form or as mixtures of different stereoisomers.
[0034] The cooling substances according to the invention, as defined in the general formulas (Va) to (Villa), can be present either in stereoisomerically pure form or as mixtures of different stereoisomers.
[0035] Within the scope of the present invention, physiological cooling agents are also included in which the oxygen atom in the oxazole ring of the basic structure of the general formulas (III), (VII) or (Vila) is replaced by a sulfur atom, i.e., the oxazole ring of the basic structure of the general formulas (III), (VII) or (Vila) is a thiazole ring.
[0036] Of the compounds of general formulas (I) to (VIII) and (Va) to (Villa), those compounds are particularly favored due to the free electron pairs suitable for forming a covalent bond (so-called Lewis bases) in which the heterocyclic ring of the basic structure of general formulas (I) to (VIII) and (Va) to (Villa) has at least two nitrogen atoms, i.e., compounds of general formulas (I), (V), and (Va) with a triazine ring in the basic structure, or compounds of general formulas (II), (VI), and (Via) with a pyrazine ring (diazine) in the basic structure, or compounds of general formulas (IV), (VIII), and (Villa) with an imidazole ring. Such compounds exhibit particularly pronounced cooling attributes, as described below.
[0037] Due to their Lewis base character, compounds of general formulas (I), (V), and (Va) with a triazine ring in the basic structure, as well as compounds of general formulas (III), (VII), and (Vila) with an oxazole ring in the basic structure, are most favored. Such compounds are characterized by a particularly intense cooling effect.
[0038] Within the scope of the present invention, in particular for the definition of the general formulas (I) to (VIII) and (Va) to (Villa), the following general meanings shall apply:
[0039] The term "or" or "and / or" is used as a function word to indicate that two words or expressions should be taken together or separately.
[0040] The terms "comprehensive", "with", "including" and "containing" are to be understood as open terms, i.e. "comprehensive", "including" or "containing", but not "limited to". 1 .
[0041] The endpoints of all areas directed at the same component or property are inclusive and can be combined independently.
[0042] The term "compound(s)" or "compound(s) of the present invention" refers to all compounds encompassed by the structural formula(s) (I) and / or (II) disclosed herein, and includes each subgenus and all specific compounds within the formula whose structure is disclosed herein. The compounds may be identified either by their chemical structure and / or their chemical name. If the chemical structure and the chemical name conflict, the chemical structure determines the identity of the compound. The compounds described herein may contain one or more chiral centers and / or double bonds and may therefore exist as stereoisomers, such as double bond isomers, i.e., geometric isomers, enantiomers, or diastereomers.Accordingly, the chemical structures of general formula (I) and / or formula (II) shown here include all possible enantiomers and diastereomers or stereoisomers.
[0043] The term "at least one coolant" 1 In the context of the present invention, this means that, for example, a composition contains at least one coolant, but may also contain two, three, four or even several different coolants.
[0044] The term "alkyl" alone or as part of another substituent according to the present invention refers to a saturated or monounsaturated linear or branched monovalent hydrocarbon radical obtained by removing a hydrogen atom from a single carbon atom of a corresponding starting alkane.
[0045] In a preferred variant, the term "alkyl" also includes all alkyl parts in derivatives such as alkoxy, alkylthio, alkylsulfonyl saturated linear or branched hydrocarbon residues with 1 to 10, 1 to 8, 1 to 6 or 1 to 4 carbon atoms.
[0046] If the alkyl group is bonded to another atom, it becomes an alkylene group. In other words, the term "alkylene" also refers to divalent alkyl. For example, -CH₂CH₃ is ethyl, while -CH₂CH₂- is ethylene.
[0047] The term "alkylene" alone or as part of another substituent refers to a saturated linear or branched divalent hydrocarbon residue obtained by removing two hydrogen atoms from a single carbon atom or two different carbon atoms of a starting alkane.
[0048] In preferred embodiments of the present invention, an alkyl group or an alkylene group comprises 1 to 10 carbon atoms. In other, even more preferred embodiments, an alkyl group or alkylene group comprises 1 to 6 carbon atoms. Most preferred are alkyl groups or alkylene groups with 1 to 4 carbon atoms.
[0047] Preferred alkyl residues or alkyl groups include, but are not limited to: Ci- bis Ce-Alkyl, umfassend Methyl, Ethyl, Propyl, 1 -Methylethyl, Butyl, 1-Methyl-propyl, 2- Methylpropyl, 1 , 1-Dimethylethyl, Pentyl, 1-Methylbutyl, 2-Methylbutyl, 3-Methylbutyl, 2,2- Dimethylpropyl, 1-Ethylpropyl, Hexyl, 1 ,1 -Dimethylpropyl, 1 ,2-Dimethylpropyl, 1 -Methylpentyl, 2- Methylpentyl, 3-Methylpentyl, 4-Methylpentyl, 1 , 1-Dimethylbutyl, 1 ,2-Dimethylbutyl, 1 ,3- Dimethylbutyl, 2,2-Dimethylbutyl, 2,3-Dimethylbutyl, 3,3-Dimethylbutyl, 1 -Ethylbutyl, 2- Ethylbutyl, 1 ,1 ,2-Trimethylpropyl, 1 ,2,2-Trimethylpropyl, 1-Ethyl-1-methylpropyl und 1-Ethyl-2- methylpropyl; Ci- to Ce-alkoxy, comprising Ci- to C4-alkoxy, such as methoxy, ethoxy, n-propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy or 1,1-dimethylethoxy; as well as pentoxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, 2,2-dimethylpropoxy, 1-ethylpropoxy, hexoxy, 1-methylpentoxy, 2-methylpentoxy, 3-methylpentoxy, 4-methylpentoxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,2-dimethylbutoxy, 2,3-dimethylbutoxy, 3,3-dimethylbutoxy, 1-ethylbutoxy, 2-ethylbutoxy, 1,1,2-trimethylpropoxy, 1,2,2-trimethylpropoxy, 1-ethyl-1-methylpropoxy or 1-Ethyl-2-methylpropoxy.
[0048] According to the invention, saturated linear or branched Ci- to Ce-alkyl groups or saturated linear or branched Ci- to Ce-alkylene groups are most preferred.
[0049] The term "alkyl" or "alkylene" also includes residues or groups with any degree of saturation, i.e., groups with exclusively single carbon-carbon bonds ("alkyl" or "alkylene"), groups with one or more double carbon-carbon bonds ("alkenyl"), residues with one or more triple carbon-carbon bonds ("alkynyl"), and groups with a mixture of single, double, and / or triple carbon-carbon bonds.
[0050] The term "alkenyl", alone or as part of another substituent according to the present invention, refers to an unsaturated linear or branched monovalent hydrocarbon radical with at least one carbon-carbon double bond (C=C double bond). The substituent can be in either the cis or trans configuration. Conformation around the double bond(s). Thus, the term "alkenyl" also includes the corresponding cis / trans isomers.
[0051] Typical alkenyl residues or alkenyl groups include, but are not limited to, ethenyl; propenyls such as prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl), prop-2-en-2-yl, cycloprop-1-en-1-yl, cycloprop-2-en-1-yl; butenyls such as but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl and the like.
[0052] In preferred embodiments according to the present invention, an alkenyl group comprises 2 to 10 carbon atoms. In other preferred embodiments, an alkenyl group comprises 2 to 6 carbon atoms. In still further preferred embodiments, an alkenyl group comprises 2 to 4 carbon atoms.
[0053] According to the invention, singly or doubly unsaturated linear or branched Ci- to Ce-alkenyl groups are most preferred.
[0054] The term "alkynyl" alone or as part of another substituent according to the present invention refers to an unsaturated linear or branched monovalent hydrocarbon radical having at least one carbon-carbon triple bond (C=C triple bond).
[0055] Typical alkynyl residues or alkynyl groups include, but are not limited to, ethinyl; propynyls such as prop-1-yn-1-yl, prop-2-yn-1-yl, etc.; butynyls such as but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl, and the like.
[0056] In preferred embodiments according to the present invention, an alkynyl group comprises 2 to 10 carbon atoms. In other preferred embodiments, an alkynyl group comprises 2 to 6 carbon atoms. In still further preferred embodiments, an alkynyl group comprises 2 to 4 carbon atoms.
[0057] The term "alkoxy" alone or as part of another substituent according to the present invention refers to a radical of the formula -OR, where R stands for alkyl or substituted alkyl, as defined herein.
[0058] The term “alkylthio” or “thioalkoxy”, alone or as part of another substituent according to the present invention, refers to a radical of the formula -S- R, where R stands for alkyl or substituted alkyl, as defined herein.
[0059] According to the invention, the term "alkyl" or "alkylene" also includes heteroalkyl groups or heteroalkyl substituents. The term "heteroalkyl," either on its own or as part of other substituents, refers to alkyl groups in which one or more of the carbon atoms are independently modified by the same or another heteroatom. or is / are replaced by the same or a different heteroatomic group(s). Typical heteroatoms or heteroatomic groups that can replace the carbon atoms include, but are not limited to, -O-, -S-, -N-, -Si-, -NH-, -S(O)-, -S(O)2-, -S(O)NH-, -S(O)2NH-, and the like, and combinations thereof. The heteroatoms or heteroatomic groups can be located at any inner position of the alkyl group.Typical heteroatomic groups that may be included in these groups include, but are not limited to, -O-, -S-, -OO-, -SS-, -0-S-, -NRR-, -NN=, -N=N-, -N=N-NRR, -PR-, -P(0)2-, -POR-, -0-P(0)2-, -SO-, -SO2-, -SR2OR- and the like, where R independently represents hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl, as defined herein.
[0060] The alkyl group or alkylene group, as defined above, can also be substituted.
[0061] The term "acyl" alone or as part of another substituent according to the present invention refers to a radical -R(C=O)-, wherein R represents hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroarylalkyl or substituted heteroarylalkyl, as defined herein.
[0062] Representative examples include, but are not limited to, formyl, acetyl, propionyl, butyryl, valeryl, benzoyl, cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzylcarbonyl and the like.
[0063] The term ‘cycloalkyl’ alone or as part of another substituent according to the present invention refers to a saturated or monounsaturated non-aromatic cyclic monovalent hydrocarbon radical in which the carbon atoms are linked together in a ring-like manner and which has no heteroatom.
[0064] The carbon ring can occur as a monocyclic compound, which has only a single ring, or as a polycyclic compound, which has two or more rings.
[0065] In a preferred embodiment, the term "cycloalkyl" comprises a three- to ten-membered monocyclic cycloalkyl residue or cycloalkyl group, or a nine- to twelve-membered polycyclic cycloalkyl residue or cycloalkyl group. In other, even more preferred embodiments, the cycloalkyl residue comprises a three-, four-, five-, six- or seven-membered monocyclic cycloalkyl residue, or a nine- to twelve-membered bicyclic cycloalkyl residue.
[0066] In a preferred embodiment according to the present invention, a cycloalkyl residue or cycloalkyl group comprises 3 to 20 carbon atoms. In a more preferred embodiment, a cycloalkyl residue comprises 3 to 15 carbon atoms. In a most preferred embodiment, a cycloalkyl residue comprises 3 to 10 carbon atoms. Monocyclic C3 to cycloalkyl groups are most preferred.
[0067] Typical cycloalkyl groups include, but are not limited to, saturated carbocyclic residues with 3 to 20 carbon atoms, such as C3 to C12 carbocyclyl, including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cycloononyl, cyclodecyl, cycloundecyl and cyclododecyl; Cyclopentyl, cyclohexyl, cycloheptyl, and cyclopropyl-methyl, cyclopropyl-ethyl, cyclobutyl-methyl, cyclobutyl-ethyl, cyclopentyl-methyl, cyclopentyl-ethyl, cyclohexyl-methyl, or C3- to CyCarbocyclyl, comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopropyl-methyl, cyclopropyl-ethyl, cyclobutyl-methyl, cyclopentyl-ethyl, are preferred. Cyclohexyl-methyl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobuta-1,3-dien-1-yl and the like.
[0068] Preferred saturated polycyclic cycloalkyl residues or cycloalkyl groups according to the invention include, but are not limited to, for example, adamantyl groups and the like.
[0069] According to the invention, the term "cycloalkyl" also includes cycloalkenyls, i.e., unsaturated cyclic hydrocarbon radicals containing C=C double bonds between two carbon atoms of the ring molecule. In a broader sense, cycloalkenyls are compounds with one, two, or more double bonds, the number of possible double bonds in the molecule, which are usually conjugated, depends on the ring size.
[0070] Typical cycloalkenyls include, but are not limited to, cyclopropenyl, cyclopentenyl, cyclohexenyl, cyclopentadienyl and the like.
[0071] According to the invention, the term "cycloalkyl" also includes cycloalkynyls, i.e., cyclic hydrocarbon radicals containing unsaturated, -C=C triple bonds between two carbon atoms of the ring molecule, wherein the triple bond depends on the ring size for reasons of ring strain.
[0072] Typical cycloalkynes include cyclooctyne.
[0073] The cycloalkyl residue or cycloalkyl group can be attached to the rest of the molecule of formula (I) and / or formula (II) via any suitable carbon atom.
[0074] The cycloalkyl residue or cycloalkyl group, as defined above, may also be substituted.
[0075] The term "aryl" alone or as part of another substituent according to the present invention refers to a monovalent aromatic hydrocarbon radical derived by removing a hydrogen atom from a single carbon atom of an aromatic ring system.
[0076] In a preferred variant, the term "aryl" comprises a three- to ten-membered monocyclic aryl residue or aryl group, or a nine- to twelve-membered polycyclic aryl residue or aryl group. In other, even more preferred variants, the carboaryl residue comprises a three-, four-, five-, six-, or seven-membered monocyclic carboaryl residue, or a nine- to twelve-membered bicyclic carboaryl residue.
[0077] In a preferred embodiment according to the present invention, the aryl group comprises 3 to 20 carbon atoms. In a more preferred embodiment, an aryl group comprises 3 to 15 carbon atoms. In a most preferred embodiment, an aryl group comprises 3 to 10 carbon atoms. Monocyclic C3 to Ci2 aryl groups are most preferred according to the invention. Monocyclic C3 to CyAryl groups are most preferred.
[0078] Typical aryl groups include, but are not limited to, benzene, phenyl, biphenyl, naphthyl such as 1- or 2-naphthyl, tetrahydronaphthyl, fluorenyl, indenyl, and phenanthrenyl. Typical carboaryl groups further include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene, and the like.
[0079] Preferred aromatic polycyclic aryl residues or aryl groups according to the invention include, but are not limited to, naphthalene, biphenyl and the like.
[0080] The attachment of the aryl residue or the aryl group to the rest of the molecule of formulas (I) to (VIII) and (Va) to (Villa) can take place via any suitable C atom.
[0081] The aryl residue or aryl group, as defined above, can also be substituted. For example, the aryl residue can form an anisole group.
[0082] The term “arylalkyl”, alone or as part of another substituent according to the present invention, refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp-carbon atom, is replaced by an aryl group as defined herein. In other words: Arylalkyl can also be considered as an alkyl substituted by aryl. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, 2-phenylethen-1-yl, naphthylmethyl, 2-naphthylethan-1-yl, 2-naphthylethen-1-yl, naphthobenzyl, 2-naphthophenylethan-1-yl, and the like.
[0083] The term “heteroarylalkyl”, alone or as part of another substituent, refers to a cyclic alkyl group in which one or more of the hydrogen atoms bonded to a carbon atom are replaced by a heteroaryl group.
[0084] In a preferred embodiment according to the present invention, the heteroarylalkyl group is a 6- to 20-membered heteroarylalkyl, e.g., the alkanyl, alkenyl, or alkynyl group of the heteroarylalkyl is a Ci to Ce alkyl, and the heteroaryl group is a 5- to 15-membered heteroaryl group. In other embodiments, the heteroarylalkyl is a 6- to 13-membered heteroarylalkyl, e.g., the alkanyl, alkenyl, or alkynyl group is a Ci to Cs alkyl, and the heteroaryl group is a 5- to 10-membered heteroaryl.
[0085] The term “heterocycloalkyl”, alone or as part of another substituent according to the present invention, refers to a saturated, non-aromatic, cyclic monovalent hydrocarbon radical in which one or more carbon atoms are / are independently replaced by the same or a different heteroatom. Typical heteroatoms for replacing the carbon atom(s) include, but are not limited to, N, P, O, S, Si, etc. Typical heterocycloalkyl groups include, but are not limited to, groups derived from epoxides, azirines, thiiranes, imidazolidine, morpholine, piperazine, piperidine, pyrazolidine, pyrrolidone, quinuclidine, and the like.
[0086] The heterocycloalkyl residue can occur as a monocyclic compound, which has only a single ring, or as a polycyclic compound, which has two or more rings.
[0087] Preferably, the term "heterocycloalkyl" includes three- to seven-membered, saturated or mono- or polyunsaturated heterocycloalkyl groups comprising one, two, three, or four heteroatoms selected from the group O, N, and S. The heteroatom or heteroatoms can occupy any position in the heterocycloalkyl ring.
[0088] In a preferred variant, the term "heterocycloalkyl" comprises a three- to ten-membered monocyclic heterocycloalkyl group or a nine- to twelve-membered polycyclic heterocycloalkyl group. In other, even more preferred variants, the heterocycloalkyl group comprises a three-, four-, five-, six-, or seven-membered monocyclic heterocycloalkyl group or a nine- to twelve-membered bicyclic heterocycloalkyl group.
[0089] In a preferred embodiment according to the present invention, the heterocycloalkyl residue or heterocycloalkyl group comprises 3 to 20 ring atoms. In a preferred embodiment, the heterocycloalkyl residue comprises 3 to 15 ring atoms. In a more preferred embodiment, the heterocycloalkyl residue comprises 3 to 10 carbon atoms. Most preferred according to the invention are monocyclic heterocycloalkyl residues with 3 to 12 carbon atoms. Most preferred are monocyclic heterocycloalkyl residues with 5 to 7 ring atoms.
[0090] Typical heterocycloalkyl groups include, but are not limited to: three- to six-membered saturated heterocycloalkyls containing one or two nitrogen atoms and / or one oxygen or sulfur atom, or one or two oxygen and / or sulfur atoms as ring members, comprising aziridinyl, oxiranyl, thiiranyl, azetidinyl, oxetanyl, thietanyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothienyl, 3-tetrahydrothienyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 3-isoxazolidinyl, 4-isoxazolidinyl, 5-isoxazolidinyl, 3-isothiazolidinyl, 4-isothiazolidinyl, 5-isothiazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, 5-pyrazolidinyl, 2-oxazolidinyl, 4-oxazolidinyl, 5-oxazolidinyl, 2-thiazolidinyl, 4-thiazolidinyl, 5-thiazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 2-pyrrolin-2-yl, 2-pyrrolin-3-yl, 3-pyrrolin-2-yl, 3-pyrrolin-3-yl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1,3-dioxan-5-yl, 2-tetrahydropyranyl, 4-tetrahydropyranyl, 2-tetrahydrothienyl, 3-Hexahydropyridazinyl, 4-Hexahydropyridazinyl, 2-Hexahydropyrimidinyl, 4- Hexahydropyrimidinyl, 5-Hexahydropyrimidinyl, 2-Piperazinyl and the like.
[0091] The heterocycloalkyl residue or heterocycloalkyl group, as defined above, may also be substituted.
[0092] The heterocycloalkyl residue or heterocycloalkyl group can be bonded to the rest of the molecule of formulas (I) to (VIII) and (Va) and (VIII) via a ring carbon atom or a ring heteroatom.
[0093] The term "heteroaryl" on its own or as part of another substituent according to the present invention refers to a monovalent heteroaromatic radical obtained by removing a hydrogen atom from a single atom of a heteroaromatic ring system. Typical heteroaryl residues or heteroaryl groups include, but are not limited to, those derived from acridine, β-carboline, chroman, chromium, cinnoline, furan, imidazole, indazole, indole, indolin, indolizine, isobenzofuran, isochrome, isoindole, isoindolin, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazine, pyrazine, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazole, xanthene, and the like.
[0094] The heteroaryl residue can occur as a monocyclic compound, which has only a single ring, or as a polycyclic compound, which has two or more rings.
[0095] In a preferred variant, the term "heteroaryl" comprises a three- to ten-membered monocyclic heteroaryl residue or a nine- to twelve-membered polycyclic heteroaryl residue. In other, even more preferred variants, the heteroaryl residue comprises a three-, four-, five-, six- or seven-membered monocyclic heteroaryl residue or a nine- to twelve-membered bicyclic heteroaryl residue.
[0096] Preferably, the term "heteroaryl" encompasses three- to seven-membered monocyclic heteroaryl residues comprising one, two, three, or four heteroatoms selected from the group O, N, and S. The heteroatom(s) can occupy any position within the heteroaryl ring.
[0097] In a preferred embodiment according to the present invention, the heteroaryl residue or heteroaryl group comprises 3 to 20 ring atoms. In a more preferred embodiment, the heteroaryl residue comprises 6 to 15 ring atoms. In a most preferred embodiment, the heteroaryl group comprises 6 to 10 ring atoms. According to the invention, monocyclic C3 to CyHeteroaryl groups are most preferred.
[0098] Particularly preferred heteroaryl residues or heteroaryl groups include, but are not limited to, those derived from furan, thiophene, pyrrole, benzothiophene, benzofuran, benzimidazole, indole, pyridine, pyrazole, quinoline, imidazole, oxazole, isoxazole and pyrazine.
[0099] Three-membered aromatic heteroaryl residues, containing in addition to carbon atoms a nitrogen or a sulfur or an oxygen atom as ring atoms, include azirinyl, oxirenyl or thiirenyl.
[0100] Four-membered aromatic heteroaryl residues, containing in addition to carbon atoms a nitrogen or a sulfur or an oxygen atom as ring atoms, include acetyl, oxetium ion or thietium ion.
[0101] Five-membered aromatic heteroaryl residues, containing, in addition to carbon atoms, one, two or three nitrogen atoms or one or two nitrogen atoms and a sulfur or oxygen atom as ring atoms, include 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-ilmidazolyl, 4-ilmidazolyl, and 1,3,4-triazol-2-yl.
[0102] Fünfgliedrige aromatische Heteroaryl-Reste, enthaltend ein, zwei, drei oder vier Stickstoffatome als Ringatome, umfassen 1-, 2- oder 3-Pyrrolyl, 1-, 3- oder 4-Pyrazolyl, 1-, 2- oder 4-lmidazolyl, 1 ,2,3-[1 H]-Triazol-1-yl, 1 ,2,3-[2H]-Triazol-2-yl, 1 ,2,3-[1 H]-Triazol-4-yl, 1 ,2,3- [1 H]-Triazol-5-yl, 1 ,2,3-[2H]-Triazol-4-yl, 1 ,2,4-[1 H]-Triazol-1-yl, 1 ,2,4-[1 H]-Triazol-3-yl, 1 ,2,4- [1 H]-Triazol-5-yl, 1 ,2,4-[4H]-Triazol-4-yl, 1 ,2,4-[4H]-Triazol-3-yl, [1 H]-Tetrazol-1-yl, [1 H]- Tetrazol-5-yl, [2H]-Tetrazol-2-yl, [2H]-Tetrazol-5-yl und dergleichen.
[0103] Five-membered aromatic heteroaryl residues, containing a heteroatom selected under oxygen or sulfur and optionally one, two or three nitrogen atoms as ring atoms, comprise 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 3- or 4-isothiazolyl, 3- or 4-isothiazolyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl, 1,3,4-thiadiazol-2-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl and 1,3,4-oxadiazol-2-yl.
[0104] Six-membered heteroaryl residues containing, in addition to carbon atoms, one or two or one, two or three nitrogen atoms as ring atoms, and include, for example, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 1,2,4-triazin-3-yl; 1,2,4-triazin-5-yl, 1,2,4-triazin-6-yl and 1,3,5-triazin-2-yl.
[0105] The heteroaryl residue or heteroaryl group, as defined above, may also be substituted.
[0106] The heteroaryl residue or heteroaryl group can be bonded to the rest of the molecule from formula (I) to formula (VIII) and (Va) and (VIII) via a ring carbon atom or a ring heteroatom.
[0107] Of the above-mentioned monocyclic heteroaryl residues, those heteroaryl residues derived from the five- or six-membered saturated compounds comprising pyrrolidone, tetrahydrofuran, tetrahydrothiophene, piperidine, tetrahydropyran, tetrahydrothipyran, or from the five- or six-membered aromatic compounds comprising pyrrole, furan, thiophene, pyridine, pyrylium ion and thiopyrylium ion, pyrazole, imidazole, imidazoline, pyrimidine, oxazole, thiazole and 1,4-thiazine are particularly preferred within the scope of the present invention.
[0108] The term "arylalkyl," alone or as part of another substituent according to the present invention, refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp-carbon atom, is replaced by an aryl group as defined herein. In other words, arylalkyl can also be considered to be alkyl substituted by an aryl. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, 2-phenylethen-1-yl, naphthylmethyl, 2-naphthylethan-1-yl, 2-naphthylethen-1-yl, naphthobenzyl, 2-naphthophenylethan-1-yl, and the like.
[0109] The term "heteroarylalkyl," alone or as part of another substituent, refers to a cyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom is replaced by a heteroaryl group. In a preferred embodiment according to the present invention, the heteroarylalkyl group is a 6- to 20-membered heteroarylalkyl, e.g., the alkanyl, alkenyl, or alkynyl group of the heteroarylalkyl is a Ci to Ce alkyl, and the heteroaryl group is a 5- to 15-membered heteroaryl group. In other embodiments, the heteroarylalkyl is a 6- to 13-membered heteroarylalkyl, e.g. the alkanyl, alkenyl or alkynyl group is a Ci- to C3 alkyl and the heteroaryl group is a 5- to 10-membered heteroaryl.
[0110] The term "substituted" in the context of the present invention means that one or more hydrogen atoms of the specified residue or radical are replaced independently by the same or a different substituent.
[0111] Substituents or substituent groups useful for substituting saturated carbon atoms in the specified group or residue include, but are not limited to, -X, Halo, =0, -OY, -Si R3, -SY, =S, -NZZ, =NY, =N-OY, Trihalomethyl, -CF3, -CN, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(O)2Y, -S(O)2OY, -OS(O)2Y, -OS(O)2OY, -P(O)(OY) 2I-P(O)(OY)(OY), -C(O)Y, -C(S)Y, -C(NY)Y, -C(O)OY, - C(S)OY, -C(O)NZZ, -C(NY)NZZ, -OC(O)Y, -OC(S)Y, -OC(O)OY, -OC(S)OY, -NYC(O)Y, - NYC(S)Y, -NYC(O)OY, -NYC(S)OY, -NYC(O)NZZ, -NYC(NY)Y or -NYC(NY)NZZ; wherein X is selected from the group consisting of optionally substituted alkyl groups, in particular optionally substituted Ci to Cw alkyl groups, in particular optionally substituted Ci-Ce alkyl groups, in particular optionally substituted Ci, C2, C3 or C4 alkyl groups, optionally substituted alkoxy groups, in particular optionally substituted Ci-Ce alkoxy groups, in particular optionally substituted Ci, C2, C3 or C4 alkoxy groups, optionally substituted alkyl thio groups, in particular optionally substituted Ci-Ce alkyl thio groups, in particular optionally substituted Ci, C2, C3 or C4 alkyl thio groups, optionally substituted cycloalkyl groups, optionally substituted aryl groups,optionally substituted carboaryl residue, optionally substituted carboarylalkyl residue, optionally substituted heteroalkyl residue, optionally substituted heterocycloalkyl residue, optionally substituted heteroaryl residue and optionally substituted heteroarylalkyl residue, and as defined above; and / or, Y means hydrogen or X means; and / or ZY means, or alternatively, two Z together with the nitrogen atom to which they are bonded, form a four-, five-, six- or seven-membered heterocycloalkyl or heteroaryl ring, wherein the heterocycloalkyl or heteroaryl ring may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
[0112] Specific preferred examples for substitution are: OH, Methyl, Ethyl, Methoxy, Ethoxy, Phenyl, which in turn can be substituted with OH, Methyl, Ethyl, Methoxy, Ethoxy or CH3-C(O)- or Thiophene.
[0113] In another variant, the one or more substituent group(s), preferably phenyl groups, together with the atoms to which they are bonded, can form a cyclic ring, including cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl.
[0114] Similarly, substituent groups useful for substituting unsaturated carbon atoms in the specified group or radical include, among others, -X, Halo, =0, -OY, -SiR3, -SY, =S, -NZZ, =NY, =N-OY, Trihalomethyl, -CF3, -CN, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(O)2Y, -S(O)2OY, -OS(O)2Y, -OS(O)2OY, -P(O)(OY) 2I-P(O)(OY)(OY), -C(O)Y, -C(S)Y, -C(NY)Y, -C(O)OY, -C(S)OY, -C(O)NZZ, -C(NY)NZZ, -OC(O)Y, -OC(S)Y, -OC(O)OY, -OC(S)OY, -NYC(O)Y, -NYC(S)Y, -NYC(O)OY, -NYC(S)OY, -NYC(O)NZZ, -NYC(NY)Y and -NYC(NY)NZZ, where X, Y and Z have the same meaning as defined above.
[0115] Substituents or substituent groups for the substitution of nitrogen atoms in heteroalkyl and heterocycloalkyl residues include, but are not limited to, -X, -OY, -SiR3, -SY, -NZZ, trihalomethyl, -CF3, -CN, -OCN, -SCN, -NO, -NO2, -N2, -N3, -S(O)2Y, -S(O)2OY, -OS(O)2Y, -OS(O)2OY, -P(O)(OY)2, -P(O)(OY)(OY), -C(O)Y, -C(S)Y, -C(NY)Y, -C(O)OY, -C(S)OY, -C(O)NZZ, -C(NY)NZZ, -OC(O)Y, -OC(S)Y, -OC(O)OY, -OC(S)OY, -NYC(O)Y, -NYC(S)Y, -NYC(O)OY -NYC(S)OY, -NYC(O)NZZ, -NYC(NY)Y and -NYC(NY)NZZ, where X, Y and Z also have the same meaning as defined above.
[0116] The term "substituted" specifically refers to one or more substitutions, i.e., two, three, four, five, six, or more, which are common in the field. However, it is generally understood among experts that the substituents should be chosen so as not to adversely affect the useful properties of the compound or its function.
[0117] Suitable substituents within the scope of the present invention preferably include halogen groups, perfluoroalkyl groups, perfluoroalkoxy groups, alkyl groups, alkenyl groups, alkynyl groups, hydroxy groups, oxo groups, mercapto groups, alkyl thio groups, alkoxy groups, aryl or heteroaryl groups, aryloxy groups or heteroaryloxy groups, arylalkyl or heteroarylalkyl groups, arylalkoxy or heteroarylalkoxy groups, amino groups, alkyl and dialkylamino groups, carbamoyl groups, alkyl carbonyl groups, carboxyl groups, alkoxy carbonyl groups, alkylamino carbonyl groups, dialkylamino carbonyl groups, aryl carbonyl groups, aryloxy carbonyl groups, alkylsulfonyl groups, arylsulfonyl groups, cycloalkyl groups, cyano groups, Ci to Ce alkyl thio groups, aryl thio groups, nitro groups, keto groups, acyl groups, boronate or boronyl groups, phosphate or phosphonyl groups, sulfamyl groups, Sulfonyl groups, sulfinyl groups and combinations thereof.In the case of substituted combinations such as substituted arylalkyl, either the aryl or the alkyl group can be substituted, or both the aryl and the alkyl group can be substituted with one or more substituents.
[0118] Preferred substituents for the above-mentioned groups or residues are in particular selected from COOH, COO-alkyl, NH2, NO2, OH, SH, CN, Si, halogens, linear or branched Ci- to Ce- alkyl groups, linear or branched Ci- to Ce- alkoxy groups or linear or branched Ci to Ce alkyl thio groups, wherein one or more H atoms in the alkyl groups may be replaced by halogen.
[0119] In addition, in some cases suitable substituents can be combined to form one or more rings as known to those skilled in the art.
[0120] The expression "optionally substituted" in the context of the present invention denotes the presence or absence of the substituent group(s), i.e., it means "substituted" or "unsubstituted". For example, the term "optionally substituted alkyl" includes both unsubstituted alkyl and substituted alkyl.
[0121] According to the invention, the substituents used to replace a particular residue or radical can in turn be further substituted, typically with one or more identical or different residues selected from the various groups specified above and as defined in detail above.
[0122] In a particularly preferred embodiment according to the first aspect of the present invention, in the general formulas (I) to (VIII) and (Va) and (VIII) the residues R1 and R2 are the same or different.
[0123] Preferably, R1 in the general formulas (I) to (VIII) and (Va) to (Villa) represents H or an optionally substituted alkyl group or an optionally substituted phenyl group or an optionally substituted thiophene group.
[0124] Furthermore preferably, R2 in the general formulas (I) to (VIII) and (Va) to (Villa) represents H or an optionally substituted alkyl group or an optionally substituted phenyl group or an optionally substituted thiophene group.
[0125] Coolants with particularly advantageous properties, i.e., a particularly intensive and effective and preferably simultaneously long-lasting cooling effect, are regularly found in structures in which, in the general formulas (I), (V) or (Va), which have a triazine ring in their basic structure, at least one of the residues R1 and R2 stands for an optionally substituted phenyl group or an optionally substituted thiophene group.
[0126] Even more preferred is at least one of the residues R1 and R2 a possibly substituted phenyl group.
[0127] Compounds of the general formulas (I), (V) or (Va) are most preferred, where both R1 and R2 represent a possibly substituted phenyl group.
[0128] Specific preferred examples for a substitution of the phenyl group are: OH, Methyl, Ethyl, Methoxy or Ethoxy.
[0129] R1 and R2 are most often preferred to represent a phenyl group.
[0130] In an even more preferred variant, the two phenyl groups, together with the atoms to which they are bonded, form a cyclic ring, including cycloalkyl or heterocycloalkyl.
[0131] Most preferred are those compounds of the general formulas (I), (V) or (Va) in which both R1 and R2 are unsubstituted phenyl groups.
[0132] In another preferred variant, in the compounds of the general formulas (I), (V) or (Va) R1 and R2 each contain a substituted or unsubstituted phenyl group which, together with the C atoms of the core structure to which they are bonded, form a conjugated or non-conjugated ring system.
[0133] It has been shown that in particular the previously described compounds of the general formulas (I), (V) or (Va), in which both R1 and R2 are a substituted or unsubstituted phenyl group, exhibit excellent TRPM8 activities and are able to produce exceptionally intense cooling effects even in small quantities.
[0134] Coolants with particularly advantageous properties, i.e., a particularly intensive and effective and preferably simultaneously long-lasting cooling effect, are also found in structures in which, in the general formulas (II), (VI) or (Via), which have a pyrazine ring in their basic structure, at least one of the residues R1 and R2 stands for an optionally substituted phenyl group or an optionally substituted thiophene group.
[0135] Even more preferred is at least one of the residues R1 and R2, possibly a substituted phenyl group.
[0136] Compounds of the general formulas (II), (VI) or (Via) are most preferred, where both R1 and R2 represent a possibly substituted phenyl group.
[0137] Specific preferred examples for substitution are: OH, Methyl, Ethyl, Methoxy or Ethoxy.
[0138] R1 and R2 are most often preferred to represent a phenyl group.
[0139] In an even more preferred variant, the two phenyl groups, together with the atoms to which they are bonded, form a cyclic ring, including cycloalkyl or heterocycloalkyl.
[0140] Most preferred are those compounds of the general formulas (II), (VI) or (Via) in which both R1 and R2 are unsubstituted phenyl groups.
[0141] In another preferred variant, in the compounds of the general formulas (II), (VI) or (Via) R1 and R2 each contain a substituted or unsubstituted phenyl group which, together with the C atoms of the core structure to which they are bonded, form a conjugated or non-conjugated ring system.
[0142] It has been shown that compounds of the general formulas (I), (V) or (Va), in which both R1 and R2 are a substituted or unsubstituted phenyl group, exhibit excellent TRPM8 activities and are able to produce exceptionally intense cooling effects even in small quantities.
[0143] Cooling agents with particularly advantageous properties, i.e., a particularly intense and effective and preferably simultaneously long-lasting cooling effect and / or optionally a particularly efficient masking of undesirable taste impressions, are also found in structures in which, in the general formulas (III), (VII) or (Vila), which have an oxazole ring in their basic structure, at least one of the residues R1 and R2 stands for an optionally substituted phenyl group or an optionally substituted thiophene group.
[0144] Even more preferred is at least one of the residues R1 and R2, possibly a substituted phenyl group.
[0145] Most preferred are compounds of the general formulas (III), (VII) or (Vila), where both R1 and R2 represent a possibly substituted phenyl group.
[0146] Specific preferred examples for substitution are: OH, Methyl, Ethyl, Methoxy or Ethoxy.
[0147] R1 and R2 are most often preferred to represent a phenyl group.
[0148] In an even more preferred variant, the two phenyl groups, together with the atoms to which they are bonded, form a cyclic ring, including cycloalkyl or heterocycloalkyl.
[0149] Most preferred are those compounds of the general formulas (III), (VII) or (Vila) in which both R1 and R2 are unsubstituted phenyl groups.
[0150] In another preferred variant, in the compounds of the general formulas (III), (VII) or (Vila) R1 and R2 each contain a substituted or unsubstituted phenyl group which, together with the C atoms of the core structure to which they are bonded, form a conjugated or non-conjugated ring system.
[0151] It has been shown that in particular these compounds of the general formulas (III), (VII) or (Vila), in which both R1 and R2 are a substituted or unsubstituted phenyl group, exhibit excellent TRPM8 activities and are able to produce extraordinarily intense cooling effects even in small amounts.
[0152] Coolants with particularly advantageous properties, i.e., a particularly intensive and effective and preferably simultaneously long-lasting cooling effect, are also found in structures in which, in the general formulas (IV), (VIII) or (Villa), which have an imidazole ring in their basic structure, at least one of the residues R1 and R2 stands for an optionally substituted phenyl group or an optionally substituted thiophene group.
[0153] Even more preferred is at least one of the residues R1 and R2, possibly a substituted phenyl group.
[0154] Compounds of the general formulas (IV), (VIII) and (Villa) are most preferred, where both R1 and R2 represent a possibly substituted phenyl group.
[0155] Specific preferred examples for substitution are: OH, Methyl, Ethyl, Methoxy or Ethoxy.
[0156] R1 and R2 are most often preferred to represent a phenyl group.
[0157] In an even more preferred variant, the two phenyl groups, together with the atoms to which they are bonded, form a cyclic ring, including cycloalkyl or heterocycloalkyl.
[0158] Most preferred are those compounds of the general formulas (IV), (VIII) or (Villa) in which both R1 and R2 are unsubstituted phenyl groups.
[0159] In another preferred variant, R1 and R2 in the compounds of the general formulas (IV), (VIII) or (Villa) each contain a substituted or unsubstituted Phenyl groups that, together with the carbon atoms of the core structure to which they are bonded, form a conjugated or non-conjugated ring system.
[0160] It has been shown that these compounds of the general formulas (IV), (VIII) or (Villa), in which both R1 and R2 are a substituted or unsubstituted phenyl group, in particular, exhibit excellent TRPM8 activities and are able to produce exceptionally intense cooling effects even in small amounts.
[0161] According to the invention, cooling agents of general formulas (I) to (VIII) are also preferred, in which Y additionally represents a linear alkylene group, an optionally branched alkylene group, an alkylaryl group, or an alkyl heteroaryl group. Preferably, the alkylene group is a methylene group (CH2-), an ethylene group (CH2-CH2-), or a propylene group (CH2-CH2-CH2-). Alternatively, in general formulas (I) to (VIII), Y also represents a branched alkylene group, preferably a methylene group substituted with a methyl group, an ethyl group, a linear or branched propyl group, or a linear or branched butyl group.
[0162] According to the invention, compounds of general formulas (I) to (VIII) are even more preferred, in which Y represents a methylene group or a methylene group substituted with a methyl group, an ethyl group, a linear or branched propyl group, or a linear or branched butyl group. Such compounds exhibit particularly pronounced cooling properties, as described below.
[0163] Even more preferred are those coolants of general formulas (I) or (V) which have one of the following structural combinations: R1 and / or R2 = optionally substituted phenyl group and Y = methylene; R1 and / or R2 = optionally substituted phenyl group and Y = linear ethylene; or R1 and / or R2 = optionally substituted phenyl group and Y = linear or branched propylene; or R1 and / or R2 = optionally substituted phenyl group and Y = methylene substituted with a methyl group, an ethyl group, a linear or branched propyl group or a linear or branched butyl group.
[0164] Furthermore, cooling materials of general formulas (II) or (VI) having one of the following structural combinations are preferred: R1 and / or R2 = optionally substituted phenyl group and Y = methylene; R1 and / or R2 = optionally substituted phenyl group and Y = linear ethylene; or R1 and / or R2 = optionally substituted phenyl group and Y = linear or branched propylene; or R1 and / or R2 = optionally substituted phenyl group and Y = methylene substituted with a methyl group, an ethyl group, a linear or branched propyl group or a linear or branched butyl group.
[0165] Coolants of general formulas (III) or (VII) which have one of the following structural combinations are also preferred: R1 and / or R2 = optionally substituted phenyl group and Y = methylene; R1 and / or R2 = optionally substituted phenyl group and Y = linear ethylene; or R1 and / or R2 = optionally substituted phenyl group and Y = linear or branched propylene; or R1 and / or R2 = optionally substituted phenyl group and Y = methylene substituted with a methyl group, an ethyl group, a linear or branched propyl group or a linear or branched butyl group.
[0166] Coolants of general formulas (IV) or (VIII) which have one of the following structural combinations are also preferred: R1 and / or R2 = optionally substituted phenyl group and Y = methylene; R1 and / or R2 = optionally substituted phenyl group and Y = linear ethylene; or R1 and / or R2 = optionally substituted phenyl group and Y = linear or branched propylene; or R1 and / or R2 = optionally substituted phenyl group and Y = methylene substituted with a methyl group, an ethyl group, a linear or branched propyl group or a linear or branched butyl group.
[0167] Even more preferred are those coolants of general formulas (I) or (V) which have one of the following structural combinations: R1 and / or R2 = phenyl group and Y = methylene; R1 and / or R2 = phenyl group and Y = linear ethylene; or R1 and / or R2 = phenyl group and Y = linear or branched propylene; or R1 and / or R2 = phenyl group and Y = methylene substituted with a methyl group, an ethyl group, a linear or branched propyl group or a linear or branched butyl group.
[0168] Furthermore, cooling materials of general formulas (II) or (VI) having one of the following structural combinations are preferred: R1 and / or R2 = phenyl group and Y = methylene; R1 and / or R2 = phenyl group and Y = linear ethylene; or R1 and / or R2 = phenyl group and Y = linear or branched propylene; or R1 and / or R2 = phenyl group and Y = methylene substituted with a methyl group, an ethyl group, a linear or branched propyl group or a linear or branched butyl group.
[0169] Refrigerants of general formulas (III) or (VII) having one of the following structures are particularly preferred: R1 and / or R2 = phenyl group and Y = methylene; R1 and / or R2 = phenyl group and Y = linear ethylene; or R1 and / or R2 = phenyl group and Y = linear or branched propylene; or R1 and / or R2 = phenyl group and Y = methylene substituted with a methyl group, an ethyl group, a linear or branched propyl group or a linear or branched butyl group.
[0170] Refrigerants of general formulas (IV) or (VIII) having one of the following structures are particularly preferred: R1 and / or R2 = phenyl group and Y = methylene; R1 and / or R2 = phenyl group and Y = linear ethylene; or R1 and / or R2 = phenyl group and Y = linear or branched propylene; or R1 and / or R2 = phenyl group and Y = methylene substituted with a methyl group, an ethyl group, a linear or branched propyl group or a linear or branched butyl group.
[0171] Of the last-mentioned refrigerants according to the general formulas (I) to (VIII), those compounds in which Y represents a methylene group substituted with a methyl group or an ethyl group are most preferred.
[0172] Such compounds are characterized by particularly intense cooling effects.
[0173] In general formulas (I) to (VIII), Z is selected from the group consisting of NH2, an NHRa group, an NRaRb group, an optionally substituted linear or branched alkyl group, an optionally substituted linear or branched alkenyl group, an optionally substituted linear or branched alkylthio group, an optionally substituted linear or branched alkoxy group, OH, an optionally substituted cycloalkyl group, an optionally substituted heterocycloalkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group, wherein Ra and / or Rb is an optionally substituted linear or branched alkyl group, or an optionally substituted linear or branched alkenyl group, or an optionally substituted linear or branched alkenyl group.or is an optionally substituted linear or branched alkynyl group, or is an optionally substituted linear or branched alkoxy group, or is an optionally substituted linear or branched alkylthio group, or is an optionally substituted acyl group R-(C=O)-, or is an optionally substituted cycloalkyl group, or is an optionally substituted aryl group, or is an optionally substituted heterocycloalkyl group, or is an optionally substituted heteroaryl group.
[0174] In another alternative variant, the residues Ra and Rb of the NRaRb group, as defined above, are linked and form a saturated or unsaturated ring, preferably a saturated or unsaturated three- to eight-membered ring.
[0175] According to the invention, cooling substances of the general formulas (I) to (VIII) are particularly preferred, in which Ra and / or Rb in the NHRa group or the NRaRb group stands for a C1 to C3 alkyl group, preferably for a methyl group.
[0176] According to the invention, even more preferred are such cooling agents of general formulas (I) to (VIII) in which Z is selected from the group consisting of: -NH2, -NH-CH3, -NH-CH2-CH3, -NH-CH2-CH2-CH3, -NH-CH2-CH2-CH2-CH3, -NH-CH(CH3)-CH(CH3)2, -NH-CH(CH3)-CH2-CH2-CH3, -NH-CH2-CH(CH3)2, -NH-CH2-CH2-O-CH3, -NH-CH(CH3)-CH2-O-CH3, -NH-C(=O)-CH3, -NH-C(=O)-O-CH3, -NH-CH(CH3)-CH2-OH, -NH-CH2-furanyl, -NH-CH2-tetrahydrofuranyl, -NH-CH2-thiophenyl, -NH-toluolyl, -NH-CH-(CH3)2, -NH-C(CH3)3, -NH-cyclopropyl, -NH-cyclobutyl, -NH-cyclopentyl, -N(CH3)2, -N(CH3)-cyclohexyl, -N(CH2-CH3)2, azetidinyl, pyrrolidinyl, piperidinyl, Azacyclobutadienyl, Pyrrolyl, Pyridinyl, -O, -OH, -O-CH3, -OC(=O)-CH3, Oxetanyl, -CH3, -CH2-CH3, -CH(CH3)2, -C(OH)-CH2-OH, Cyclopropyl, Phenyl, and -CH2-S-CH3.
[0177] In a preferred embodiment according to the first aspect of the present invention, therefore, cooling materials of the general formulas (I) to (VIII) have the following structures:
[0178] According to the invention, cooling materials of general formulas (I), (II), (V) or (VI) having the following structures are even more preferred:
[0179] According to the invention, even more preferred are those cooling substances of general formulas (III), (IV), (VII) or (VIII) which have the following structures:
[0180] Furthermore, compounds of the general formulas (I) to (VIII) in which n and m are each 1 appear to be preferred with regard to the determined TRPM8 activity.
[0181] Of the physiological cooling agents defined and described above, those in which X represents a sulfur atom in the general formulas (I) to (IV) are particularly preferred. Such compounds exhibit especially pronounced cooling attributes, as described below.
[0182] Surprisingly, particularly advantageous cooling attributes are exhibited by such compounds according to the present invention in which, in the general formulas (I) to (VIII), R1 and R2 each represent an unsubstituted phenyl group, X represents a sulfur atom, Y represents a methylene group or a methylene group substituted with a methyl group, an ethyl group, a linear or branched propyl group or a linear or branched butyl group, and Z has the meaning as defined above.
[0183] Such compounds represent particularly efficient cooling substances, as illustrated below.
[0184] According to the invention, compounds of the general formulas (Va) to (Villa) are most preferred, in which the residues R1 and / or R2 represent an unsubstituted phenyl group or a substituted phenyl group, Y represents a branched alkylene group, preferably a methylene group substituted with a methyl group, an ethyl group, a linear or branched propyl group or a linear or branched butyl group, and Z has the meaning as defined above for the compounds of the general formulas (I) to (VIII).
[0185] Such compounds exhibit pronounced TRPM8 activity and are exceptionally intense refrigerants even in small quantities.
[0186] Particularly preferred are those coolants of the general formulas (Va) or (Via) which have one of the following structural combinations: R1 and / or R2 = optionally substituted phenyl group and Y = methylene substituted with a methyl group; or R1 and / or R2 = optionally substituted phenyl group and Y = methylene substituted with an ethyl group; or R1 and / or R2 = optionally substituted phenyl group and Y = methylene substituted with a linear or branched propyl group; or R1 and / or R2 = optionally substituted phenyl group and Y = methylene substituted with a linear or branched butyl group.
[0187] Particularly preferred are those coolants of the general formulas (Vila) or (Villa) which have one of the following structural combinations: R1 and / or R2 = optionally substituted phenyl group and Y = methylene substituted with a methyl group; or R1 and / or R2 = optionally substituted phenyl group and Y = methylene substituted with an ethyl group; or R1 and / or R2 = optionally substituted phenyl group and Y = methylene substituted with a linear or branched propyl group; or R1 and / or R2 = optionally substituted phenyl group and Y = methylene substituted with a linear or branched butyl group.
[0188] Coolants of the general formulas (Va) or (Via) having one of the following structural combinations are also preferred: R1 and / or R2 = phenyl group and Y = methylene substituted with a methyl group; or R1 and / or R2 = phenyl group and Y = methylene substituted with an ethyl group; or R1 and / or R2 = phenyl group and Y = methylene substituted with a linear or branched propyl group; or R1 and / or R2 = phenyl group and Y = methylene substituted with a linear or branched butyl group.
[0189] Also preferred are refrigerants of the general formulas (Vila) or (Villa) which have one of the following structural combinations: R1 and / or R2 = phenyl group and Y = methylene substituted with a methyl group; or R1 and / or R2 = phenyl group and Y = methylene substituted with an ethyl group; or R1 and / or R2 = phenyl group and Y = methylene substituted with a linear or branched propyl group; or R1 and / or R2 = phenyl group and Y = methylene substituted with a linear or branched butyl group.
[0190] Surprisingly, outstanding cooling attributes are exhibited by such compounds according to the present invention in which, in the general formulas (Va) to (Villa), R1 and R2 each represent an unsubstituted phenyl group, Y represents a branched alkylene group, preferably a methylene group connected to a methyl group, an ethyl group, a linear or branched propyl group, or a linear or is substituted with a branched butyl group and Z has the meaning as defined above for the compounds of general formulas (I) to (VIII).
[0191] Therefore, refrigerants of the general formulas (Va) or (Via) which have one of the following structural combinations are most preferred: R1 and R2 = phenyl group and Y = methylene substituted with a methyl group; or R1 and R2 = phenyl group and Y = methylene substituted with an ethyl group; or R1 and R2 = phenyl group and Y = methylene substituted with a linear or branched propyl group; or R1 and R2 = phenyl group and Y = methylene substituted with a linear or branched butyl group; and Coolants of the general formulas (Vila) or (Villa) which have one of the following structural combinations: R1 and R2 = phenyl group and Y = methylene substituted with a methyl group; or R1 and R2 = phenyl group and Y = methylene substituted with an ethyl group; or R1 and R2 = phenyl group and Y = methylene substituted with a linear or branched propyl group; or
[0192] R1 and R2 = phenyl group and Y = methylene substituted with a linear or branched butyl group.
[0193] Of the refrigerants mentioned last, according to the general formulas (Va) to (Villa), those compounds in which Y represents a methylene group substituted with a methyl group or an ethyl group are most preferred.
[0194] Such compounds exhibit a particularly high TRPM8 activity and are able to produce exceptionally intense cooling effects even in small quantities.
[0195] In the general formulas (Va), (Via), (Vila) and (Villa), Z is selected from the group consisting of NH2, an NHRa group, an NRaRb group, an optionally substituted linear or branched alkyl group, an optionally substituted linear or branched alkenyl group, an optionally substituted linear or branched alkylthio group, an optionally substituted linear or branched alkoxy group, OH, an optionally substituted cycloalkyl group, an optionally substituted heterocycloalkyl group, an optionally substituted aryl group or an optionally substituted heteroaryl group, wherein Ra and / or Rb is an optionally substituted linear or branched alkyl group, or an optionally substituted linear or branched alkenyl group, or an optionally substituted linear or branched alkenyl group.or is an optionally substituted linear or branched alkynyl group, or is an optionally substituted linear or branched alkoxy group, or is an optionally substituted linear or branched alkylthio group, or is an optionally substituted acyl group R-(C=O)-, or, a cycloalkyl group that may be substituted, or a ryl group that may be substituted, or a heterocycloalkyl group that may be substituted, or a heteroaryl group that may be substituted.
[0196] In another alternative variant, the residues Ra and Rb of the NRaRb group, as defined above, are linked and form a saturated or unsaturated ring, preferably a saturated or unsaturated three- to eight-membered ring.
[0197] According to the invention, cooling substances of the general formulas (Va) to (Villa) are particularly preferred, in which Ra and / or Rb in the NHRa group or the NRaRb group stands for a C1 to C3 alkyl group, preferably for a methyl group.
[0198] According to the invention, even more preferred are such coolants of the general formulas (Va), (Vila) and (Villa) where Z is selected from the group consisting of: -NH2, -NH-CH3, -NH-CH2-CH3, -NH-CH2-CH2-CH3, -NH-CH2-CH2-CH2-CH3, -NH-CH(CH3)-CH(CH3)2, -NH-CH(CH3)-CH2-CH2-CH3, -NH-CH2-CH(CH3)2, -NH-CH2-CH2-O-CH3, -NH-CH(CH3)-CH2-O-CH3, -NH-C(=O)-CH 3I -NH-C(=O)-O-CH3, -NH-CH(CH3)-CH2-OH, -NH-CH2-furanyl, -NH-CH2-tetrahydrofuranyl, -NH-CH2-thiophenyl, -NH-toluolyl, -NH-CH-(CH3)2, -NH-C(CH3)3, -NH-cyclopropyl, -NH-cyclobutyl, -NH-cyclopentyl, -N(CH3)2, -N(CH3)-cyclohexyl, -N(CH2-CH3)2, azetidinyl, pyrrolidinyl, piperidinyl, Azacyclobutadienyl, Pyrrolyl, Pyridinyl, -O, -OH, -O-CH3, -OC(=O)-CH3, Oxetanyl, -CH3, -CH2-CH3, -CH(CH3)2, -C(OH)-CH2-OH, Cyclopropyl, Phenyl, and -CH2-S-CH3.
[0199] According to the invention, cooling agents of the general formula (Via) are even more preferred, in which Z is selected from the group consisting of -NH2, -NH-CH3, -NH-CH2-CH3, -NH-CH2-CH2-CH3, -NH-CH2-CH2-CH2-CH3, -NH-CH(CH3)-CH(CH3)2, -NH-CH(CH3)-CH2-CH2-CH3, -NH-CH2-CH(CH3)2, -NH-CH2-CH2-O-CH3, -NH-CH(CH3)-CH2-O-CH3, -NH-C(=O)-CH3, -NH-C(=O)-O-CH3, -NH-CH(CH3)-CH2-OH, -NH-CH2-Furanyl, -NH-CH2- Tetrahydrofuranyl, -NH-CH2-thiophenyl, -NH-toluolyl, -NH-CH-(CH3)2, -NH-C(CH3)3, -NH-cyclopropyl, -NH-cyclobutyl, -NH-cyclopentyl, -N(CH3)2, -N(CH3)-cyclohexyl, -N(CH2-CH3)2, azetidinyl, Pyrrolidinyl, piperidinyl, azacyclobutadienyl, pyrrolyl, pyridinyl, -O, -O-CH3, -O- C(=O)-CH3, oxetanyl, -CH3, -CH2-CH3, -CH(CH3)2, -C(OH)-CH2-OH, cyclopropyl, phenyl, and- CH2-S-CH3.
[0200] In the general formula (Via), Z does not stand for -NH-phenyl, -N(CH3)-phenyl, -OH, -OC2H5 or -OC(CH3)3.
[0201] In a preferred embodiment according to the first aspect of the present invention, therefore, cooling materials of the general formulas (Va) to (Villa) have the following structures:
[0202] According to the invention, cooling substances of the general formulas (Va) or (Via) which have the following structures are even more preferred:
[0203] According to the invention, even more preferred are those cooling substances of the general formulas (Vila) or (Villa) which have the following structures:
[0204] Furthermore, compounds of the general formulas (Va) to (Villa), in which m is 1 in each case, appear preferable with regard to the determined TRPM8 activity.
[0205] The cooling agents according to the general formula (Via) specifically exclude those compounds in which, in the general formula (Via), R1 and R2 stand for phenyl, Y stands for branched alkyl, in particular Y stands for methylene substituted with -CH3 or with -CH2CO2C2H5, and Z in the general formula (Via) stands for -NH-phenyl, -N(CH3)-phenyl, -OH, -OC2H5 or -OC(CH3)3
[0206] The physiological refrigerants according to the general formulas (I) to (VIII) and (Va) to (VIII) exist either in neutral, i.e. uncharged form, or in the form of their salts, such as acid addition salts with inorganic or organic acids.
[0207] The term "salt" in the context of the present invention refers to a salt of a compound that possesses the desired effect or pharmacological activity of the starting compound. Such salts include: (1) Acid addition salts formed with inorganic acids or with organic acids, preferably mono- or polyhydric carboxylic acids; or (2) Salts formed when an acidic proton present in the starting compound is replaced by a metal ion, e.g. an alkali metal ion, an alkaline earth ion or an aluminum ion; or coordinated with an organic base.
[0208] Among the salts, acid addition salts are particularly preferred, since the physiological coolant according to the general formulas (I) to (VIII) comprises a protonatable N atom.
[0209] The inorganic acids that form acid addition salts with the physiological refrigerants of the present invention are preferably selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Among the salts, the hydrochlorides or sulfates are most preferred. The hydrochloride salt or the sulfate salt is particularly preferred.
[0210] Acid addition salts with organic mono- or polycarboxylic acids are even more preferred. Acid addition salts with organic mono- or polycarboxylic acids are further preferred, wherein the carboxylic acid is selected from saturated or mono- or polyunsaturated C1 to C30 monocarboxylic acids, or saturated or mono- or polyunsaturated C3 to C10 di- or tricarboxylic acids. The carboxylic acid may be mono- or multiply substituted with hydroxyl groups, preferably α-hydroxycarboxylic acids in which the hydroxyl group is located on the carbon atom adjacent to the carboxyl group. Many representatives occur naturally as so-called fruit acids. Preferred α-hydroxycarboxylic acids are: malic acid, citric acid, 2-hydroxy-4-methylmercaptobutyric acid, glycolic acid, isocitric acid, mandelic acid, lactic acid, tartronic acid, or tartaric acid.
[0211] The organic acids that form acid addition salts with the physiological refrigerants according to the present invention are preferably selected from the group consisting of amino acids, acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, oxalic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-Butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, 4-hydroxybutanoic acid, and the like.
[0212] Among the organic acids that form acid addition salts with the physiological cooling agents of the present invention, acetic acid, lactic acid, malonic acid, succinic acid, malic acid, citric acid or tartaric acid are most preferred.
[0213] The metal ions for salt formation, which replace an acidic proton present in the starting compound, are selected from the group consisting of alkali metal ions, preferably Na+ or K+, alkaline earth metal ions, preferably Ca++, Mg++, and aluminium+++.
[0214] The coordinating organic base for salt formation is selected from the group consisting of ethanolamine, diethanolamine, triethanolamine, N-methylglucamine and the like.
[0215] In the following description and in the patent claims, the terms “physiological coolant” or “compound” include both the neutral, uncharged form of the coolant / compound and the salt form of the coolant / compound.
[0216] Due to their superior solubility, the salts of physiological refrigerants according to the present invention are particularly preferred. The improved water solubility also results in better availability of the refrigerants or compounds during their application.
[0217] Surprisingly, it was found that the compounds or cooling agents or their salts according to the invention have the common property of achieving a particularly long-lasting and intensive cooling effect on the skin or mucous membranes in vivo, even at low doses in the low ppm range of approximately 5 ppm. This means that a lower dose of the cooling agent or its salt according to the invention is required in the final preparation to produce an intensive cooling effect. Thus, the compounds described herein represent The described compounds represent particularly efficient cooling substances. This was not foreseeable for the TRPM8 modulators mentioned in this application.
[0218] The cooling substances according to the invention are further characterized by the fact that their cooling effect begins quickly; other cooling substances according to the invention, on the other hand, have a progressive cooling effect, i.e., an increasing cooling effect over time, which produces a longer and more intensive cooling effect.
[0219] The cooling agents according to the invention are also colorless and non-discoloring, which is particularly advantageous for their storage and / or use in the final product. Consequently, the compounds described herein are particularly suitable additives in various preparations. Furthermore, the compounds according to the invention described herein are largely tasteless and odorless, making them ideally suited for incorporation into neutral and / or flavored preparations without imparting any negative taste, such as a bitter taste, or adversely affecting the intended taste or smell.
[0220] The salts of the cooling agents according to the invention show better solubility in vitro than their neutral, uncharged equivalents, which is particularly advantageous when used in the oral care sector.
[0221] Previously, there was no evidence in the prior art that the compounds or their salts to be used according to the invention could produce a cooling effect at all, and certainly not a particularly long-lasting cooling effect.
[0222] Equally surprising was the fact that the cooling agents according to the invention, or their salts, are able to mask the known disadvantages of flavorings, especially sweeteners such as steviosides. In particular, the pungent, bitter, and metallic aftertaste is effectively masked even when small amounts are added.
[0223] Therefore, the compounds described herein are particularly suitable as efficient cooling agents that can be readily incorporated into a wide variety of formulations. Due to their superior solubility, the salts, and even more preferably the acid addition salts, of the compounds according to the invention are particularly advantageous for use in oral care applications.
[0224] Particularly preferred are the physiological refrigerants of general formulas (I), (II), (V) or (VI), selected from the group consisting of the compounds shown in Table 1:
[0225] Table 1: Inventive structures with relative TRPM8 activation in %
[0226] The refrigerants according to the invention listed in Table 1, according to the general formulas (I), (II), (V) or (VI), are either in neutral, uncharged form or in the form of their salts, such as acid addition salts, with inorganic or organic, mono- or polyvalent carboxylic acids, as described in detail above. The above also applies here.
[0227] The cooling agents according to Table 1 can be present in stereoisomerically pure form or as mixtures of different stereoisomers and can therefore be used in formulations as such.
[0228] It has surprisingly been shown that the compounds according to the invention, as shown in Table 1, exhibit particularly high TRPM8 activations and are therefore ideally suited as cooling agents.
[0229] The most preferred refrigerants, i.e., refrigerants with particularly efficient and strong TRPM8 activation, i.e., efficient and intensive cooling effect at low usage levels, are compounds B-01, B-02, B-03, B-04, B-05, B-06, B-07, B-11, B14, B-15, B-17, B-18, B-19 and B-21 (TRPM8 activation > 90%) and especially compounds B-01, B-02, B-03, B-04, B-05, B-06, B-07, B-11, B-14, B-15, B-17, B-18 and B-19 (TRPM8 activation > 100%). Compounds B-01, B-02, B-03, B-04, B-05, B-06, and B-07 are particularly preferred, as they exhibit an exceptionally high TRPM8 activity (TRPM8 activation > 150%).
[0230] Because of their outstanding relative TRPM8 activation, compounds B-01 (TRPM8 activation of 262%), B-02 (TRPM8 activation of 227%), B-03 (TRPM8 activation of 221%), B-04 (TRPM8 activation of 210%), B-05 (TRPM8 activation of 205%), B-06 (TRPM8 activation of 205%) and B-07 (TRPM8 activation of 203%) are most preferred.
[0231] The compound B-01 (triazine derivative) is characterized in that in the general formula (V) R1 and R2 represent a phenyl group, Y stands for a branched methylene group substituted with an ethyl group, and Z stands for a -NH- cyclopropyl group.
[0232] The compound B-02 (pyrazine derivative) is characterized in that in the general formula (VI) R1 and R2 represent a phenyl group, Y stands for a branched methylene group substituted with an ethyl group, and Z stands for an -NH-CH3- group.
[0233] The compound B-03 (triazine derivative) is characterized in that in the general formula (V) R1 and R2 represent a phenyl group, Y stands for a branched methylene group substituted with an ethyl group, and Z stands for an -NH-CH3- group.
[0234] The compound B-04 (pyrazine derivative) is characterized by the fact that in the general formula (VI) R1 and R2 represent a phenyl group, Y stands for a methylene group, and Z stands for an -NH-CHs group.
[0235] The compound B-05 (triazine derivative) is characterized in that in the general formula (V) R1 and R2 represent a phenyl group, Y stands for a branched methylene group substituted with an ethyl group, and Z stands for an -N(CHs)2- group.
[0236] The compound B-06 (triazine derivative) is characterized by the fact that in the general formula (V) R1 and R2 represent a phenyl group, Y stands for a methylene group and Z for an azetidine group.
[0237] The compound B-07 (triazine derivative) is characterized in that in the general formula (V) R1 and R2 represent a phenyl group which together with the C atoms of the triazine ring to which they are bonded form a condensed ring system, i.e. a 1,2,4-triazatriphenylene, Y stands for a branched methylene group substituted with a methyl group, and Z stands for an -NH-CHs group.
[0238] Even more preferred are the physiological refrigerants of the general formulas (Va) or (Via), selected from the group consisting of the compounds shown in Table A:
[0239] Table A: Inventive structures with relative TRPM8 activation in %
[0240] The refrigerants according to the invention, listed in Table A and corresponding to the general formulas (Va) or (Via), are either in neutral, uncharged form or in the form of their salts, such as acid addition salts, with inorganic or organic, mono- or polyvalent carboxylic acids, as described in detail above. The above also applies here.
[0241] The cooling agents according to Table A can be present in stereoisomerically pure form or as mixtures of different stereoisomers and can therefore be used in formulations as such.
[0242] It has surprisingly been shown that the compounds according to the invention, as shown in Table A, exhibit particularly high TRPM8 activations and are therefore ideally suited as cooling agents.
[0243] The most preferred refrigerants, i.e., refrigerants with particularly efficient and strong TRPM8 activation, meaning efficient and intensive cooling at low usage levels, are compounds B-01, B-02, B-03, B-05, B-07, B-11, B14, B-15, and B-18 (TRPM8 activation > 100%). Compounds B-01, B-02, B-03, B-05, and B-07, which exhibit exceptionally high TRPM8 activity (TRPM8 activation > 150%), are particularly preferred.
[0244] Because of their outstanding relative TRPM8 activation, compounds B-01 (TRPM8 activation of 262%), B-02 (TRPM8 activation of 227%), B-03 (TRPM8 activation of 221%), B-05 (TRPM8 activation of 205%), and B-07 (TRPM8 activation of 203%) are most preferred.
[0245] Equally preferred are the physiological refrigerants of general formulas (III), (IV), (VII) or (VIII), selected from the group consisting of the compounds shown in Table 2:
[0246] Table 2: Inventive structures with relative TRPM8 activation in %
[0247] The refrigerants according to the invention listed in Table 2, based on the general formulas (III), (IV), (VII) or (VIII), are either in neutral, uncharged form or in the form of their salts, such as acid addition salts, with inorganic or organic, mono- or polyvalent carboxylic acids, as described in detail above. The above statements apply equally here as well.
[0248] The cooling agents according to Table 2 can be present in stereoisomerically pure form or as mixtures of different stereoisomers and can therefore be used in formulations in this way.
[0249] It has surprisingly been shown that the compounds according to the invention exhibit particularly high TRPM8 activations and are therefore ideally suited as coolants.
[0250] The most preferred refrigerants, i.e., refrigerants with particularly efficient and strong TRPM8 activation, i.e., efficient and intensive cooling effect at low usage levels, are compounds A-01, A-02, A-03, A-04, A-05, A-06, A-07, A-08, A-09, A-10, A-11, A-12, A-15, A-16 and A-17 (TRPM8 activation > 90%) and especially compounds A-01, A-02, A-03, A-04, A-05, A-06, A-07, A-08, A-09, A-10, A-11, A-12, A-15 and A-16 (TRPM8 activation > 100%). Compounds A-01, A-02, A-03, A-04, A-05, A-06, A-07 and A-08 are particularly preferred, as they exhibit an exceptionally high TRPM8 activity (TRPM8 activation > 150%).
[0251] Because of their outstanding relative TRPM8 activation, compounds A-01 (TRPM8 activation of 278%), A-02 (TRPM8 activation of 265%), A-03 (TRPM8 activation of 260%), A-04 (TRPM8 activation of 215%), A-05 (TRPM8 activation of 190%), A-06 (TRPM8 activation of 186%), A-07 (TRPM8 activation of 183%), and A-08 (TRPM8 activation of 177%) are most preferred.
[0252] The compound A-01 (oxazole derivative) is characterized in that in the general formula (VII) R1 and R2 represent a phenyl group, X stands for a sulfur atom, Y stands for a branched methylene group substituted with a methyl group, and Z stands for an -NH-CHs group.
[0207] The compound A-02 (oxazole derivative) is characterized in that in the general formula (VII) R1 and R2 represent a phenyl group, X represents a sulfur atom, Y represents a branched methylene group substituted with a methyl group, and Z represents an -NH-CHs group.
[0208] The compound A-03 (oxazole derivative) is characterized in that in the general formula (VII) R1 and R2 represent a phenyl group, X represents a sulfur atom, Y represents a branched methylene group substituted with a methyl group, and Z represents an -NH-CHs group.
[0209] The compound A-04 (oxazole derivative) is characterized in that in the general formula (VII) R1 and R2 represent a phenyl group, X represents a cis-cyclopropyl group, and Z represents an -NH-CHs group.
[0210] The compound A-05 (oxazole derivative) is characterized in that in the general formula (VII) R1 represents a CH3 group and R2 a phenyl group, X represents a s atom, Y represents a branched methylene group substituted with a methyl group, and Z represents an -NH-CHs group.
[0211] The compound A-06 (oxazole derivative) is characterized in that in the general formula (VII) R1 and R2 represent a phenyl group, X represents a s atom, Y represents a methylene group, and Z represents an -NH cyclopropyl group.
[0212] The compound A-07 (oxazole derivative) is characterized in that in the general formula (VII) R1 and R2 represent a phenyl group, X and Y stand for a methylene group, and Z stands for an -NH-CH2-CHs group.
[0253] Even more preferred are the physiological cooling agents of the general formulas (Vila) or (Villa), selected from the group consisting of the compounds shown in Table B:
[0254] Table B: Inventive structures with relative TRPM8 activation in %
[0255] The refrigerants according to the invention listed in Table B, based on the general formulas (Vila) or (Villa), are either in neutral, uncharged form or in the form of their salts, such as acid addition salts, with inorganic or organic, mono- or polyvalent carboxylic acids, as described in detail above. The above also applies here.
[0256] The cooling agents according to Table B can be present in stereoisomerically pure form or as mixtures of different stereoisomers and can therefore be used in formulations in this way.
[0257] It has surprisingly been shown that the compounds according to the invention, as shown in Table B, exhibit particularly high TRPM8 activations and are therefore ideally suited as cooling agents.
[0258] The most preferred refrigerants, i.e., refrigerants with particularly efficient and strong TRPM8 activation, meaning efficient and intensive cooling at low usage levels, are compounds A-01, A-02, A-03, A-05, A-09, A-10, and A-12 (TRPM8 activation > 100%). Compounds A-01, A-02, A-03, and A-05, which exhibit exceptionally high TRPM8 activity (TRPM8 activation > 150%), are particularly preferred.
[0259] Because of their outstanding relative TRPM8 activation, compounds A-01 (TRPM8 activation of 278%), A-02 (TRPM8 activation of 265%), A-03 (TRPM8 activation of 260%) and A-05 (TRPM8 activation of 190%) are most preferred.
[0213] It has been shown that the preferred compounds B-01, B-02, B-03, B-04, B-05, B-06, B-07, B-11, B-14, B-15, B-17, B-18, B-19 and B-21 and A-01, A-02, A-03, A-04, A-05, A-06, A-07, A-08, A-09, A-10, A-11, A-12, A-15, A-16 and A-17 described above exhibit particularly high TRPM8 activities and consequently show intensive and simultaneously efficient cooling effects; i.e., to produce an intensive cooling effect, only small amounts in the low ppm range of about 5 ppm of the substance according to the invention are necessary (low EC50 values, see experimental data below). Even in sensory evaluation, i.e., the tasting of the respective samples, intense cooling effects were demonstrated. For example, the panelists rated the cooling effect of compound B-11 with a score of 5.3 at a dosage of 5 ppm.Accordingly, the sensorially evaluated cooling intensity, taking into account the amount of compound used, was comparable to that determined for the cooling substance WS-3 as a reference at a six times higher concentration (amount used: 30 ppm; sensorially determined cooling intensity: score 5.4).
[0214] Compounds A-2 and A-10 also exhibit very high TRPM8 activities as well as intensely perceived cooling effects (sensorially determined cooling intensities: score 5.4 and score 5.38 respectively) and are therefore particularly suitable as a highly efficient coolant.
[0215] Of the compounds defined above with general formulas (I) to (IV), the compounds with general formulas (V), (VI), (VII) and (VIII) are most preferred. The compounds with general formulas (Va), (Via), (Vila) and (Villa) are most preferred. These cooling agents are characterized by high TRPM8 activation and simultaneously exhibit very high sensing cooling intensities. They produce intense cooling effects even at low concentrations and are generally well below the EC50 reference value of 1.72 pM for substance WS-3, as will be shown in the following experimental section.
[0216] Although the physiological amine cooling agents according to the invention are not yet known from the prior art, they can be produced using generally known standard methods of preparative organic chemistry, which are shown in an exemplary generalized manner in the following schemes.
[0217] Schema 1:
[0218] Schema 2: Oxalyl Chloride Ar1 \ .N R1-0H / NR2H Ar1 ^N Jj CI - > J NR2 / 0 / S-R1 DCM / DMF, Reflux Ar2 / 0 Base, Solvent, Heating Ar2'^'° R1-X Base, Solvent, Heating
[0219] Schema 3:
[0220] Schema 4: Y=-(CH2) n -
[0221] Schema 5: Y=-(CH2) n -
[0222] Schema 6: S
[0223] Schema 7:
[0224] Schema 8:
[0225] Schema 9: Y = CH oder N
[0226] Schema 10:
[0228] In principle, the present invention encompasses all mixtures of the individual compounds of the general formulas (I) to (IV) and consequently also of the general formulas (V) to (VIII) or (Va) to (VIII) and their use as refrigerants or refrigerant mixtures. Nevertheless, the present compounds are also suitable for mixing with other, already known refrigerants.
[0229] Another object of the invention relates to a physiological cooling agent mixture comprising or consisting of: (a) one, two, three or more refrigerant(s) of general formulas (I) to (VIII), (Va), (Via), (Vila) or (Villa) or as listed in Table 1, Table 2, Table A or Table B and defined above; and, where appropriate, (b) at least one other physiological coolant; and / or, if applicable (c) at least one solvent.
[0230] In a preferred embodiment, the present invention relates to a coolant mixture comprising or consisting of at least one of the compounds according to the invention of the general formulas (I) to (VIII), (Va), (Via), (Vila), or as listed in Table 1, Table 2, Table A, or Table B and as defined above. Optionally, the coolant mixture also comprises a further physiological coolant and optionally at least one suitable solvent.
[0231] The particular advantage of such coolant mixtures is that a synergistic enhancement of the cooling effect can be observed.
[0232] Suitable refrigerants forming component (b) and different from the refrigerant(s) forming component (a) are selected from the group consisting of menthol, menthol methyl ether (FEMA GRAS 4054), monomenthyl glutamate (FEMA GRAS 4006), menthoxy-1,2-propanediol (FEMA GRAS 3784), dimenthyl glutarate (FEMA GRAS 4604), hydroxymethylcyclohexylethanone (FEMA GRAS 4742), 2-(4-ethylphenoxy)-N-(1H-pyrazole-3-yl)-N-(thiophen-2-ylmethyl)acetamide (FEMA GRAS 4880), WS-23 (2-isopropyl-N,2,3-trimethylbutyramide, FEMA GRAS 3804), N-(4-(Cyanomethyl)phenyl)-2-isopropyl-5,5-dimethylcyclohexane carboxamide (FEMA GRAS 4882), N-(3-Hydroxy-4-methoxyphenyl)-2-isopropyl-5,5-dimethylcyclohexane carboxamide (FEMA GRAS 4881), N-(2-Hydroxy-2- phenylethyl)-2-isopropyl-5,5-dimethylcyclohexane-1-carboxamide (FEMA GRAS 4896), 3,4-methylenedioxy cinnamic acid, (E)-3-benzo[1,3]dioxol-5-yl-N,N-diphenyl-2-propenamide (FEMA GRAS 4788),Menthol Propylen Glykol Carbonat (FEMA GRAS 3806), Menthyl-N- ethyloxamat, Monomethyl Succinat (FEMA GRAS 3810), WS-3 (N-Ethyl-p-menthan-3- carboxamide, FEMA GRAS 3455), Menthol Ethylen Glykol Carbonat (FEMA GRAS 3805), WS-5 (Ethyl-3-(p-menthan-3-carboxamido)acetat, FEMA GRAS 4309), WS-12 (1 R,2S,5R)-N- (4-Methoxyphenyl)-p-menthancarboxamid (FEMA GRAS 4681), WS-27 (N-Ethyl-2,2- diisopropylbutanamid, FEMA GRAS 4557), N-Cyclopropyl-5-methyl-2- isopropylcyclohexancarboxamid (FEMA GRAS 4693), WS-116 (N-(1 ,1-Dimethyl-2- hydroxyethyl)-2,2-diethylbutanamid, FEMA GRAS 4603), Menthoxyethanol (FEMA GRAS 4154), N-(4-Cyanomethylphenyl)-p-menthancarboxamid (FEMA GRAS 4496), N-(2-(Pyridin- 2-yl)ethyl)-3-p-menthancarboxamid (FEMA GRAS 4549), N-(2-Hydroxyethyl)-2-isopropy-1-, 2.3-dimethylbutanamid (FEMA GRAS 4602), (2S,5R)-N-[4-(2-Amino-2-oxoethyl)phenyl]-p- menthancarboxamid (FEMA GRAS 4684), N-Cyclopropyl-5-methyl-2- isopropylcyclohexancarboncarboxamid (FEMA GRAS 4693), 2-[(2-p-Menthoxy)ethoxy]- ethanol (FEMA GRAS 4718), (2,6-Diethyl-5-isopropyl-2-methyltetrahydropyran (FEMA GRAS 4680), trans-4-tert-Butylcyclohexanol (FEMA GRAS 4724), 2-(p-Tolyloxy)-N-(1 H-pyrazol-5-yl)- N-((thiophen-2-yl)methyl)acetamid (FEMA GRAS 4809), Menthon glycerol ketal (FEMA GRAS 3807 und 3808), (-)-Menthoxypropan-1 ,2-diol, 3-(1-Menthoxy)-2-methylpropan-1 ,2-diol (FEMA GRAS 3849), Isopulegol, (+)-cis und (-)-trans-p-Menthan-3,8-diol (62:38, FEMA GRAS 4053), 2.3-Dihydroxy-p-menthan, 3,3,5-trimethylcyclohexanon glycerol ketal, Menthyl pyrrolidon carboxylat, (1 R,3R,4S)-3-menthyl-3,6-dioxaheptanoat, (1 R,2S,5R)-3-menthyl methoxyacetat, (1 R,2S,5R)-3-Menthyl-3,6,9-trioxadecanoat, (1 R,2S,5R)-3-menthyl-3,6,9-trioxadecanoat, (1 R,2S,5R)-3-Menthyl-(2-hydroxyethoxy)acetat, (1 R,2S,5R)-Menthyl-11-hydroxy-3,6,9- trioxaundecanoat, Cubebol (FEMA GRAS 4497), 2-lsopropyl-5-methylcyclohexyl-4- (dimethylamino)-4-oxobutanoat (FEMA GRAS 4230), Menthyllactat (FEMA GRAS 3748), 6- lsopropyl-3,9-dimethyl-1 ,4-dioxaspiro[4.5]decan-2-on (FEMA GRAS 4285), N-Benzo[1 ,3]- dioxol-5-yl-3-p-menthancarboxamid, N-(1-Isopropyl-1 ,2-dimethylpropyl)-1 ,3-benzodioxol-5- carboxamid, N-(R)-2-Oxotetrahydrofuran-3-yl-(1 R,2S,5R)-p-menthan-3-carboxamid, Mischung aus 2,2,5,6,6-Pentamethyl-2,3,6,6a-tetrahydropentalen-3a(1 H)-ol und 5-(2- Hydroxy-2-methylpropyl)-3,4,4-trimethylcyclopent-2-en-1-on; (2S,5R)-2-lsopropyl-5-methyl-N- (2-(pyridin-4-yl)ethyl)cyclohexancarboxamide; (1S,2S,5R)-N-(4-(cyanomethyl)phenyl)-2- isopropyl-5-methylcyclohexancarboxamid, 1 ,7-lsopropyl-4,5-methyl-bicyclo[2.2.2]oct-5-en Derivate, 4-Methoxy-N-phenyl-N-[2-(pyridin-2-yl)ethyl]benzamid, 4-Methoxy-N-phenyl-N-[2- (pyridin-2-yl)ethyl]benzensulfonamid, 4-Chloro-N-phenyl-N-[2-(pyridin-2- yl)ethyl]benzensulfonamid, 4-Cyano-N-phenyl-N-[2-(pyridin-2-yl)ethyl]-benzensulfonamid, 4- ((Benzhydrylamino)methyl)-2-methoxyphenol, 4-((Bis(4- methoxyphenyl)methylamino)methyl)-2-methoxyphenol, 4-((1 ,2-diphenylethylamino)methyl)- 2-methoxyphenol, 4-((Benzhydryloxy)methyl)-2- methoxyphenol, 4-((9H-Fluoren-9- ylamino)methyl)-2-methoxyphenol, 4- ((benzhydrylamino)methyl)-2-ethoxyphenol, 1-(4- Methoxyphenyl)-2-(1-methyl-1 H-benzo[d]imidazol-2-yl)vinyl-4-methoxybenzoat, 2-(1- lsopropyl-6-methyl-1 H- enzo[d]imidazol-2-yl)-1-(4-methoxyphenyl)vinyl-4-methoxybenzoat, (Z)-2-(1-lsopropyl-5-methyl-1 H-benzo[d]imidazol-2-yl)-1-(4-methoxyphenyl)vinyl-4- methoxybenzoat, 3-Alkyl-p-methan-3-ol Derivate, Derivate von Fenchyl, D-Bornyl, L-Bornyl, exo-Norbornyl, 2-Methylisobornyl, 2-Ethylfenchyl, 2-Methylbornyl, cis-Pinan-2-yl, Verbanyl und Isobornyl, Menthyloxamat-Derivate, Menthyl 3-oxocarbonsäureester,N-alpha-(menthanecarbonyl)amino acid amides, p-menthane carboxamide and WS-23 analogues, (-)-(1R,2R,4S)-dihydroumbellulol, p-menthane alkyloxyamide, cyclohexane derivatives, butanone derivatives, mixture of 3-menthane-1-propanol and 1-menthane-2-propanol, 1-[2-hydroxyphenyl]-4-[2-nitrophenyl]-1,2,3,6-tetrahydropyrimidin-2-one, 4-methyl-3-(1-pyrrolidinyl)-2-[5H]-furanone, and mixtures thereof. FEMA stands for "Flavor and Extracts Manufacturers Association," and GRAS is defined as "Generally Regarded As Safe." A FEMA GRAS designation means that the substance so marked has been tested according to standard methods and is considered toxicologically safe.
[0233] In principle, all known substances with a cooling effect are suitable as component (b). However, for reasons of food safety, those compounds which have a designation according to FEMA GRAS are preferred, or where the aforementioned cooling mixture requires it.
[0234] A first important representative of the substances that form component (b) is monomenthyl succinate (FEMA GRAS 3810). Both the succinate and the analogous monomenthyl glutarate (FEMA GRAS 4006) are important representatives of monomenthyl esters based on di- and polycarboxylic acids.
[0235] The next important group of menthol compounds preferred in the sense of the invention comprises carbonate esters of menthol and polyols, such as glycols, glycerol or carbohydrates, such as menthol ethylene glycol carbonate (FEMA GRAS 3805 = Frescolat® MGC), menthol propylene glycol carbonate (FEMA GRAS 3784 = Frescolat® MPC), menthol 2-methyl-1,2-propanediol carbonate (FEMA GRAS 3849) or the corresponding sugar derivatives. Also preferred are N-(4-Cyanomethylphenyl)-p-menthanecarboxamide (FEMA GRAS 4496), N-(2-(Pyridin-2-yl)ethyl)-3-p-menthanecarboxamide (FEMA GRAS 4549) and (E)-3-Benzo[1 ,3]dioxol-5-yl-N,N-diphenyl-2-propenamide (FEMA GRAS 4788) as component (b).
[0236] In accordance with the invention, the menthol compounds menthyl lactate (FEMA GRAS 3748 = Frescolat® ML) and in particular the menthone glyceryl acetal (FEMA GRAS 3807) or Menthone Glyceryl Ketal (FEMA GRAS 3808), which is marketed under the name Frescolat® MGA.
[0237] This group of compounds also includes 3-(1-Menthoxy)-1,2-propanediol, also known as Cooling Agent 10 (FEMA GRAS 3784), and 3-(1-Menthoxy)-2-methyl-1,2-propanediol (FEMA GRAS 3849), which has an additional methyl group.
[0238] Among the above-mentioned substances, menthone glyceryl acetal / ketal, menthyl lactate, menthol ethylene glycol carbonate, and menthol propylene glycol carbonate have proven to be particularly advantageous and are marketed by the applicant under the names Frescolat® MGA, Frescolat® ML, Frecolat® MGC and Frescolat® MPC.
[0239] Further preferred components (b) are shown in Table 3 below:
[0240] Table 3: Other suitable substances as component (b)
[0241] In the 1970s, menthol compounds were first developed which have a C-C bond at the 3-position, and a number of these can also be used in accordance with the invention. These substances are generally referred to as WS types. The basic structure is a menthol derivative in which the hydroxyl group is replaced by a carboxyl group (WS-1). All other WS types are derived from this structure, such as the species WS-3, WS-4, WS-5, WS-12, WS-14, WS-23, WS-27 and WS-30, which are also preferred in accordance with the invention, or the esters or N-substituted amides of the aforementioned compounds.
[0242] The coolant 2-(p-tolyloxy)-N-(1 H-pyrazol-5-yl)-N-((thiophen-2-yl)methyl)acetamide (FEMA GRAS 4809) is particularly preferred. Also preferred are 2-(4-ethylphenoxy)-N-(1 H-pyrazol-3-yl)-N-(thiophen-2-ylmethyl)acetamide (FEMA GRAS 4880) and / or N-(3-hydroxy-4-methoxyphenyl)-2-isopropyl-5,5-dimethylcyclohexane carboxamide (FEMA GRAS 4881) and / or N-(4-(cyanomethyl)phenyl)-2-isopropyl-5,5-dimethylcyclohexane carboxamide (FEMA GRAS 4882).
[0243] Further preferred components (b) which are combined with at least one cooling agent of the general formulas (I) to (VIII) according to the invention or as listed in Table 1 or Table 2 and defined above, are shown in Table 4 below:
[0244] Table 4: Other suitable substances as component (b) as well as their salts, preferably acid addition salts, with inorganic or organic acids.
[0245] The coolant mixtures according to the invention can consist of the components (a) and (b) in a weight ratio of about 0.1 : 99.9 to about 99.0 : 0.1, preferably from about 1 : 99 to about 99 : 1, more preferably from about 10 : 90 to about 90 : 10, and even more preferably from approximately 25 : 75 to approximately 75 : 25 and especially from approximately 40 : 60 to approximately 60 : 40 based on the total coolant mixture.
[0246] In order to fully utilize and optimize the cooling effect of the cooling agents, and to ensure simpler processing in flavorings, semi-finished products, or other end products, the cooling agents must be dissolved in a solution before processing. However, the solubility of the cooling agents according to the invention is insufficient in some cases, which causes problems during storage, handling, or further processing.
[0247] Firstly, the aforementioned cooling agents that form component (b) of the cooling mixture can act as solvents for the cooling substance or substances that form component (a) of the cooling mixture.
[0248] Advantageously, the cooling mixture according to the invention comprises, secondly, as a further component (c), at least one solvent.
[0249] Individual solvents or solvent systems have proven to be advantageous, wherein the solvent is selected from the group consisting of: benzyl alcohol, 2-phenylethanol, benzyl benzoate, diethyl succinate, triethyl citrate, triacetin, ethanol, peppermint oil, anethole, optamint, propylene glycol, phenoxyethanol and mixtures thereof.
[0250] Optamint, for example, is a mixture of more than 50 different natural essential oils and natural or nature-identical flavorings. Optamins have variable compositions of various (partially fractionated) oils, which preferably represent a mixture of, for example, different peppermint and spearmint oils, as well as eucalyptus globulus oil, star anise oil, menthol, menthone, isomenthone, menthyl acetate, anethole, eucalyptol, etc. An exact representation of the composition of the Optamins is therefore not possible. The Optamint® product line is commercially available from Symrise AG.
[0251] For example, benzyl alcohol or 2-phenylethanol or benzyl benzoate can be used as solvents in the cooling mixture according to the invention.
[0252] The use of benzyl alcohol or 2-phenyethanol or benzyl benzoate can, for example, be used to dissolve the cooling agents according to the invention and also to obtain a stable solution, i.e. cooling agent mixture, for appropriate storage.
[0253] Solvent systems, i.e., solvent combinations of two or more solvents, can also be used to dissolve the cooling agents according to the invention. Especially with regard to the later application area, the use of by using solvents that can also have a cooling effect, a further step in the (final) production step can be saved.
[0254] In an exemplary embodiment, the solvent in the coolant mixture is therefore a binary system of two solvent substances selected from the group consisting of benzyl alcohol, 2-phenylethanol, benzyl benzoate, diethyl succinate, triethyl citrate, triacetin, ethanol, peppermint oil, anethole, optamint, propylene glycol, phenoxyethanol and other coolants as described above as component (b).
[0255] According to the present invention, suitable examples are binary solvent systems of benzyl alcohol and a further substance selected from the group consisting of 2-phenylethanol, benzyl benzoate, diethyl succinate, triethyl citrate, triacetin, ethanol, peppermint oil, anethole, optamint, propylene glycol, phenoxyethanol and further cooling agents, as described above as component (b).
[0256] Binary solvent combinations or mixtures are also suitable, which, for example, contain or consist of benzyl alcohol with another solvent. The following binary solvent combinations or mixtures are also suitable in this case: benzyl alcohol and 2-phenylethanol, benzyl alcohol and benzyl benzoate, benzyl alcohol and diethyl succinate, benzyl alcohol and triethyl citrate, benzyl alcohol and triacetin, benzyl alcohol and ethanol, benzyl alcohol and peppermint oil, benzyl alcohol and anethole, benzyl alcohol and optamint, benzyl alcohol and propylene glycol, benzyl alcohol and menthol, benzyl alcohol and menthyl lactate (Frescolat® ML), benzyl alcohol and menthol propylene glycol carbonate (Frescolat® MPC), benzyl alcohol and menthol ethylene glycol carbonate (Frescolat® MGC), benzyl alcohol and menthone glyceryl acetal (Frescolat® MGA), benzyl alcohol and menthane carboxylic acid esters and amides.
[0257] Furthermore, the following binary solvent combinations or mixtures are also suitable: 2-phenylethanol and menthol propylene glycol carbonate (Frescolat® MPC), diethyl succinate and 2-phenylethanol, triacetin and benzyl benzoate, triethyl citrate and triacetin, 2-phenylethanol and peppermint oil, 2-phenylethanol and Optamint, anethole and triacetin, peppermint oil and menthyl lactate (Frescolat® ML), triacetin and menthone glyceryl acetal (Frescolat® MAG), Optamint and menthyl lactate (Frescolat® ML), triethyl citrate and menthol ethylene glycol carbonate (Frescolat® MGC).
[0258] Suitable coolant mixtures according to the present invention therefore contain as solvent (c) for example a binary solvent combination or mixture as described above.
[0259] The binary solvent mixtures according to the present invention have, for example, the following ratios: solvent (1) : solvent (2) in a Ratio of 10 : 1 to 1 : 10, preferably in a ratio of 8 : 2 to 2 : 8, even more preferably in a ratio of 6 : 4 to 4 : 6 and most preferably in a ratio of 5 : 5.
[0260] The aforementioned suitable binary solvent mixtures can dissolve the cooling agents according to the invention and, depending on the solvent or combination of the aforementioned solvents, keep the cooling agents stably in solution in an amount of 2 wt.% to 50 wt.%, preferably 5 wt.% to 40 wt.% and further preferably 5 wt.% to 20 wt.%.
[0261] In a further exemplary embodiment, the solvent or solvent system for the cooling agents according to the invention is a ternary system of three solvents selected from the group consisting of benzyl alcohol, 2-phenylethanol, benzyl benzoate, diethyl succinate, triethyl citrate, triacetin, ethanol, peppermint oil, anethole, optamint, propylene glycol, phenoxyethanol and further cooling agents as described above as component (b).
[0262] Suitable examples include ternary solvent combinations or mixtures of benzyl alcohol and two other substances selected from the group consisting of 2-phenylethanol, benzyl benzoate, diethyl succinate, triethyl citrate, triacetin, ethanol, peppermint oil, anethole, optamint, propylene glycol, phenoxyethanol and other refrigerants, as described above as component (b).
[0263] Suitable solvent combinations or mixtures include, for example, benzyl alcohol with two other solvents, where the two other solvents are selected from the following group: 2-phenylethanol and benzyl benzoate, 2-phenylethanol and diethyl succinate, triethyl citrate and triacetin, triacetin and ethanol, triacetin and peppermint oil, menthol ethylene glycol carbonate (Frescolat® MGC) and anethole, 2-phenylethanol and Optamint, Optamint and propylene glycol, diethyl succinate and menthol, triacetin and menthyl lactate (Frescolat® ML), anethole and menthol propylene glycol carbonate (Frescolat® MPC), triacetin and menthol ethylene glycol carbonate (Frescolat® MGC), 2-phenylethanol and menthone glyceryl acetal (Frescolat® MGA), 2-phenylethanol and menthane carboxylic acid esters and amides, 2-phenylethanol and menthol, propylene glycol carbonate (Frescolat® MPC), triacetin and benzyl benzoate, 2-phenylethanol and peppermint oil,Anethole and triacetin, peppermint oil and menthyl lactate (Frescolat® ML), triacetin and menthone glyceryl acetal (Frescolat® MGA), Optamint and menthyl lactate (Frescolat® ML), triethyl citrate and menthol ethylene glycol carbonate (Frescolat® MGC), benzyl benzoate and menthol ethylene glycol carbonate (Frescolat® MGC), 2-phenylethanol and triethyl citrate, triethyl citrate and diethyl succinate, peppermint oil and menthyl lactate (Frescolat® ML), and ethanol and menthyl lactate (Frescolat® ML).
[0264] Other suitable options include, for example, the following ternary solvent combinations or mixtures: Triethyl citrate, triacetin, menthyl lactate (Frescolat® ML), Triacetin, 2-phenylethanol and peppermint oil, 2-Phenylethanol, Optamint and peppermint oil, 2-Phenylethanol, Triacetin and Optamint, Anethole, benzyl alcohol and triacetin, 2-Phenylethanol, Benzyl benzoate and Optamint 2-Phenylethanol, diethylsuccinate and Optamint Triethyl citrate, triacetin and peppermint oil, Optamint, triacetin and ethanol, Triacetin, menthol, ethylene glycol carbonate (Frescolat® MGC) and anethole, 2-Phenylethanol, Optamint and propylene glycol, Diethyl succinate, triacetin and menthol, Triacetin, benzyl benzoate and menthyl lactate (Frescolat® ML), Anethole, Menthol Propylene Glycol Carbonate (Frescolat® MPC) and Menthol Ethylene Glycol Carbonate (Frescolat® MGC), Triacetin, 2-phenylethanol and menthone glyceryl acetal (Frescolat® MGA), peppermint oil, 2-phenylethanol and menthane carboxylic acid esters and amides, triacetin, 2-phenylethanol and menthol propylene glycol carbonate (Frescolat® MPC), menthyl lactate (Frescolat® ML), 2-phenylethanol and peppermint oil, anethole, triacetin and menthone glyceryl acetal (Frescolat® MGA), Optamint, benzyl benzoate and menthyl lactate (Frescolat® ML), and benzyl benzoate, triethyl citrate and menthol ethylene glycol carbonate (Frescolat® MGC).
[0265] The ternary solvent mixtures according to the present invention have, for example, the following ratios: solvent (1) : solvent (2) : solvent (3) in a ratio of 10 : 1 : 15 to 5 : 1 : 3, or in a ratio of 4 : 1 : 7 to 7 : 1 : 4, or in a ratio of 2 : 2 : 4 to 4 : 4 : 2.
[0266] The aforementioned suitable ternary solvent mixtures proved particularly good in their ability to dissolve the cooling agents according to the invention and to keep the cooling agents stably in solution in an amount of 2 wt.% to 50 wt.%, preferably 5 wt.% to 40 wt.% and further preferably 5 wt.% to 20 wt.%, over a wide range, depending on the solvent or combination of the aforementioned solvents.
[0267] This has the advantage that the coolant(s) according to the invention can be represented in a variable quantity suitable for the final formulation, so that the range of coolant mixtures in which the coolant(s) is dissolved is broad.
[0268] In a further suitable embodiment, the solvent or solvent system for the cooling agents according to the invention is a quaternary system of four solvents selected from the group consisting of: benzyl alcohol, 2-phenylethanol, benzyl benzoate, diethyl succinate, triethyl citrate, triacetin, ethanol, Peppermint oil, anethole, optamint, propylene glycol, phenoxyethanol and other refrigerants as described above as component (b).
[0269] Suitable examples include quaternary solvent combinations of benzyl alcohol and three other substances selected from the group consisting of: 2-phenylethanol, benzyl benzoate, diethyl succinate, triethyl citrate, triacetin, ethanol, peppermint oil, anethole, optamint, propylene glycol, phenoxyethanol and other refrigerants as described above as component (b).
[0270] Suitable quaternary solvent combinations or mixtures include, for example, benzyl alcohol with three other solvents, where the three other solvents are selected from the group consisting of: 2-Phenylethanol, triethyl citrate and triacetin, Peppermint oil, 2-phenylethanol and triethyl citrate, Triethyl citrate, menthyl lactate (Frescolat® ML) and diethyl succinate Triethyl citrate, triacetin and anethole, 2-Phenylethanol, Triacetin, and Optamint, Peppermint oil, benzyl alcohol and menthyl lactate (Frescolat® ML), Optamint, ethanol and menthyl lactate (Frescolat® ML), 2-Phenylethanol, benzyl benzoate and diethyl succinate, Triethyl citrate, triacetin and ethanol, Peppermint oil, anethole and optamint, 2-Phenylethanol, benzyl benzoate and propylene glycol, 2-Phenylethanol, Benzyl benzoate and Menthol, Propylene Glycol Carbonate (Frescolat® MPC), Triethyl citrate, Optamint and Ethanol, Triacetin, benzyl benzoate and menthoxy-2-methyl-1,2-propanediol, Menthone Glyceryl Acetal (Frescolat® MGA), Triacetin and Anethole.
[0271] Other suitable options include, for example, the following quaternary solvent combinations and solvent mixtures: Anethole, triacetin, peppermint oil and menthol; ethylene glycol carbonate (Frescolat® MGC), triacetin, ethanol, 2-phenylethanol and peppermint oil; 2-phenylethanol, Optamint, diethyl succinate and peppermint oil; anethole, 2-phenylethanol, benzyl alcohol and triacetin.
[0272] The aforementioned suitable quaternary solvent mixtures proved particularly good in their ability to dissolve the cooling agents according to the invention and to keep the cooling agents stably in solution in an amount of 2 wt.% to 50 wt.%, preferably 5 wt.% to 40 wt.% and further preferably 5 wt.% to 20 wt.%, over a wide range, depending on the solvent or combination of the aforementioned solvents.
[0273] This has the advantage that the coolant(s) according to the invention can be represented in a variable quantity suitable for the final formulation, so that the range of coolant mixtures in which the coolant(s) is dissolved is broad.
[0274] The coolant mixtures according to the invention preferably contain or consist of component (a) and / or component (b) in an amount of 2 wt.% to 20 wt.%, preferably 2 wt.% to 10 wt.%, even more preferably 5 wt.% to 10 wt.%, most preferably 5 wt.% to 8 wt.%, and / or component (c) in an amount of 80 wt.% to 98 wt.%, preferably 90 wt.% to 98 wt.%, even more preferably 90 wt.% to 95 wt.%, most preferably 92 wt.% to 95 wt.%, based on the total coolant mixture, with the proviso that components (a) and / or (b) and / or (c) together make up 100 wt.%.
[0275] This composition of the coolant mixture according to the invention is particularly advantageous because it allows the amount of coolant(s) in the final formulation to be controlled.
[0276] Preferably, the final product contains the cooling agent(s) in an amount of approximately 0.00001 wt.% to 50 wt.%, preferably 0.0001 wt.% to 10 wt.%, more preferably 0.001 wt.% to 5 wt.%, and even more preferably 0.005 wt.% to 1 wt.% or 0.1 wt.% to 20 wt.%, more preferably 0.5 wt.% to 15 wt.% or 1 wt.% to 5 wt.% based on the weight of the final product, particularly in the case of oral care compositions.
[0277] Suitable coolant mixtures according to the invention have, for example, the following composition or consist, for example, of: 5-10 wt% coolant(s) in 95-90 wt% benzyl alcohol, or 8-10 wt% coolant(s) in 92-90 wt% benzyl alcohol, or 1 - 4 wt% coolant(s) in 99 - 96 wt% triethyl citrate, or 1 - 3 wt% coolant(s) in 99 - 97 wt% triacetin, or 3 - 6 wt% coolant(s) in 97 - 94 wt% diethyl succinate, or 5 - 15 wt% coolant(s) in 95 - 85 wt% 2-phenylethanol, or 5 - 10 wt% coolant(s) in 95 - 90 wt% benzyl benzoate, or 1 - 3 wt.% coolant(s) in 99 - 97 wt.% Optamint, or 1 - 4 wt.% refrigerant(s) in 99 - 96 wt.% other refrigerants as described above as component (b), or 2 - 4 wt.% coolant(s) in 98 - 96 wt.% propylene glycol, or 0.5 - 2 wt.% coolant(s) in 95.5-98 wt.% ethanol, or 0.5 - 2 wt% coolant(s) in 95.5 - 98 wt% menthyl acetate, or 1 - 4 wt.% coolant(s) in 99 - 96 wt.% peppermint oil, or 2-5 wt% coolant(s) in 98-95 wt% anethole, wherein both components (coolant(s) and solvent) in the coolant mixture always add up to 100 wt.%. For example, a suitable coolant mixture according to the invention consists of 5–10 wt.% coolant(s) in 95–90 wt.% benzyl alcohol, particularly preferably 8–10 wt.% coolant(s) in 92–90 wt.% benzyl alcohol.
[0278] Another aspect of the present invention relates to a flavor preparation comprising or consisting of (d) one, two, three or more refrigerant(s) of general formulas (I) to (VIII) or as listed in Table 1 or Table 2 and defined above; and (e) at least one flavouring substance.
[0279] The particular advantage of these mixtures or flavor preparations is that the cooling agents are able to mask unpleasant, for example bitter or astringent, taste impressions of flavors, especially sweeteners, even in small concentrations, while simultaneously providing an intense and efficient cooling effect.
[0280] The above applies equally to component (d) as to component (a) of the physiological coolant mixture according to the invention, comprising or consisting of: (a) one, two, three or more coolant(s) of the general formulas (I) to (VIII), (Va), (Via), (Vila) or (Villa) or as listed in Table 1, Table 2, Table A or Table B and defined above.
[0281] The flavor preparations according to the invention comprise one or more flavoring substances as component(s) selected from the group consisting of acetophenone, allyl capronate, alpha-ionone, beta-ionone, anisaldehyde, anisyl acetate, anisyl formate, anethole, benzaldehyde, benzothiazole, benzyl acetate, benzyl alcohol, benzyl benzoate, beta-ionone, butyl butyrate, butyl capronate, butylidene phthalide, carvone, camphene, caryophyllene, cineole, cinnamyl acetate, citral, citronellol, citronellal, citronellyl acetate, cyclohexyl acetate, cymene, damascone, decalactone, dihydrocoumarin, dimethyl anthranilate, dimethyl anthranilate, dodecalactone, ethoxyethyl acetate, ethyl butyric acid, ethyl butyrate, ethyl caprinate, ethyl capronate, ethyl crotonate, and ethylfuraneol. Ethyl guaiacol, ethyl isobutyrate, ethyl isovalerianate, ethyl lactate, ethyl methyl butyrate, ethyl propionate, eucalyptol, eugenol, ethyl heptylate, 4-(p-hydroxyphenyl)-2-butanone, gamma-decalactone, geraniol, geranyl acetate, geranyl acetate, grapefruit aldehyde,Methyldihydrojasmonate (e.g., Hedione®), heliotropin, 2-heptanone, 3-heptanone, 4-heptanone, trans-2-heptenal, cis-4-heptenal, trans-2-hexenal, cis-3-hexenol, trans-2-hexenic acid, trans-3-hexenic acid, cis-2-hexenyl acetate, cis-3-hexenyl acetate, cis-3-hexenyl capronate, trans-2-hexenyl capronate, cis-3-hexenyl formate, cis-2-hexyl acetate, cis-3-hexyl acetate, trans-2-hexyl acetate, cis-3-hexyl formate, para-, Hydroxybenzylacetone, isoamyl alcohol, isoamyl isovalerianate, isobutyl butyrate, isobutyraldehyde, isoeugenol methyl ether, isopropylmethylthiazole, lauric acid, leavulinic acid, linalool, linalool oxide, linalyl acetate, menthol, menthofuran, methyl anthranilate, methyl butanol, Methylbutyric acid, 2-methylbutyl acetate, methyl caproate, methyl cinnamate, 5-methylfurfural, 3.2.2-Methylcyclopentenolon, 6,5,2-Methylheptenon, Methyldihydrojasmonat, Methyljasmonat, 2-Methylmethylbutyrat, 2-Methyl-2-Pentenolsäure, Methylthiobutyrat, 3,1- Methylthiohexanol, 3-Methylthiohexylacetat, Nerol, Nerylacetat, trans, trans-2,4-Nonadienal, 2,4-Nonadienol, 2,6-Nonadienol, 2,4-Nonadienol, Nootkaton, delta Octalacton, gamma Octalacton, 2-Octanol, 3-Octanol, 1 ,3-Octenol, 1-Octylacetat, 3-Octylacetat, Palmitinsäure, Paraldehyd, Phellandren, Pentandion, Phenylethylacetat, Phenylethylalkohol, Phenylethylalkohol, Phenylethylisovalerianat, Piperonal, Propionaldehyd, Propylbutyrat, Pulegon, Pulegol, Sinensal, Sulfurol, Terpinen, Terpineol, Terpinoien, 8,3-Thiomenthanon, 4.4.2-Thiomethylpentanon, Thymol, delta-Undecalacton, gamma-Undecalacton, Valencen, Valeric acid, vanillin, acetoin, ethyl vanillin, ethyl vanillin isobutyrate (= 3-ethoxy-4-isobutyryloxybenzaldehyde), 2,5-dimethyl-4-hydroxy-3(2H)-furanone and its derivatives (preferably homofuraneol (= 2-ethyl-4-hydroxy-5-methyl-3(2H)-furanone), homofuronol (= 2-ethyl-5-methyl-4-hydroxy-3(2H)-furanone and 5-ethyl-2-methyl-4-hydroxy-3(2H)-furanone), maltol and maltol derivatives (preferably ethyl maltol), coumarin and coumarin derivatives, gamma-lactones (preferably gamma-undecalactone, gamma-nonalactone, gamma-decalactone), delta-lactones (preferably 4- Methyl deltadecalactone, massoilactone, deltadecalactone, tuberolactone), methyl sorbate, divanillin, 4-hydroxy-2(or 5)-ethyl-5(or 2)-methyl-3(2H)-furanone, 2-hydroxy-3-methyl-2-cyclopentenone, 3-hydroxy-4,5-dimethyl-2(5H)-furanone, isoamyl acetate, ethyl butyrate, n-butyl butyrate, isoamyl butyrate, 3-ethyl methylbutyrate, ethyl n-hexanoate, yl n-hexanoaten-Hexansäure-n- butylester, n-Octansäureethylester, Ethyl-3-methyl-3-phenylglycidat, Ethyl-2-trans-4-cis- decadienoat, 4-(p-Hydroxyphenyl)-2-butanon, 1 ,1-Dimethoxy-2,2,5-trimethyl-4-hexan, 2,6- Dimethyl-5-hepten-1-al und Phenylacetaldehyd, 2-Methyl-3-(methylthio)furan, 2-Methyl-3- furanthiol, bis(2-Methyl-3-furyl)disulfid, Furfurylmercaptan, Methional, 2-Acetyl-2-thiazolin, 3- Mercapto-2-pentanon, 2,5-Dimethyl-3-furanthiol, 2,4,5-Trimethylthiazol, 2- Acetylthiazol, 2,4- Dimethyl-5-ethylthiazol, 2-Acetyl-1-pyrrolin, 2-Methyl-3-ethylpyrazin, 2-Ethyl-3,5- dimethylpyrazin, 2-Ethyl-3,6-dimethylpyrazin, 2,3-Diethyl-5-methylpyrazin, 3-lsopropyl-2- methoxypyrazin, 3-lsobutyl-2-methoxypyrazin, 2-Acetylpyrazin, 2-Pentylpyridin, (E,E)-2,4- Decadienal, (E,E)-2,4-Nonadienal, (E)-2-Octenal, (E)-2-Nonenal, 2-Undecenal, 12- Methyltridecanal, 1-Penten-3-on, 4-Hydroxy-2,5-dimethyl-3(2H)-furanon, Guajakol, 3- Hydroxy-4,5-dimethyl-2(5H)-furanon, 3-Hydroxy-4-methyl-5-ethyl-2(5H)-furanon, Cinnamaldehyde, cinnamyl alcohol, methyl salicylate, isopulegol as well as (not explicitly mentioned here) stereoisomers, enantiomers, positional isomers, diastereomers, cis / trans isomers or epimers of these substances.
[0282] In accordance with the present invention, artificial and natural sweeteners and sweetener enhancers are particularly suitable as flavoring substances of component (e). These may be selected from the group consisting of • sugar alcohols (e.g. erythritol, threitol, arabitol, ribotol, xylitol, sorbitol, mannitol, dulcitol, lactitol); • Proteins (e.g., miraculin, monellin, thaumatin, curculin, brazzein); • Synthetic sweeteners (e.g., Magap, sodium cyclamate, acesulfame K, neohesperidin dihydrochalcone, saccharin sodium salt, aspartame, superaspartame, neotame, alitame, sucralose, steviosides, rebaudiosides, lugduname, carrelame, sucrononate, sucrooctate, Monatin, phenylodulcine); • Sweet-tasting amino acids (e.g., glycine, D-leucine, D-threonine, D-asparagine, D-phenylalanine, D-tryptophene, L-proline); • Sweet-tasting low-molecular-weight substances, such as hernandulcin, dihydrochalcone glycosides, glycyrrhizin, glycerrhetinic acid, their derivatives and salts, extracts of licorice (Glycyrrhizza glabra ssp.), Lippia dulcis extracts, Momordica ssp. extracts and / or • Plant extracts, such as Momordica grosvenori [Luo Han Guo] and the mogrosides obtained from it, Hydrangea dulcis or Stevia ssp. (e.g. Stevia rebaudiana) extracts or steviosides obtained from them.
[0283] The component (e) comprises at least one of the flavoring substances mentioned above.
[0284] The aroma preparations according to the invention can contain the components (d) and (e) to each other in a weight ratio of about 1 : 99 to about 99 : 1, preferably about 10 : 90 to about 90 : 10, more preferably about 25 : 75 to about 75 : 25 and particularly about 40 : 60 to 60 : 40.
[0285] In a further preferred embodiment, the one or more coolant(s), the coolant mixture, or the flavor preparation is in encapsulated form. This is of particular interest, for example, when the capsules loaded with the one or more coolant(s) are applied to textile surfaces, for example, as a component of fabric softeners or laundry after-treatment products, or when a finish is applied by forcibly applying the capsules loaded with the one or more coolant(s), for example, to pantyhose.
[0286] Capsules are defined as spherical aggregates containing at least one solid or liquid core enclosed by at least one continuous shell. During encapsulation, one or more coolants, coolant mixtures, or flavor preparations are encapsulated using a coating / shell material, resulting in macrocapsules with diameters of approximately 0.1 to 5 mm or microcapsules with diameters of approximately 0.0001 to 0.1 mm.
[0287] Consequently, a further embodiment of the present invention also relates to physiological cooling agents or physiological cooling agent mixtures or flavor preparations in encapsulated form.
[0288] Suitable coating materials include, for example, starches, including their degradation products, as well as chemically or physically produced derivatives (in particular Dextrins and maltodextrins), gelatin, gum arabic, agar-agar, ghatti gum, gellan gum, modified and non-modified celluloses, pullulan, curdlan, carrageenans, alginic acid, alginates, pectin, inulin, xanthan gum and mixtures of two or more of these substances.
[0289] Among the aforementioned coating materials, gelatin (especially porcine, beef, poultry and / or fish gelatin) is preferred, preferably having a swelling factor of greater than or equal to 20, and more preferably of greater than or equal to 24. Furthermore, gelatin is particularly preferred because it is readily available and can be obtained with different swelling factors.
[0290] Maltodextrins (especially those based on cereals, particularly maize, wheat, tapioca, or potatoes) are also preferred, preferably having DE values in the range of 10 to 20. Celluloses (e.g., cellulose ethers), alginates (e.g., sodium alginate), carrageenan (e.g., beta-, iota-, lambda-, and / or kappa-carrageenan), gum arabic, curdlan, and / or agar-agar are also preferred.
[0291] Alginate capsules are also preferred, as described in detail in the following documents: EP 0389700 A1 , US 4,251 ,195 , US 6,214,376 , WO 2003 055587 or WO 2004 050069 A1.
[0292] In another preferred embodiment, the capsule shell consists of melamine-formaldehyde resins or coacervation products of cationic monomers or biopolymers (such as chitosan) and anionic monomers, such as (meth)acrylates or alginates.
[0293] The capsules generally consist of finely dispersed liquid or solid phases coated with film-forming polymers. During their production, the polymers are deposited onto the material to be coated after emulsification and coacervation or interfacial polymerization. Another method involves embedding molten waxes in a matrix ("microsponge"), which, as microparticles, can also be coated with film-forming polymers. A third method involves coating particles alternately with polyelectrolytes of different charges ("layer-by-layer" process). These microscopically small capsules can be dried and used like powders.
[0294] In addition to mononuclear microcapsules, multinucleated aggregates, also called microspheres, are known, containing two or more nuclei distributed within a continuous shell material. Mononuclear or multinucleated microcapsules can also be enclosed by an additional second, third, etc., shell. The shell can consist of natural, semi-synthetic, or synthetic materials. Examples of natural shell materials include gum arabic, agar-agar, agarose, maltodextrins, alginic acid or its salts, e.g., sodium or calcium alginate, fats and fatty acids, cetyl alcohol, and collagen. Chitosan, lecithins, gelatin, albumin, shellac, polysaccharides such as starch or dextran, polypeptides, protein hydrolysates, sucrose, and waxes. Semi-synthetic coating materials include chemically modified celluloses, especially cellulose esters and ethers, e.g., cellulose acetate, ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and carboxymethylcellulose, as well as starch derivatives, especially starch ethers and esters. Synthetic coating materials include polymers such as polyacrylates, polyamides, polyvinyl alcohol, and polyvinylpyrrolidone.
[0295] Examples of state-of-the-art coating / encapsulation materials for the production of microcapsules are the following commercial products (the coating material is indicated in parentheses): Hallcrest Microcapsules (gelatin, gum arabic), Coletica Thalaspheres (marine collagen), Lipotec Millicapsules (alginic acid, agar-agar), Induchem Unispheres (lactose, microcrystalline cellulose, hydroxypropyl methylcellulose), Unicerin C30 (lactose, microcrystalline cellulose, hydroxypropyl methylcellulose), Kobo Glycospheres (modified starch, fatty acid esters, phospholipids), Softspheres (modified agar-agar) and Kuhs Probiol Nanospheres (phospholipids) as well as Primaspheres and Primasponges (chitosan, alginates) and Primasys (phospholipids).
[0296] Chitosan microcapsules and methods for their production are well known from the prior art: WO 01 / 01926, WO 01 / 01927, WO 01 / 01928, WO 01 / 01929. Microcapsules with mean diameters in the range of 0.0001 mm to 5 mm, preferably 0.001 mm to 0.5 mm and particularly 0.005 mm to 0.1 mm, consisting of a shell membrane and a matrix containing the active ingredients, can be obtained, for example, by (1) prepare a matrix from gelling agents, cationic polymers and active ingredients, (2) optionally dispersing the matrix in an oil phase, (3) the dispersed matrix is treated with aqueous solutions of anionic polymers, and the oil phase is removed if necessary.
[0297] The aforementioned steps (1) and (3) are interchangeable insofar as anionic polymers are used instead of the cationic polymers in step (1) and vice versa.
[0298] The capsules can also be produced by alternately coating the active ingredient with layers of differently charged polyelectrolytes (layer-by-layer technology). In this context, reference should be made to European patent EP 1064088 B1 (Max Planck Society).
[0299] As mentioned, the two essential properties of the new cooling agents or new cooling agent mixtures are, firstly, to modulate the TRPM8 receptor as antagonists or agonists, thereby triggering a physiological response, namely an intense and efficient cooling effect on the skin or mucous membranes, and secondly, to reduce or mask unpleasant tastes. Primarily However, the ability to produce intensive and efficient cooling effects even with small application quantities should be emphasized.
[0300] Another aspect of the present invention therefore relates to the use of the physiological coolant or the physiological coolant mixture according to the invention as a modulator, preferably for in vivo and / or in vitro modulation, of the cold menthol receptor TRPM8, in particular as a TRPM8 receptor agonist or as a TRPM8 receptor antagonist.
[0301] In the use according to the invention, the TRPM8 receptor is brought into contact with at least one cooling substance or physiological cooling substance mixture according to the invention, which(s) determine the permeability of cells to Ca in a cellular activity test using cells that recombinantly express the human TRPM8 receptor. 2+ -Ions modulate / modulate.
[0302] Suitable modulators can act either as antagonists or agonists, particularly as agonists only, or as both antagonists and agonists. In particular, the agonistic or antagonistic effect can occur depending on the specific modulator concentration chosen.
[0303] An "agonist" is a substance that mediates activation of the TRPM8 receptor, i.e., a calcium channel blocker. 2+ -Induces an influx of ions into the cold-sensitive neurons, thus conveying a sensation of cold.
[0304] In contrast, an “antagonist” is a compound that can counteract this activation of the TRPM8 receptor.
[0305] The modulators according to the invention, i.e., the physiological coolant or the coolant mixture, can exert their effect by binding reversibly or irreversibly, specifically or non-specifically, to a TRPM8 receptor molecule. Binding usually occurs non-covalently via ionic and / or non-ionic interactions, such as hydrophobic interactions, with the receptor molecule. The term "specific" encompasses both exclusive interaction with one or more different TRPM8 receptor molecules (such as TRPM8 molecules of different origins or different isoforms). The term "non-specific," on the other hand, refers to an interaction of the modulator with several different receptor molecules of different function and / or sequence, whereby a desired agonistic and / or antagonistic modulation (as described above) of the TRPM8 receptor can be observed as a result.
[0306] In one use according to the invention, preferably in a variant designated above as preferred, the modulator acts on the cellular Ca 2+ -Ion- permeability agonistic or antagonistic.
[0307] A particularly preferred variant of the use according to the invention is one in which the modulator is a TRPM8 receptor agonist.
[0308] Due to its physiological property, namely to trigger a cooling effect on skin or mucous membrane, another aspect of the present invention relates to the use of the cooling substance or cooling substance mixture according to the invention to generate a physiological cooling effect on skin or mucous membrane in a human being or in an animal.
[0309] Alternatively, the refrigerant or refrigerant mixture according to the invention is used to induce a cooling effect by means of packaging or textile containing the physiological refrigerant or refrigerant mixture.
[0310] Due to its additional properties, namely reducing or masking unpleasant taste notes such as bitter or astringent ones, a further aspect of the present invention relates to the use of the physiological cooling agent or cooling agent mixture according to the invention for improving the taste properties of flavorings. This allows known taste disadvantages of flavorings, especially sweeteners such as steviosides, to be reduced or masked. In particular, the pungent, bitter, or metallic aftertaste is effectively reduced or masked even with the addition of small amounts.
[0311] The cooling substances or physiological cooling substance mixtures or flavor preparations according to the invention have a wide range of applications, particularly in food, food supplements, cosmetic or pharmaceutical preparations, animal feed, textiles, packaging or tobacco products.
[0312] In particular, the physiological cooling substances or the physiological cooling substance mixtures or the flavor preparations according to the invention are used for the manufacture of foodstuffs, food supplements, cosmetic or pharmaceutical preparations, animal feed, textiles, packaging or tobacco products because of their cooling properties and / or flavor-enhancing properties.
[0313] A further object of the present invention is therefore the use of a cooling agent or several cooling agents according to the invention, or the cooling agent mixture according to the invention, or the flavor preparation according to the invention for the production of foodstuffs, food supplements, cosmetic or pharmaceutical preparations, animal feed, textiles, packaging or tobacco products.
[0314] Due to the advantageous properties described, the cooling substances according to the invention, as represented and defined by the general formulas (I) to (VIII), (Va), (Via), (Vila) or (Villa) or as shown in Table 1, Table 2, Table A or Table B, are preferably selected from the group consisting of the compounds, in the uses according to the invention, namely the use as a modulator, to generate a physiological cooling effect on skin or mucous membranes in humans or animals or to induce a cooling effect, to improve the taste properties of flavorings, in particular to reduce or mask an unpleasant taste, for the manufacture of foodstuffs, food supplements, cosmetic or pharmaceutical preparations, animal feed, textiles, packaging or tobacco products, or for use as a drug, as described in detail herein.which are shown in Table 5 or Table 6.
[0315] Table 5: Preferably used structures according to the invention
[0316] Table 6: Preferably used structures according to the invention
[0317] Of the compounds mentioned above, the use of compounds B-01, B-02, B-03, B-04, B-05, B-06, B-07, B-11, B14, B-15, B-17, B-18, B-19 and B-21 and the use of compounds A-01, A-02, A-03, A-04, A-05, A-06, A-07, A-08, A-09, A-10, A-11, A-12, A-15, A-16 and A-17 is preferred because of their pronounced TRPM8 activation, EC50 value and cooling intensity. However, the most preferred use is one of compounds B-01, B-02, B-03, B-04, B-05, B-06, B-07 and B-11, as well as one of compounds A-01, A-02, A-03, A-04, A-05, A-06, A-07, A-08, A-09, A-10, A-11 and A-12, due to their outstanding TRPM8 activation, EC50 value and cooling intensity.
[0318] In another aspect, the present invention therefore also encompasses foodstuffs, food supplements, cosmetic or pharmaceutical preparations, animal feed, textiles, packaging or tobacco products, which incorporate a feature of the invention. comprising physiological refrigerant or a physiological refrigerant mixture according to the invention or an aroma preparation according to the invention.
[0319] The concentration of one or more cooling agents depends on the type and use of the aforementioned products and is preferably approximately 0.1 ppm to 10 wt.%, preferably 1 wt.% to 10 wt.%, based on the total weight of the final product. In oral care applications, for example in toothpastes or mouthwashes, the concentration ranges from 0.1 ppm to 500 ppm of one or more cooling agents.
[0320] A wide concentration range typically used to provide the desired degree of sensory modulation may be approximately 0.001 ppm to 1000 ppm, or approximately 0.01 ppm to approximately 500 ppm, or approximately 0.05 ppm to approximately 300 ppm, or approximately 0.1 ppm to approximately 200 ppm, or approximately 0.5 ppm to approximately 150 ppm, or approximately 1 ppm to approximately 100 ppm.
[0321] The foodstuffs preferably consist of baked goods, for example bread, dry biscuits, cakes, other pastries, confectionery (for example chocolates, chocolate bar products, other bar products, fruit gums, hard and soft caramels, chewing gum), alcoholic or non-alcoholic beverages (for example coffee, tea, iced tea, wine, wine-based drinks, beer, beer-based drinks, liqueurs, schnapps, brandies, (carbonized) fruit-based soft drinks, (carbonized) isotonic drinks, (carbonized) soft drinks, nectars, spritzers, fruit and vegetable juices, fruit or vegetable juice preparations, instant drinks (for example instant cocoa drinks, instant tea drinks, instant coffee drinks, instant fruit drinks), meat products (for example ham, fresh or raw sausage preparations, seasoned or marinated fresh or cured meat products), eggs or egg products (dried eggs, egg whites, egg yolk),Cereal products (e.g., breakfast cereals, muesli bars, pre-cooked instant rice products), dairy products (e.g., milk drinks, buttermilk drinks, ice cream, yogurt, kefir, cream cheese, soft cheese, hard cheese, powdered milk, whey, whey drinks, butter, buttermilk, partially or fully hydrolyzed milk protein products), products made from soy protein or other soybean fractions (e.g., soy milk and products made from it, fruit drinks with soy protein, preparations containing soy lecithin, fermented products such as tofu or tempeh or products made from them), products from other plant protein sources, e.g., oat protein drinks, fruit preparations (e.g., jams, fruit ice cream, fruit sauces, fruit fillings), vegetable preparations (e.g., ketchup, sauces, dried vegetables, frozen vegetables, pre-cooked vegetables, canned vegetables),Snack products (e.g., baked or fried potato chips or potato dough products, extrudates based on corn or peanuts), fat- and oil-based products or emulsions thereof (e.g., mayonnaise, remoulade, dressings), other ready meals and soups (e.g., dry soups, instant soups, pre-cooked soups), spices, seasonings, and especially sprinkle-on seasonings, which are used, for example, in the snack sector.
[0322] The above-mentioned foodstuffs contain, in addition to conventional food ingredients, at least an effective, i.e., cooling-acting, amount of at least one cooling substance or cooling substance mixture or flavor preparation according to the invention.
[0323] The content of coolant or coolant mixture or flavor preparation in these preparations is preferably about 0.1 wt.% to about 10 wt.% and in particular about 1 wt.% to 2 wt.%, based on the total weight of the finished preparation.
[0324] Suitable excipients can be used to manufacture the products according to the invention, such as foodstuffs, dietary supplements, cosmetic or pharmaceutical preparations, animal feed, textiles, packaging, or tobacco products. Suitable excipients include, but are not limited to, emulsifiers, thickeners, food acids, acidity regulators, vitamins, antioxidants, flavor enhancers, agents for masking unpleasant tastes, food colorings, and the like.
[0325] In particular, other usual additives or auxiliary substances can be added to the products according to the invention, such as flavorings or active ingredients to mask unpleasant taste impressions.
[0326] Flavorings: Preferred flavorings are those that produce a sweet odor impression, wherein the further flavoring(s) that produce a sweet odor impression are preferably selected from the group consisting of: vanillin, ethyl vanillin, ethyl vanillin isobutyrate (= 3 ethoxy-4-isobutyryloxybenzaldehyde), furaneol (2,5-dimethyl-4-hydroxy-3(2H)-furanone) and derivatives (e.g., homofuraneol, 2-ethyl-4-hydroxy-5-methyl-3(2H)-furanone), homofuronol (2-ethyl-5-methyl-4-hydroxy-3(2H)-furanone and 5-ethyl-2-methyl-4-hydroxy-3(2H)-furanone), maltol and derivatives (e.g., ethyl maltol), coumarin and derivatives, gamma-lactones (e.g., gamma-undecalactone, gamma-nonalactone). delta-lactones (e.g. 4-methyldeltalactone, massoilactone, deltadecalactone, tuberolactone), methyl sorbate, divanillin, 4-hydroxy-2(or 5)-ethyl-5(or 2)-methyl-3(2H)furanone, 2-hydroxy-3-methyl-2-cyclopentenone, 3-Hydroxy-4,5-dimethyl-2(5H)-furanone, fruit esters and fruit lactones (e.gethyl acetate, isoamyl acetate, ethyl propionate, ethyl butyrate, n-butyl butyrate, isoamyl butyrate, ethyl 3-methylbutyrate, ethyl n-hexanoate, allyl n-hexanoate, ethyl n-hexanoate, ethyl n-octanoate, ethyl 3-methyl-3-phenylglycidate, ethyl 2-trans-4-cis-decadienoate, 4-(p-hydroxyphenyl)-2-butanone, 1,1-dimethoxy-2,2,5-trimethyl-4-hexane, 2,6-dimethyl-5-hepten-1-al, 4-hydroxycinnamic acid, 4-methoxy-3-hydroxycinnamic acid, 3-methoxy-4-hydroxycinnamic acid, 2-hydroxycinnamic acid, 2,4-dihydroxybenzoic acid 3-Hydroxybenzoic acid, 3,4-Dihydroxybenzoic acid, vanillic acid, homovanillic acid, vanillomandelic acid and phenylacetaldehyde.
[0327] Active ingredients for masking unpleasant taste sensations: Furthermore, the oral preparations may also include other substances that also serve to mask bitter and / or astringent taste sensations. These additional flavorings are selected, for example, from the following list: from nucleotides (e.g., adenosine 5'-monophosphate, cytidine 5'-monophosphate) or their physiologically acceptable salts, lactisols, sodium salts (e.g., sodium chloride, sodium lactate, sodium citrate, sodium acetate, sodium gluconoate), hydroxyflavanones, preferably eriodictyol, sterubine (eriodictyol-7-methyl ether), homoeriodictyol, and their sodium, potassium, calcium, magnesium, or zinc salts (especially those as described in EP 1258200 A2), hydroxybenzoic acid amides, preferably 2,4-dihydroxybenzoic acid vanillylamide, 2,4-dihydroxybenzoic acid / V-(4-hydroxy-3-methoxybenzyl)amide, 2,4,6-T rihydroxybenzoic acid / V-(4-hydroxy-3-methoxybenzyl)amide,2-hydroxybenzoic acid / V-4-(hydroxy-3-methoxybenzyl)amide, 4-hydroxybenzoic acid / V-(4-hydroxy-3-methoxybenzyl)amide, 2,4-dihydroxybenzoic acid / V-(4-hydroxy-3-methoxybenzyl)amide mono-sodium salt, 2,4-dihydroxybenzoic acid / V-2-(4-hydroxy-3-methoxy-phenyl)ethylamide, 2,4-dihydroxybenzoic acid / V-(4-hydroxy-3-ethoxybenzyl)amide, 2,4-dihydroxybenzoic acid / V-(3,4-dihydroxybenzyl)amide and 2-hydroxy-5-methoxy-N-[2-(4- hydroxy-3-methoxyphenyl)ethyl]amide; 4-Hydroxybenzoic acid vanillylamides (particularly those as described in WO 2006 / 024587); Hydroxydeoxybenzoins, preferably 2-(4-hydroxy-3-methoxyphenyl)-1-(2,4,6-trihydroxyphenyl)ethanone, 1-(2,4-dihydroxyphenyl)-2-(4-hydroxy-3-methoxyphenyl)ethanone and 1-(2-hydroxy-4-methoxyphenyl)-2-(4-hydroxy-3-methoxyphenyl)ethanone) (especially those as described in WO 2006 / 106023); hydroxyphenylalkanedions, such as gingerdione-[2], gingerdione-[3], gingerdione-[4], dehydrogingerdione-[2], dehydrogingerdione-[3],Dehydrogingerdione-[4]) (especially those as described in WO 2007 / 003527); diacetyl trimers (especially those as described in WO 2006 / 058893); gamma-aminobutyric acids (especially those as described in WO 2005 / 096841); Divanillins (especially those as described in WO 2004 / 078302) and 4-hydroxydihydrochalcones (preferably as described in US 2008 / 0227867 A1), in particular phloretin and davidigenin, amino acids or mixtures of whey proteins with lecithins, hesperetin as disclosed in WO 2007 / 014879, 4-hydroxydihydrochalcones as disclosed in WO 2007 / 107596, or propenylphenyl glycosides (chavicol glycosides) as described in EP 1955601 A1, or extracts of Rubus suavissimus, extracts of Hydrangea macrophylla as described in EP 2298084 A1, pellitorin and derived flavor compositions as described in EP 2008530 A1, umami compounds as described in WO 2008 / 046895 A1 and EP 1989944 A1 described,Umami compounds as described in EP 2064959 A1 or EP 2135516 A1, vanillyl lignans, enterodiol, as well as N-decadienoyl amino acids and their mixtures.
[0328] Another object of the invention relates to cosmetic or pharmaceutical preparations which contain either one or more of the cooling agent(s) according to the invention, or a cooling agent mixture according to the invention, or an aroma preparation according to the invention.
[0329] The products according to the invention may be, in particular, skin cosmetics, hair cosmetics, dermatological, hygienic, or pharmaceutical products. In particular, the active ingredients according to the invention, especially those with a cooling effect, are used for skin and / or hair cosmetics or as oral care products.
[0330] The hair or skin care products or preparations according to the invention are preferably in the form of an emulsion, a dispersion, a suspension, an aqueous surfactant preparation, a milk, a lotion, a cream, a balm, an ointment, a gel, granules, a powder, a stick preparation (e.g., a lipstick), a foam, an aerosol, or a spray. Such formulations are well suited for topical preparations. Suitable emulsions include oil-in-water emulsions, water-in-oil emulsions, and microemulsions. As a rule, the hair or skin cosmetic preparation is used for application to the skin (topically) or hair. "Topical preparations" are understood to mean those preparations that are suitable for applying the active ingredients to the skin in a fine distribution, such as in a form that can be absorbed through the skin. Examples of suitable preparations include...Aqueous and aqueous-alcoholic solutions, sprays, foams, foam aerosols, ointments, aqueous gels, O / W or W / O emulsions, microemulsions, or cosmetic stick preparations. According to one embodiment of the cosmetic product according to the invention, it contains a carrier. Preferably, the carrier is water, a gas, a water-based liquid, an oil, a gel, an emulsion or microemulsion, a dispersion, or a mixture thereof. The aforementioned carriers exhibit good skin compatibility. Aqueous gels, emulsions, or microemulsions are particularly advantageous for topical preparations.
[0331] The invention also encompasses the use of the active ingredients described herein for medical purposes, particularly in pharmaceuticals for the treatment of an individual, preferably a mammal, especially a human, farm animal, or domestic animal. The active ingredients are administered in the form of pharmaceutical compositions comprising a pharmaceutically compatible excipient with at least one active ingredient according to the invention and optionally further active ingredients. These compositions can be administered, for example, orally, rectally, transdermally, subcutaneously, intravenously, intramuscularly, or intranasally.
[0332] Examples of suitable pharmaceutical formulations or compositions include solid dosage forms such as powders, granules, tablets, lozenges, sachets, cachets, coated tablets, capsules such as hard and soft gelatin capsules, suppositories, or vaginal dosage forms; semi-solid dosage forms such as ointments, creams, hydrogels, pastes, or patches; and liquid dosage forms such as solutions, emulsions, in particular oil-in-water emulsions, suspensions (e.g., lotions), injection and infusion preparations, and eye and ear drops. Implanted delivery devices can also be used to administer inhibitors according to the invention. Furthermore, liposomes, microspheres, or polymer matrices can also be used. Examples include cold syrups, wound ointments, or wound sprays. Incorporating the substances into plasters or tablets is also possible, especially if these contain active ingredients that themselves have an unpleasant taste.
[0333] A further object of the present invention therefore comprises the cooling substances or cooling substance mixtures according to the invention as medicinal products, in particular as medicinal products for use in relieving pain and inflammatory conditions of the skin and mucous membranes. Due to their cooling properties, the cooling substances according to the invention are particularly suitable for preventing, combating or relieving symptoms of coughs, colds, inflammation, sore throats or hoarseness.
[0334] Furthermore, the substances and preparation described herein are suitable for the treatment of inflammatory conditions of the skin, mucous membranes and joints due to their efficient cooling effect.
[0335] Due to their ability to modulate the TRPM8 receptor, whose gene expression, i.e., that of the TRPM8 gene, is upregulated in cancers, for example in prostate carcinomas, the pharmaceutical preparations according to the invention are preferably also used in oncology, preferably in the treatment of prostate or bladder carcinomas, or for the treatment of bladder weakness. The corresponding proteins in the cell are encoded by corresponding genes in the cell nucleus. The reading of the genes in the nucleus (transcription) leads to the generation of messenger RNA (mRNA), which is then "translated" into a protein at ribosomes in the cell. The entirety of both processes is often referred to as gene expression.
[0336] Astringent, bitter, and / or metallic tastes are not only found in flavorings and sweeteners, as described above, but also in connection with many pharmaceutical agents, which makes their use particularly difficult for children. Typical examples of such pharmaceutical agents include: aspirin, minoxidil, erythromycin, Fenistil, betamethasone, ibuprofen, ketoprofen, dicyclofenac, metronidazole, acyclovir, imiquimod, terbafine, cyclopiroxolamine, paracetamol, and other nonsteroidal anti-inflammatory drugs (NSAIDs) and mixtures thereof.
[0337] The present invention therefore also includes medicaments comprising one or more cooling substances or a cooling substance mixture or a flavor preparation according to the invention in combination with at least one further pharmaceutical active ingredient selected from the group consisting of aspirin, minoxidil, erythromycin, Fenistil, betamethasone, ibuprofen, ketoprofen, dicyclofenac, metronidazole, acyclovir, imiquimod, terbafine, cyclopiroxolamine, paracetamol and mixtures thereof.
[0338] Furthermore, studies with test subjects have shown that the cooling agents or cooling agent mixtures according to the invention enhance the pain-relieving properties of non-steroidal anti-inflammatory drugs (NSAIDs), in particular ibuprofen and ketoprofen, beyond their cooling effect, which was also unexpected for those skilled in the art. Therefore, the present invention also relates in particular to the combination with pharmaceutical active ingredients of the non-steroidal anti-inflammatory drug (NSAID) type.
[0339] Such pharmaceutical combinations are therefore particularly advantageous for use in the treatment of inflammatory conditions of the skin and mucous membranes as well as the joints.
[0340] The medications can contain the cooling agents or cooling agent mixtures according to the invention and the pharmaceutical active ingredients in a weight ratio of about 1:99 to about 10:90 and in particular 2:98 to about 5:95.
[0341] The physiological cooling effect is also used, for example, in the formulation of wound and burn ointments as well as preparations against insect bites.
[0342] In the manufacture of the cosmetic or pharmaceutical preparations according to the invention, the cooling agent(s) or the cooling agent mixture according to the invention are usually mixed or diluted with an excipient. Excipients can be solid, semi-solid, or liquid materials that serve as vehicles, carriers, or mediums for the active ingredient. The active ingredient content (of one or more simultaneously contained cooling agents according to the invention) can vary over a wide range and is approximately, based on the total weight of the preparation, from about 0.05 ppm to 10 wt.%, preferably 0.1 ppm to 10 wt.%.
[0343] Suitable excipients include, for example, lactose, dextrose, sucrose, sorbitol, mannitol, starches, acacia gum, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup and methylcellulose.Furthermore, the formulations may contain pharmaceutically acceptable carriers or common excipients, such as lubricants (e.g., tallow, magnesium stearate, and mineral oil), wetting agents, emulsifying and suspending agents, preservatives (e.g., methyl and propyl hydroxybenzoates), antioxidants, anti-irritants, chelating agents, coating aids, emulsion stabilizers, film formers, gelling agents, odor masking agents, flavor correctors, resins, hydrocolloids, solvents, solubilizers, neutralizing agents, permeation accelerators, pigments, quaternary ammonium compounds, refatting and superfatting agents, ointment, cream, or oil bases, silicone derivatives, spreading aids, stabilizers, sterilizers, suppository bases, tablet excipients (e.g., binders, fillers, lubricants, disintegrants, or coatings), propellants, drying agents, and opacifiers. Thickening agents; waxes; plasticizers; white oils are included. The specific formulation is based on expert knowledge and is sufficiently described in the relevant technical literature. The preparations according to the invention may, in addition to conventional additives or excipients, also contain cosmetically and / or dermatologically and / or pharmacologically active substances. Non-limiting examples of suitable further active substances include: cosmetically and / or dermatologically active substances; antimicrobial substances; Surfactants (anionic surfactants, non-ionic surfactants, cationic surfactants, amphoteric or zwitterionic surfactants), oils, emulsifiers, fats and waxes, pearlescent waxes, consistency enhancers and thickeners, superfatting agents and stabilizers, polymers, silicone compounds, UV filters, pigments, especially sun protection pigments, humectants, biogenic agents and antioxidants, deodorants and antimicrobial agents, enzyme inhibitors, odor absorbers, antiperspirants, film formers, anti-dandruff agents, swelling agents, insect repellents, hydrotropes, preservatives, perfume oils and flavorings, dyes, etc.
[0344] Preferred preparations according to the invention are selected from the group of products for the treatment, protection, care and cleansing of the skin and / or hair or as a makeup product, either as leave-on or rinse-off products.
[0345] The formulations include, for example, dispersions, suspensions, creams, lotions or milks, depending on the manufacturing method and ingredients; gels (including hydrogels, e.g., hydrodispersion gels, oleogels); sprays (e.g., pump sprays or sprays with propellant); foams or impregnating solutions for cosmetic wipes; soaps; washing liquids; shower and bath preparations; bath products (capsules, oils, tablets, salts, bath salts, soaps, etc.); effervescent preparations; skin care products, such as emulsions, ointments, pastes, gels (as described above); oils; balms; serums; powders (e.g., face powder, body powder); masks; sticks; roll-on sticks; aerosols (foaming, non-foaming, or post-foaming); deodorants and / or antiperspirants; mouthwashes and rinses; insect repellents; sunscreens; after-sun preparations; shaving products; aftershave balms; pre- and Aftershave lotions, depilatory products, hair care products such as e.g.Shampoos (including 2-in-1 shampoos, anti-dandruff shampoos, baby shampoos, shampoos for dry scalp, concentrated shampoos), conditioners, hair tonics, hair lotions, hair rinses, styling creams, pomades, perming and fixing lotions, hairsprays, e.g. styling aids (e.g. gel or wax), hair straightening products (detangling agents, relaxing agents), hair dyes such as temporary hair dyes, semi-permanent hair dyes, permanent hair dyes, hair conditioners, hair foams, eye care products, make-ups, make-up removers or baby products.
[0346] The formulations according to the invention are particularly preferably in the form of an emulsion, especially in the form of a W / O, O / W, W / O / W, O / W / O emulsion, PIT- Emulsion, e.g. a Pickering emulsion, a low oil emulsion, a micro- or nanoemulsion, a gel (including hydrogel, hydrodispersion gel, oleogel) or a solution.
[0347] The total proportion of auxiliary and additive materials can range from 1 wt.% to 50 wt.%, preferably 5 wt.% to 40 wt.%, based on the final preparation. The preparation of the agents can be carried out by conventional cold or hot processes; preferably, the phase inversion temperature method is used.
[0348] The present invention also includes oral care products containing one or more cooling substances or a cooling substance mixture or an aroma preparation according to the invention.
[0349] Oral hygiene products according to the invention can be formulated in a manner known per se, e.g. as toothpaste, tooth cream, tooth gel, tooth powder, tooth cleaning liquid, tooth cleaning foam, aqueous or aqueous-alcoholic oral care products (mouthwash), mouthwash as a 2-in-1 product, lozenge, mouth spray, dental floss and dental care chewing gum.
[0350] Toothpastes are generally understood to be gel-like or pasty preparations consisting of water, thickeners, humectants, abrasives or polishing agents, surfactants, sweeteners, flavorings, deodorizing agents, and active ingredients against oral and dental diseases. The toothpastes according to the invention can incorporate all conventional polishing agents, such as chalk, dicalcium phosphate, insoluble sodium metaphosphate, aluminum silicates, calcium pyrophosphate, finely divided synthetic resins, silicas, aluminum oxide, and aluminum oxide trihydrate.
[0351] Preferred abrasive materials for the toothpastes according to the invention are primarily finely divided xerogel silicas, hydrogel silicas, precipitated silicas, aluminum oxide trihydrate, and finely divided alpha-aluminum oxide, or mixtures of these abrasive materials in amounts of 15 to 40% by weight of the toothpaste. Suitable humectants include primarily low-molecular-weight polyethylene glycols, glycerin, sorbitol, or mixtures of these products in amounts up to 50% by weight. Among the known thickening agents, suitable are thickening, finely divided gel silicas and hydrocolloids, such as carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylguar, hydroxyethyl starch, polyvinylpyrrolidone, high-molecular-weight polyethylene glycol, plant gums such as tragacanth, agar-agar, carrageen moss, gum arabic, xantham gum, and carboxyvinyl polymers (e.g., Carbopol® types).In addition to mixtures of menthofuran and menthol compounds, the oral and dental care products may contain, in particular, surface-active substances, preferably anionic and non-ionic foaming surfactants, such as the substances already mentioned above, but especially alkyl ether sulfate salts, alkyl polyglucosides and their mixtures.
[0352] Other common toothpaste additives include: • Preservatives and antimicrobial substances such as p-hydroxybenzene methyl, ethyl or propyl esters, sodium sorbate, sodium benzoate, bromochlorophene, phenyl salicylic acid esters, thymol and the like; • Anti-tartar agents, e.g. organophosphates such as 1-hydroxyethane- 1,1-diphosphonic acid, 1-phosphonpropane- 1,2,3-tricarboxylic acid and others, which are known e.g. from US 3,488,419, DE 2224430 A1 and DE 2343196 A1; • other caries-inhibiting substances such as sodium fluoride, sodium monofluorophosphate, stannous fluoride; • Sweeteners, such as saccharin sodium, sodium cyclamate, sucrose, lactose, maltose, fructose or Apartam®, (L-aspartyl-L-phenylalanine methyl ester), Stivia extracts or their sweetening components, especially ribeaudiosides; • Additional flavorings such as eucalyptus oil, anise oil, fennel oil, caraway oil, methyl acetate, cinnamaldehyde, anethole, vanillin, thymol, and mixtures of these and other natural and synthetic flavorings; • Pigments such as titanium dioxide; • Dyes; • Buffer substances such as primary, secondary or tertiary alkali phosphates or citric acid / sodium citrate; • Wound-healing and anti-inflammatory substances such as allantoin, urea, azulene, chamomile extracts and acetylsalicylic acid derivatives.
[0353] To improve flow properties, hydrotropes such as ethanol, isopropyl alcohol, or polyols can also be used; these substances largely correspond to the carriers described above. Polyols suitable for this purpose preferably have 2 to 15 carbon atoms and at least two hydroxyl groups. The polyols may also contain further functional groups, in particular amino groups, or be modified with nitrogen.
[0354] Suitable preservatives include, for example, phenoxyethanol, formaldehyde solution, parabens, pentanediol or sorbic acid, as well as the silver complexes known under the name Surfacine® and other classes of substances known and suitable to those skilled in the art.
[0355] Perfume oils are those defined above. Suitable aromas include, in particular, peppermint oil, spearmint oil, anise oil, star anise oil, caraway oil, eucalyptus oil, fennel oil, lemon oil, wintergreen oil, clove oil, menthol, and similar oils.
[0356] A preferred embodiment of the cosmetic preparations are toothpastes in the form of an aqueous, pasty dispersion containing polishing agents, humectants, viscosity regulators and optionally other usual components, as well as the mixture of menthofuran and menthol compounds in amounts of 0.5 to 2% by weight.
[0357] In mouthwashes, a combination with aqueous-alcoholic solutions of varying strengths of essential oils, emulsifiers, astringent and tonic drug extracts, tartar-inhibiting and antibacterial additives, and flavor enhancers is readily possible. Another preferred embodiment of the invention is a mouthwash in the form of an aqueous or aqueous-alcoholic solution containing a mixture of menthofuran and menthol compounds in amounts of 0.5 to 2% by weight. In mouthwashes that are diluted before use, sufficient effects can be achieved with higher concentrations, according to the intended dilution ratio.
[0358] Oral care preparations according to the invention contain, based on the total weight of the composition, preferably 0.1 ppm to 1 wt.%, preferably 1 ppm to 0.2 wt.%, at least one active ingredient according to the invention, i.e. a cooling agent, or an active ingredient mixture, i.e. a cooling agent mixture or aroma preparation.
[0359] The total content of the active ingredient or of the several active ingredients according to the invention, or of the cooling agent mixture or flavor preparation according to the present invention, is preferably 0.01 to 1 wt.%, preferably 0.05 to 0.5 wt.%, and particularly preferred is a content of 0.1 to 0.3 wt.%, in each case based on the total mouthwash.
[0360] In mouthwash concentrates, the total content of the active ingredient or the several active ingredients according to the invention, or of the cooling agent mixture or flavor preparation according to the present invention, is 0.1 to 15 wt.%, preferably a content of 0.5 to 8 wt.%, particularly preferably 1 to 5 wt.%, in each case based on the total mouthwash concentrate.
[0361] In toothpastes, the total content of the active ingredient or of the several active ingredients according to the invention, or of the cooling agent mixture or flavor preparation according to the present invention, is 0.1 to 5 wt.%, preferably 0.5 to 2 wt.%, particularly preferably 0.8 to 1.5 wt.%, in each case based on the entire toothpaste.
[0362] The present invention also includes chewing gum containing one or more cooling substances or a cooling substance mixture or a flavor preparation according to the invention.
[0363] Chewing gum compositions typically contain a water-insoluble and a water-soluble component. The water-insoluble base, also referred to as the "gum base," usually comprises natural or synthetic elastomers, resins, fats and oils, plasticizers, fillers, colorants, and optionally waxes. The proportion of the base in the total composition is typically 5 to 95 wt.%, preferably 10 to 50 wt.%, and particularly 20 to 35 wt.%. In a typical embodiment of the invention, the base consists of 20 to 60 wt.% synthetic Elastomers, 0 to 30 wt.% natural elastomers, 5 to 55 wt.% plasticizers, 4 to 35 wt.% fillers and in subordinate quantities additives such as colorants, antioxidants and the like, together, provided that they are only soluble in water in small quantities.
[0364] Suitable synthetic elastomers include, for example, polyisobutylenes with average molecular weights (according to GPC) of 10,000 to 100,000 and preferably 50,000 to 80,000, isobutylene-isoprene copolymers (butyl elastomers), styrene-butadiene copolymers (styrene : butadiene ratio e.g. 1 : 3 to 3 : 1), polyvinyl acetates with average molecular weights (according to GPC) of 2,000 to 90,000 and preferably 10,000 to 65,000, polyisoprenes, polyethylene, vinyl acetate-inyl laurate copolymers and mixtures thereof. Examples of suitable natural elastomers are rubbers such as smoked or liquid latex or guayule, as well as natural rubber materials such as Jelutong, Lechi caspi, Perillo, Sorva, Massaranduba balata, Massaranduba chocolate, Nispero, Rosindinba, Chicle, Gutta hang 1 kang and their mixtures.The selection of synthetic and natural elastomers and their mixing ratios depends primarily on whether the chewing gum is intended to produce bubbles ("bubble gums") or not. Preferably, elastomer mixtures containing jelutong, chicle, sorba, and massaranduba are used.
[0365] Suitable fillers or texturizing agents include magnesium or calcium carbonate, ground pumice, silicates, especially magnesium or aluminum silicates, clays, aluminum oxides, talc, titanium dioxide, mono-, di- and tricalcium phosphate, and cellulose polymers.
[0366] Suitable emulsifiers are tallow, hydrogenated tallow, hydrogenated or partially hydrogenated vegetable oils, cocoa butter, partial glycerides, lecithin, triacetin and saturated or unsaturated fatty acids with 6 to 22 and preferably 12 to 18 carbon atoms, as well as mixtures thereof.
[0367] Suitable colorants and whitening agents include, for example, FD and C types approved for coloring food, plant and fruit extracts, and titanium dioxide.
[0368] The base masses may contain waxes or be wax-free; examples of wax-free compositions can be found, among others, in patent specification US 5,286,500.
[0369] In addition to the water-insoluble gum base, chewing gum preparations regularly contain a water-soluble component, which consists, for example, of softeners, sweeteners, fillers, flavorings, flavor enhancers, emulsifiers, colorings, acidulants, antioxidants, and the like, provided that the components possess at least sufficient water solubility. Depending on the water solubility of the specific components, individual ingredients can therefore be distinguished. Components may belong to both the water-insoluble and water-soluble phases. However, it is also possible to use combinations, for example, of a water-soluble and a water-insoluble emulsifier, in which case the individual components are located in different phases. Typically, the water-insoluble fraction makes up 5 to 95 wt.% and preferably 20 to 80 wt.% of the preparation.
[0370] Water-soluble softeners or plasticizers are added to chewing gum formulations to improve chewability and texture, and are typically present in mixtures in amounts of 0.5 to 15% by weight. Typical examples include glycerin, lecithin, and aqueous solutions of sorbitol, hydrogenated starch hydrolysates, or corn syrup.
[0371] Suitable sweeteners include both sugar-containing and sugar-free compounds, used in amounts of 5 to 95% by weight, preferably 20 to 80% by weight, and particularly 30 to 60% by weight, based on the chewing gum composition. Typical saccharide sweeteners are sucrose, dextrose, maltose, dextrin, dried invert sugar, fructose, levulose, galactose, corn syrup, and mixtures thereof. Suitable sugar substitutes include sorbitol, mannitol, xylitol, hydrogenated starch hydrolysates, maltitol, and mixtures thereof. Furthermore, so-called HIAS ("High Intensity Artificial Sweeteners") are also considered as additives, such as sucralose, aspartame, acesulfame salts, alitame, saccharin and saccharin salts, cyclamic acid and its salts, glycyrrhizins, dihydrochalcones, thaumatin, monellin and the like, alone or in mixtures.Hydrophobic HIAS, which are the subject of international patent application WO 2002 091849 A1 (Wrigley's), as well as stevia extracts and their active components, especially ribeaudioside A, are also particularly effective. The amount of these substances used depends primarily on their potency and is typically in the range of 0.02 to 8% by weight.
[0372] Fillers such as polydextrose, raftilose, raftilin, fructooligosaccharides (NutraFlora), palatinose oligosaccharides, guar gum hydrolysate (Sun Fiber) and dextrins are particularly suitable for the production of low-calorie chewing gum.
[0373] The selection of other flavorings is practically unlimited and uncritical to the essence of the invention. Typically, the total proportion of all flavorings is between 0.1 and 15% by weight, and preferably between 0.2 and 5% by weight, based on the chewing gum composition. Suitable additional flavorings include, for example, essential oils, synthetic flavorings, and the like, such as anise oil, star anise oil, caraway oil, eucalyptus oil, fennel oil, lemon oil, wintergreen oil, clove oil, and the like, as are also used, for example, in oral and dental care products.
[0374] The chewing gum may also contain excipients and additives suitable for dental care, specifically for combating plaque and gingivitis, such as chlorhexidine, CPC, or trichlosan. Furthermore, it may contain pH regulators (e.g., buffers). or urea), active ingredients against caries (e.g. phosphates or fluorides), biogenic active ingredients (antibodies, enzymes, caffeine, plant extracts) may be included, as long as these substances are approved for use in food and do not interact with each other in an undesirable way.
[0375] The present invention also includes cooling plasters. Plasters according to the invention can be constructed in any way, for example according to the matrix system, the membrane system or the nonwoven system.
[0376] The plasters according to the invention are manufactured in the usual way.
[0377] The matrix system consists of three simple parts: a flexible support film, an adhesive matrix containing the active ingredient, and a release liner. If a non-adhesive matrix is used, an edge zone of the support film must be coated with adhesive to ensure adhesion to the skin.
[0378] In contrast, a membrane system has at least 5 parts: a flexible support film, a reservoir with dissolved or suspended active ingredient, a membrane for controlling the release of the active ingredient, an adhesive layer applied to the membrane, and a release film.
[0379] In nonwoven systems, the active ingredient layer consists of an absorbent nonwoven fabric or porous polymer impregnated with an active ingredient solution or suspension. This layer, which is firmly bonded to the backing film, is covered by a release liner. The edge of the backing film is coated with adhesive for application to the skin.
[0380] In principle, all active ingredients according to the invention can be formulated in this way. The excipients to be used are those customary for the manufacture of plasters. In addition to the adhesive agent, generally a polymer with a glass transition temperature between -70 and -10 °C, in particular -55 and -25 °C, and a carrier film coated with this adhesive agent, and the active ingredient, emulsifiers, thickeners, substances intended to influence the release of the active ingredient, and other excipients are frequently added.
[0381] The sticky polymers with the aforementioned low glass transition temperatures are known. The self-adhesive tapes and films are intended to adhere to human skin on mere contact, but the cohesion of the adhesive layer and its adhesion to the backing film should be greater than the adhesion to the skin, allowing them to be removed largely without leaving any residue. These are generally copolymers based on acrylic and methacrylic acid esters of alcohols with 2 to 12, particularly 4 to 8, carbon atoms, which may contain numerous other comonomers polymerized into them, for example, (meth)acrylic acid, (meth)acrylonitrile, (meth)acrylamide, N-tert-butyl-(meth-)acrylamide, vinyl esters such as vinyl acetate, propionate, or butyrate, other vinyl compounds such as styrene, and also butadiene. Butyl acrylate and 2-ethylhexyl acrylate are particularly noteworthy. The polymers can be modified by adding small amounts of comonomers with 2 or more carbon atoms. These polymers can be cross-linked by copolymerizable double bonds, for example, those of diacrylates such as butanediol diacrylate, or divinyl compounds such as divinylbenzene, or by the addition of other cross-linking agents, e.g., melamine-formaldehyde resins. Polyisobutylenes and polyvinyl ethers of varying molecular weights can also be used as sticky polymers.
[0382] The particle size of the dispersions should be between 50 and 500 nm, particularly between 50 and 200 nm. The particle size and degree of cross-linking can be adjusted in a known manner depending on the polymerization conditions and the comonomers. Smaller particle sizes and a higher degree of cross-linking can lead to increased drug release.
[0383] Matrix patches can be manufactured in the usual way by dissolving or finely dispersing the active ingredient in a suitable polymer solution and then drawing this drug-containing self-adhesive mass into a film using roller or doctor blade application methods. In some cases, it is advantageous to dissolve or finely disperse the active ingredient in an organic solvent, e.g., ethanol or acetone, before adding it to the polymer solution. This can achieve better distribution of the active ingredient within the polymer.
[0384] The patches can also be produced by incorporating the active ingredient in fine powder form (particle size below 200 pm, particularly below 50 pm) into the aqueous latex dispersion, or by dispersing or dissolving it in an aqueous emulsifier solution and adding this mixture to the aqueous latex dispersion at a temperature of 10 to 80 °C, particularly 30 to 70 °C. Alternatively, the salt of an active ingredient in aqueous solution can be mixed with the polymer dispersion at a pH value at which the active ingredient is predominantly present in its water-soluble ionized form. By shifting the pH, the active ingredient is then converted into its uncharged, water-insoluble form and simultaneously imulsified into the dispersion.
[0385] The active ingredient is conveniently placed first, followed by the emulsifier and water, and then mixed with the polymer dispersion. The resulting active ingredient-containing dispersion is optionally combined with further excipients and, as mentioned, drawn onto a support film in a known manner and dried. The drying temperature can range from room temperature to 100 °C, with an optimum between the desired rapid drying time and the avoidance of bubble formation in the film, as well as thermal stress on the active ingredient, generally being between 35 and 45 °C. This method has the significant advantage of avoiding organic solvents. However, in principle, all other common manufacturing processes for matrix patches are also suitable.
[0386] The resulting films have thicknesses of 10 to 800 µm, preferably 50 to 300 µm. Film production can be continuous or batch. The deposition process This process can be repeated several times until the film reaches the desired thickness. The sticky polymer layer contains the active ingredient in a concentration ranging from 1 to 40 wt%, particularly 5 to 25 wt%. The same concentration applies to the reservoir fluid in the membrane system and to the active ingredient solution or dispersion used to impregnate the nonwoven fabric or porous polymer in the nonwoven system.
[0387] The surfactants commonly used for this purpose are employed as emulsifiers for both the active ingredients according to the invention, i.e. the cooling agent or the cooling agent mixture or the flavor preparation according to the invention, as well as the polymers, such as the sodium salt of long-chain fatty acids and the sulfuric acid half-ester of a (possibly oxyethylated) fatty alcohol as examples of anionic surfactants, as well as polyoxyethylated alkylphenols and long-chain fatty alcohols (e.g. hexadecan-(l)-ol) and glycerol fatty acid partial esters as examples of non-ionic surfactants and co-emulsifiers.
[0388] The desired viscosity of the ready-to-draw compound can be adjusted, for example, with polyacrylic acids or cellulose derivatives. Melamine-formaldehyde resins, for example, can be used as additional crosslinking agents to improve cohesion and thus the adhesive properties of the films.
[0389] To improve drug release, swelling agents such as polyvinylpyrrolidone, cellulose derivatives, or polyacrylates are used because the film can absorb more water, thereby reducing diffusion resistance. Drug release can be further enhanced by adding hydrophilic plasticizers such as glycerin, 1,2-propanediol, or polyethylene glycols, and lipophilic plasticizers such as triacetin, dibutyl phthalate, or isopropyl myristate.
[0390] Matrix patches typically result in first-order drug release. The use of fillers that adsorb the drug, such as Aerosil, microcrystalline cellulose, or lactose, results in an almost zero-order release.
[0391] The backing film, onto which the drug-containing adhesive is dried, is advantageously practically impermeable to both the active ingredient and water vapor. It can consist, for example, of an aluminum-plastic composite film, a metallized plastic film, a plastic film with a barrier layer of, for example, polyvinylidene chloride on the drug-containing side, or a simple plastic film, such as a polyester film.
[0392] The patches according to the invention, which are based on the membrane system, are also manufactured in the usual manner. The patches based on the nonwoven system are manufactured by impregnating nonwovens or porous polymers attached to the backing film with a solution or dispersion of the active ingredient in a hydrophilic or lipophilic solvent or solvent mixture. The impermeable release liner is then applied.
[0393] In principle, the active ingredient content in the preparations according to the invention can vary over a wide range, such as 0.1 ppm to 10 wt.%, preferably 1 ppm to 10 wt.%.
[0394] Furthermore, the present invention relates to textile products equipped with a cooling agent or a cooling agent mixture according to the invention.
[0395] The treatment of textiles with cooling agents is particularly useful where garments can come into direct contact with the skin, allowing the active ingredient to exert its effects, e.g., locally or systemically, through transdermal transfer. Recently, reports have surfaced on textiles treated with so-called wellness additives, i.e., substances that promote well-being.
[0396] Insecticidal treatment, in turn, is of interest with regard to material protection, e.g., treating textiles against moth damage, etc., but especially also for repelling parasitic insects such as mosquitoes.
[0397] A fundamental problem in treating textiles with active ingredients is the binding of the active ingredient to the textile substrate. This binding must, on the one hand, ensure the permanence of the treatment and, on the other hand, be chosen in such a way that the active ingredient does not lose its effectiveness. Various approaches are proposed in the prior art to address this.
[0398] For example, cyclodextrins have been proposed for binding active ingredients to textiles. Cyclodextrins are cyclic oligosaccharides formed by the enzymatic breakdown of starch. The most common cyclodextrins are α-, β-, and γ-cyclodextrins, which consist of six, seven, and eight α-1,4-linked glucose units, respectively. A characteristic property of cyclodextrin molecules is their ring structure with largely unchanging dimensions. The inner diameter of the rings is approximately 570 pm for α-cyclodextrin, approximately 780 pm for β-cyclodextrin, and approximately 950 pm for γ-cyclodextrin. Due to their structure, cyclodextrins are able to encapsulate guest molecules, especially hydrophobic ones, in varying amounts until saturation is reached.
[0399] The prior art describes the finishing of textiles with fragrances and other low-molecular-weight organic active ingredients, which are bound to the textile via an amylose-containing substance with an amylose content of at least 30%. The amylose component of the amylose-containing substance binds the active ingredient to the textile and releases it in a controlled manner, thus maintaining its effect over a long period. It is assumed that, similar to cyclodextrins, the active ingredient acts as an inclusion compound within the cavities formed by the helical conformation of the amylose. It is reversibly bound, which on the one hand achieves a fixation of the active ingredient on the surface of the textile carrier and on the other hand allows a controlled release.
[0400] For the finishing of textiles according to the invention, in addition to amylose, all substances are suitable in principle, in particular starches containing amylose, i.e., native starches, modified starches, and starch derivatives, whose amylose content is at least 30% by weight and, in particular, at least 40% by weight. The starch can be native, e.g., corn starch, wheat starch, potato starch, sorghum starch, rice starch, or maranta starch, obtained by partial hydrolysis of native starch, or chemically modified. Pure amylose as such is also suitable, e.g., enzymatically produced amylose, e.g., amylose derived from sucrose. Mixtures of amylose and starch are also suitable, provided that the total amylose content is at least 30% by weight, based on the total weight of the mixture. It is understood that all values given here and in the following are in weights.-%, which refers to amylose or amylose-containing substances, in mixtures of amylose and starch, always refers to the total weight of amylose + starch, unless expressly stated otherwise. According to the invention, amylose-containing substances, in particular amylose and amylose-containing starches, as well as amylose / starch mixtures, are particularly suitable, provided their amylose content is at least 40% by weight and, in particular, at least 45% by weight, based on the total weight of the substance. As a rule, the amylose content will not exceed 90% by weight and, in particular, 80% by weight. Such substances are known and commercially available. For example, amylose-containing starches are marketed by Cerestar under the trade name Amylogel® and by National Starch under the trade names HYLON® V and VII.
[0401] To achieve binding of the active ingredient(s) to the textile, the textile can generally be treated with the amylose-containing substance in an amount of at least 0.5 wt.%, preferably at least 1 wt.%, and particularly at least 2 wt.%, based on the weight of the textile. As a rule, the amylose-containing substance will be used in an amount of no more than 25 wt.%, often no more than 20 wt.%, and particularly no more than 15 wt.%, based on the weight of the textile, in order not to adversely affect the tactile properties of the textile. First, the textile material is treated with the amylose-containing substance as such, and then the treated textile is treated with a suitable preparation of the active ingredient. This loads the amylose-containing substance on the textile material with the active ingredient.However, the amylose-containing substance can also be used together with an active ingredient to finish the textile. The active ingredient and the amylose-containing substance can be used either as a mixture of separate components or in the pre-formulated form of the amylose-active ingredient complex. Generally, the active ingredient is used in an amount sufficient for the desired effect. The upper limit is determined by the maximum absorption capacity of the amylose units in the amylose-containing substance used and will generally not exceed 20% by weight, and often 10% by weight, based on the amylose content of the substance. If desired, the active ingredient is usually added in an amount of 0.00001 to 15% by weight. 0.0001 to 10 wt%, 0.001 to 5 wt%, 0.005 to 1 wt% or 0.1 to 10 wt% or 0.5 to 5 wt%, based on the amylose content of the amylose-containing substance.
[0402] For textile finishing, combinations of active ingredients according to the invention with other active ingredients known per se and suitable for textile finishing can also be used.
[0403] In principle, all organic compounds and mixtures of organic compounds known to be active substances and capable of inducing a physiological effect in living organisms such as humans and animals, including microorganisms, are suitable as further active ingredients. This includes active ingredients known to form inclusion compounds with cyclodextrins. Particularly suitable are active ingredients containing hydrocarbon groups, especially aliphatic, cycloaliphatic, and / or aromatic structures. The molecular weight of the active ingredients is typically below 1000 Daltons and often in the range of 100 to 600 Daltons. Inorganic compounds such as hydrogen peroxide, which are known to bind in cyclodextrins, are also suitable.
[0404] Other active ingredients include, in particular, pharmaceutical agents and those that promote the well-being of living beings, especially humans, and which are commonly referred to as "wellness additives." Unlike pharmaceutical agents, wellness additives do not necessarily have a therapeutic effect. Rather, their well-being-promoting effect can be based on a variety of factors such as nourishing, stimulating, cosmetic, or other effects. Organic active ingredients that act against parasitic organisms are equally suitable. These include, for example, active ingredients that act against fungi and / or microorganisms, such as fungicides and bactericides, or those that act against animal pests such as slugs, worms, mites, insects, and / or rodents, such as nematicides, molluscicides, insecticides, acaricides, rodenticides, and repellents, as well as active ingredients against weeds, i.e., herbicides, or fragrances.
[0405] Preferred pharmaceutical agents are those known to be absorbed through the skin. Examples include ibuprofen, flurbiprofen, acetylsalicylic acid, acetamidophene, apomorphine, butylated hydroxytoluene, chamzulene, gujazulene, chlorthalidone, cholecalciferol, dicumarol, digoxin, diphenylhydantoin, furosemide, hydroflumethiazide, indomethacin, iproniazid phosphate, nitroglycerin, nicotine, nicotinamide, oubine, oxprenolol, papaverine alkaloids such as papaverine, laudanosine, ethaverine and narcotine, as well as berberine, retinol, trans-retinoic acid, pretinol, spironolactone, sulpiride, theophylline, theobromine, corticosteroids and derivatives such as testosterone, 17-methyltestosterone, cortisone, corticosterone, dexamethasone, triamcinolone. Methylprednisolone, fludrocortisone, fluocortolone, prednisone, prednisolone, progesterone, among othersEstrogens and progestogens such as estradiol, estriol, ethinylestradiol-3-methyl ether, norethisterone and ethisterone, as well as phenethylamine and derivatives such as tyramine, adrenaline, noradrenaline and. Dopamine. Examples of suitable active substances according to the invention with an effect against parasitic organisms are, for example, nematicides, bactericides, fungicides, insecticides, insect repellents, acaricides, and molluscicides. Examples of bactericidal and fungicidal substances include: Antibiotics, for example cycloheximide, griseofulvin, kasugamycin, natamycin, polyoxin, streptomycin, penicillin or gentamycin; Organic compounds and complexes of biocidal metals, e.g., complexes of silver, copper, tin and / or zinc such as bis-(tributylltin) oxide, copper, zinc and tin naphthenates, oxine coppers such as Cu-8, tris-N-(cyclohexyldiazeniumdioxy)-aluminium, N-(cyclohexyldiazeniumdioxy)-tributyltin, bis-N-(cyclohexyldiazeniumdioxy)-copper; Quaternary ammonium salts, e.g. benzyl-Cs- to cis-alkyldimethylammonium halides, especially chlorides (benzalkonium chlorides); Aliphatic nitrogen fungicides and bactericides such as cymoxanil, dodine, dodicin, guazidine, iminoctadine, dodemorph, fenpropimorph, fenpropidin, tridemorph; Substances with peroxide groups such as hydrogen peroxide, and organic peroxides such as dibenzoyl peroxide; Organic chlorine compounds such as chlorhexidine; triazole fungicides such as azaconazole, cyproconazole, diclobutrazol, difenoconazole, diniconazole, epoxiconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, metconazole, propiconazole, tetraconazole, tebuconazole and triticonazole; strobilurins such as dimoxystrobin, fluoxastrobin, kresoxim-methyl, metominostrobin, orysastrobin, picoxystrobin, pyraclostrobin and trifloxystrobin; Sulfonamide wie Tolylfluanid und Diclofluanid; lodverbindungen wie Diiodmethyl-p-tolylsulfon, Napcocide 3-lod-2-propinylalkohol, 4- Chlorphenyl-3-iodpropargylformal, 3-Brom-2,3-diiod-3-propenylethylcarbonat, 2,3,3- Triiodallylalkohol, 3-lod-2-propinyl-n-hexylcarbamat, 3-Brom-2,3-diiod-2-propenylalkohol, 3- lod-2-propinylphenylcarbamat, 3-lod-2-propinyl-n-butylcarbamat, 0-1-(6-lod-3-oxohex-5- inyl)phenylcarbamat, 0-1-(6-lod-3-oxohex-5- inyl)butylcarbamat; Isothiazolinone wie N-Methylisothiazolin-3-on, 5-Chloro-N-methylisothiazolin-3-on, 4,5- Dichloror-N-octylisothiazolin-3-on, 1 ,2-Benzisothiazol-3(2H)on, 4,5-T rimethylisothiazol-3-on und N-Octyl-isothiazolin-3-on.
[0406] Beispiele für Insektizide und Acarizide sind: Organophosphate wie Acephate, Azamethiphos, Azinphos-methyl, Chlorpyrifos, Chlorpyriphos-methyl, Chlorfenvinphos, Diazinon, Dichlorvos, Dicrotophos, Dimethoate, Disulfoton, Ethion, Fenitrothion, Fenthion, Isoxathion, Malathion, Methamidophos, Methidathion, Methyl-Parathion, Mevinphos, Monocrotophos, Oxydemeton-methyl, Paraoxon, Parathion, Phenthoate, Phosalone, Phosmet, Phosphamidon, Phorate, Phoxim, Pirimiphos-methyl, Profenofos, Prothiofos, Sulprophos, Triazophos, Trichlorfon; insbesondere Pyrethroide wie Acrinatrin, Allethrin, Bioallethrin, Barthrin, Bifenthrin, Bioethanomethrin, Cyclethrin, Cycloprothrin, Cyfluthrin, beta- Cyfluthrin, Cyhalothrin, gamma-Cyhalothrin, lambda-Cyhalothrin, Cypermethrin, a- Cypermethrin, ß-Cypermethrin, A-Cypermethrin, zeta-Cypermethrin, Cyphenothrin, Deltamethrin, Dimefluthrin, Dimethrin, Empenthrin, Fenfluthrin, Fenprithrin, Fenpropathrin, Fenvalerate, esfenvalerate, flucythrinate, fluvinates, tau-fluvinates, furethrin, permethrin, biopermethrin, trans-permethrin, phenothrin, prallethrin, profluthrin, pyresmethrin, resmethrin, bioresmethrin, cismethrin, tefluthrin, terallethrin, tetramethrin, tralomethrin, transfluthrin, etofenprox, flufenprox, halfenprox, protrifenbute and silafulfen; pyrrole and pyrazole insecticides such as acetoprole, ethiprole, fipronil, tebufenpyrad, tolfenpyrad, chlorfenapyr and vaniliprole.
[0407] Examples of repellent active ingredients include, in particular, anthraquinone, acridine bases, copper naphthenate, butopyronoxyl, dibutyl phthalate, dimethyl phthalate, dimethyl carbate, ethohexadiol, hexamides, methoquinobutyl, N-methylneodecanamide, camphor, bergamot oil, pyrethrum, clove oil, geranium oil, thyme oil and, in particular, diethyl-m-toluamide and 1-piperidinecarboxylic acid-2-(2-hydroxyethyl)-1-methylpropyl ester (picardin). Examples of wellness additives include, in particular, the following substances and mixtures of substances, e.g., fats, preferably of plant origin, e.g., lecithins; plant oils such as jojoba oil, tea tree oil, clove oil, evening primrose oil, almond oil, coconut oil, avocado oil, soybean oil, and the like; fatty acids, e.g., omega-6 fatty acids, linolenic acid, linoleic acid; waxes of animal or plant origin such as beeswax, candelilla wax, shea butter, Shorea butter, mango kernel butter, Japan wax, and the like; vitamins, especially fat-soluble vitamins, e.g.Tocopherols, vitamin E, vitamin A and the like, corticosteroids such as cortisone, corticosterone, dexamethasone, triamcinolone, methylprednisolone, fludrocortisone, fluocortolone, prednisone, prednisolone, progesterone, amino acids, e.g. arginine, methionine; plant extracts such as algae extract, horse chestnut extract, mango extract and the like.
[0408] To improve the wash permanence of the finish according to the invention, it has proven effective to fix the amylose-containing substance to the textile with a binder. Suitable binders include, on the one hand, film-forming, water-insoluble polymers and, on the other hand, low-molecular-weight reactive substances that polymerize upon heating. Generally, the binder is used in an amount such that the weight ratio of amylose-containing substance to water-insoluble polymer is in the range of 1:1 to 100:1, preferably in the range of 1.5:1 to 50:1, and particularly in the range of 2:1 to 20:1.
[0409] The film-forming polymers are typically used in the form of an aqueous dispersion of finely divided polymer particles. The particle size is of secondary importance for the success of the invention. However, it is generally below 5 pm (weight average) and typically ranges from 50 nm to 2 pm.
[0410] The film-forming polymer can, in particular, have a glass transition temperature TG in the range of -40 to 100 °C, preferably -30 to +60 °C, and more specifically -20 to +40 °C. If the polymeric binder comprises several polymer components, at least the main component should have a glass transition temperature in this range. In particular, the glass transition temperature of the main component is in the range of -30 °C. The glass transition temperature range is from -20°C to +60°C, and particularly preferably from -20°C to +40°C. Preferably, all polymeric components exhibit a glass transition temperature within this range. The specified glass transition temperatures refer to the midpoint temperature determined by DSC according to ASTM D 3418-82. In the case of crosslinkable binders, the glass transition temperature refers to the uncrosslinked state.
[0411] Examples of suitable film-forming polymers are based on the following Polymer classes: (1) Polyurethane resins; (2) Acrylate resins (pure acrylates: copolymers of alkyl acrylates and alkyl methacrylates); (3) Styrene acrylates (copolymers of styrene and alkyl acrylates); (4) Styrene / butadiene- Copolymers; (5) Polyvinyl esters, in particular polyvinyl acetates and copolymers of vinyl acetate with vinyl propionate; (6) Vinyl ester-olefin copolymers, e.g. vinyl acetate / ethylene copolymers; (7) Vinyl ester-acrylate copolymers, e.g. vinyl acetate / alkyl acrylate copolymers and vinyl acetate / alkyl acrylate ethylene terpolymers.
[0412] Such polymers are known and commercially available, e.g., polymers of classes (2) to (7) in the form of aqueous dispersions under the names ACRONAL, STYROFAN, BUTOFAN (BASF AG), MOWILITH, MOWIPLUS, APPRETAN (Clariant), VINNAPAS, VINNOL (WACKER). Aqueous polyurethane dispersions (1) suitable for the process according to the invention are, in particular, those used for coating textiles. Suitable substances are well known to those skilled in the art. Aqueous polyurethane dispersions are, for example, commercially available under the trade names Alberdingk® (Alberdingk), Impranil® (BAYER AG), Permutex® (Stahl, Waalwijk, Netherlands), and BASF SE, or can be produced according to known processes, such as those described in the relevant technical literature. The film-forming polymers can be self-crosslinking, i.e.,The polymers possess functional groups (crosslinkable groups) that react with each other, with the functional groups of the amylose, or with a low-molecular-weight crosslinker upon drying of the composition, and optionally upon heating, forming bonds. Examples of crosslinkable functional groups include aliphatic OH groups, NH-CH₂-OH groups, carboxylate groups, anhydride groups, disguised isocyanate groups, and amino groups. Often, a polymer is used that still contains free OH groups as reactive groups. Typically, the proportion of reactive functional groups is 0.1 to 3 mol / kg of polymer. Crosslinking within the polymer can be achieved by the reaction of complementary reactive functional groups. Preferably, the polymer is crosslinked by adding a crosslinker that possesses reactive groups complementary in their reactivity to the functional groups of the crosslinker.Suitable pairs of functional groups exhibiting complementary reactivity are known to those skilled in the art. Examples of such pairs are OH / COOH, OH / NCO, NH2 / COOH, NH2 / NCO, and M. 2+ / COOH, where M 2+ for a divalent metalion such as Zn 2+ , Ca 2+ , or Mg 2+Examples of suitable crosslinking agents are the diols or polyols mentioned below for polyurethanes; primary or secondary diamines, preferably primary diamines, e.g., alkylenediamines such as hexamethylenediamine, diethylenetriamine, triethylenetetramine, tetraethylenepentamine, N,N-bis[(aminopropyl)amino]ethane, 3,6-dioxaoctanediamine, 3,7-dioxanonanediamine, 3,6,9-trioxaunediamine or jeffamine, (4,4-diaminodicyclohexyl)methane, (4,4'-diamino-3,3-dimethyldicyclohexyl)methane; amino alcohols such as ethanolamine, hydroxypropylamine; ethoxylated di- and oligoamines; dihydrazides of aliphatic or aromatic dicarboxylic acids such as adipic acid dihydrazide; dialdehydes such as glyoxal; Partially or completely O-methylated melamines, as well as compounds or oligomers which on average have two or more, preferably three or more isocyanate groups or reversibly blocked isocyanate groups, e.g. hydrogen sulfite.In this case, the ratio of crosslinker to polymeric binder is adjusted such that the molar ratio of reactive groups in the polymeric binder (total amount of reactive groups in the polymers) to the reactive groups in the crosslinker is typically in the range of 1:10 to 10:1 and preferably in the range of 3:1 to 1:3. The weight ratio of polymeric binder (calculated as a solid) to crosslinker is usually in the range of 100:1 to 1:1 and particularly in the range of 50:1 to 5:1.
[0413] As an alternative to fixing the amylose-containing substance with water-insoluble polymers, the amylose or the amylose-containing substance can also be fixed to the textile material with reactive compounds that have at least one group reactive towards the OH groups of the amylose and at least one further functional group that is reactive towards the functional groups on the fibers of the textile material, e.g., OH groups, NH₂ groups, or COOH groups. Reactive compounds include the crosslinking agents mentioned above as well as the substances proposed in DE 40 35 378 A for fixing cyclodextrins, e.g.,N-Hydroxymethyl and N-alkoxymethyl derivatives of urea or urea-like compounds such as dimethylolurea (bis(hydroxymethyl)urea), di(methoxymethyl)urea, dimethylolalkanediol diurethanes such as N,N-dimethylolethyleneurea (N,N-bis(hydroxymethyl)imidazolin-2-one), N,N-dimethylol-dihydroxyethyleneurea (N,N-bis(hydroxymethyl)-4,5-dihydroxyimidazolin-2-one), dimethylolpropylene urea, and the like. Such materials are commercially available in aqueous formulations for textile finishing, e.g., under the trade names Fixapret® and Fixapret®-eco from BASF SE. Reactive materials that can be used to fix the amylose-containing substance to the textile material include, in particular, compounds with 2, 3, 4 or more (possibly reversibly blocked) isocyanate groups, especially those with bisulfite or CH-acidic compounds or oximenes, e.g.Butanone oxime reversibly blocked polyisocyanate prepolymers based on polyether and polyester urethanes, as described in DE 2837851, DE 19919816 and the earlier patent application EP 03015121. Such products are also commercially available, for example under the trade names PROTOI-AN® 367 and PROTOI-AN® 357 from Rotta GmbH, Mannheim.
[0414] The procedure known for fixing cyclodextrins can also be used analogously to fix the amylose-containing substance, whereby the cyclodextrin, or in this case the amylose-containing substance, is provided with reactive anchors, for example by reacting it with dicarboxylic acids or dicarboxylic anhydrides such as maleic acid, fumaric acid, maleic anhydride, succinic acid, succinic anhydride or adipic acid, with diisocyanates, e.g. toluene diisocyanate, isophorone diisocyanate, tetramethylene diisocyanate or hexamethylene diisocyanate, or with aminocarboxylic acids in a manner known per se, such that only one of the functionalities present in these compounds reacts with the OH groups of the amylose-containing substance and the other remains available for attachment to the reactive groups of the fiber material.Reactive anchors can also be generated on the amylose-containing substance by reaction with 1,3,5-trichlorotriazine, 2,3-dichloroquinoxaline-5,6-carboxylic acid chloride, and chlorodifluoropyrimidine. Furthermore, alkoxysilanes such as diethoxydimethylsilane, dimethoxydimethylsilane, triethoxyphenylsilane, tetraethoxysilane, and dimeric, trimeric, and higher condensation products of these compounds can also be used to fix the amylose.
[0415] In this way, virtually all textile materials can be finished, i.e., both unfinished and finished goods. Textile materials, as used here and in the following, include woven, knitted, and nonwoven fabrics. These materials can be composed of natural fiber yarns, synthetic fiber yarns, and / or blended yarns. In principle, all fiber materials commonly used in textile production are suitable. These include cotton, wool, hemp fiber, sisal fiber, flax, ramie, polyacrylonitrile fiber, polyester fiber, polyamide fiber, viscose fiber, silk, acetate fiber, triacetate fiber, aramid fiber, and the like, as well as blends of these fiber materials.
[0416] The finishing or treatment of the textile materials with the amylose-containing substance can be carried out in a manner known per se, e.g. by means of methods described for the finishing of textiles with cyclodextrins.
[0417] Examples include processes in which the amylose-containing substance, possibly as a complex with the active ingredient, is already spun into the fiber, filament and / or yarn from which the fabric is made.
[0418] However, the textile material is often treated with the amylose-containing substance or a complex of amylose-containing substance and active ingredient before or after garment production. This is usually done by treating the textile with an aqueous solution containing a sufficient quantity of the amylose-containing substance and, if applicable, the active ingredient. Depending on the application method and the desired quantity of amylose-containing substance to be applied, the concentration of the amylose-containing substance in the solution ranges from 1 to 40% by weight, particularly from 2 to 20% by weight, and specifically from 4 to 15% by weight.
[0419] The type of treatment is of secondary importance and can be carried out, for example, as a minimal application (e.g., by spraying), as a normal application using a foulard, or as a high-moisture application. In this case, the textile material is saturated with the aqueous solution. If necessary, excess solution can then be removed, e.g., by squeezing to a solution absorption of approximately 30 to 120%. Another way to treat the textile with an amylose-containing substance or a complex of amylose-containing substance and active ingredient is to prepare a solution with water containing the desired amount of amylose-containing substance and, if applicable, active ingredient, e.g., 0.5 to 20% by weight (based on the mass of the textile to be finished). The textile material is then immersed in the treatment solution for a certain period of time, e.g., 10 to 60 minutes, in suitable finishing equipment (e.g., reel skid, roller skid, paddle, etc.).) soaked and then squeezed and / or spun off as described above. The fleet ratio is generally in the range of 1:2 to 1:50 and especially in the range of 1:3 to 1:20.
[0420] Such methods are known to those skilled in the art from the relevant technical literature.
[0421] Treatment with the liquor is generally followed by a drying process. Temperatures are typically in the range of 100 to 200 °C, and preferably in the range of 120 to 180 °C. Drying can be carried out using standard equipment; for finished goods, for example, by dry tumble drying at the temperatures specified above. For unfinished goods, the textile material is usually passed over one or more tumbler frames after the drying process.
[0422] If the amylose-containing substance is used together with a film-forming polymer, drying leads to the fixation of the amylose-containing substance onto the textile fibers. The drying temperature is generally not to fall below 100 °C and is preferably in the range of 120 to 200 °C, and particularly in the range of 140 to 180 °C. Drying generally takes place over a period of 1 to 10 minutes, particularly 1 to 2 minutes, although longer drying times are also suitable. For treatment with an aqueous solution, it has proven advantageous if the aqueous solution contains, in addition to the amylose-containing substance and optionally the active ingredient, at least one surfactant (or interfacial active substance) suitable for dispersing the amylose-containing substance and the active ingredient in the aqueous solution.Preferably, the surfactant is an oligomeric or polymeric dispersant. In contrast to low-molecular-weight surfactants, the term oligomeric or polymeric dispersant encompasses dispersants whose number-average molecular weight is generally at least 2000 Daltons, e.g., 2000 to approximately 100,000 Daltons, and particularly in the range of approximately 3000 to 70,000 Daltons. The aqueous solution typically contains the polymeric or oligomeric dispersant in an amount of 0.5 to 20% by weight. preferably 1 to 18 wt.% and in particular 5 to 15 wt.%, based on the amylose-containing substance.
[0423] Suitable oligomeric or polymeric dispersants are water-soluble and include both neutral and amphoteric water-soluble polymers as well as cationic and anionic polymers, the latter being preferred. Examples of neutral polymeric dispersants are polyethylene oxide, ethylene oxide / propylene oxide copolymers, preferably block copolymers, polyvinylpyrrolidone, and copolymers of vinyl acetate with vinylpyrrolidone.
[0424] Preferred anionic oligomeric or polymeric dispersants are characterized by the presence of carboxyl and / or sulfonic acid groups and are typically used as salts, e.g., alkali metal salts or ammonium salts. Preferred anionic dispersants include, for example, carboxylated cellulose derivatives such as carboxymethylcellulose, homopolymers of ethylene-unsaturated C3- to C8 mono- and C4- to C8 dicarboxylic acids, e.g., acrylic acid, methacrylic acid, maleic acid, itaconic acid, copolymers of at least two different ethylene-unsaturated C3- to C8 mono- and C4- to C8 dicarboxylic acids as mentioned above, and copolymers of at least one of the aforementioned ethylene-unsaturated C3- to C8 mono- or C4- to C8 dicarboxylic acid with at least one neutral comonomer.Examples of neutral comonomers include N-vinyl lactams such as N-vinylpyrrolidone, vinyl esters of aliphatic C2 to C16 carboxylic acids such as vinyl acetate, vinyl propionate, amides of the aforementioned ethylene-unsaturated carboxylic acids, such as acrylamide, methacrylamide and the like, hydroxy-C1 to C4-alkyl(meth)acrylates such as hydroxyethyl acrylate and methacrylate, esters of ethylene-unsaturated C3 to C8 mono- or C4 to C8 dicarboxylic acids with polyethers, e.g., esters of acrylic acid or methacrylic acid with polyethylene oxides or ethylene oxide / propylene oxide block copolymers, vinyl aromatics such as styrene and C2 to C16 olefins such as ethylene, propene, 1-hexene, 1-octene, 1-decene, 1-dodecene and the like. Homopolymers of ethylene-unsaturated sulfonic acids such as styrenesulfonic acid and acrylamidopropanesulfonic acid, and their copolymers with the aforementioned comonomers, are also preferred. In the copolymers, the proportion of the ethylene-unsaturated acid is generally at least 20 wt.-% and not exceed 90 wt% and, in particular, 80 wt%, in each case based on the total weight of all monomers constituting the polymer. Copolymers of at least one of the above-mentioned acids and at least one comonomer are known and commercially available for this purpose, for example, the copolymers of acrylic acid and maleic acid under the Sokalan trademarks of BASF SE.
[0425] Other preferred anionic dispersants are phenolsulfonic acid-formaldehyde condensates and naphthalenesulfonic acid-formaldehyde condensates (e.g., BASF's Tamol and Setamol brands) and lignosulfonates.
[0426] Suitable dispersants also include low-molecular-weight anionic, non-ionic, cationic, ampholytic, and zwitterionic surfactants. Suitable surfactants are: For example, the alkali metal, ammonium, or amine salts of C8 to C18 alkyl sulfates, such as sodium lauryl sulfate; C8 to C18 alkyl sulfonates, such as dodecyl sulfonate; C8 to C18 alkyl ether sulfates; as well as C8 to C18 alkyl ethoxylates; polyoxyethylene sorbitan esters; C8 to C18 alkyl glycinates; C8 to C18 alkyl dimethylamine oxides; betaines, etc. Alkyl sulfates and alkyl sulfonates are preferred.
[0427] If the amylose-containing substance is not used together with a film-forming, water-insoluble polymer, the textile can be treated with the polymer in a separate step. In particular, the treatment is carried out together with the amylose-containing substance. Accordingly, a particular embodiment relates to a process in which the aqueous bath additionally comprises a dispersed, film-forming, water-insoluble polymer of the type described above. The amount of film-forming polymer is selected such that the weight ratio of amylose-containing substance to water-insoluble polymer is in the range of 1:1 to 100:1, preferably in the range of 1.5:1 to 50:1, and particularly in the range of 2:1 to 20:1.
[0428] The treatment of the textile with the cooling agent or the cooling agent mixture according to the invention can be carried out in a separate process or in one step together with the treatment with the amylose-containing substance.
[0429] If the textile is treated with the active ingredient in a separate step, it is advantageous to also treat the textile with an aqueous solution of the active ingredient. For this purpose, the active ingredient, which is usually insoluble in water, is generally emulsified or dispersed in water, optionally using suitable surfactants. Suitable surfactants include, in particular, the aforementioned low-molecular-weight surfactants, and preferably nonionic surfactants, especially polyoxyethylene sorbitan esters, esters of mono- or oligosaccharides with C6 to C18 fatty acids, and particularly preferably C8 to C18 alkyl ethoxylates, especially those with a degree of ethoxylation in the range of 6 to 50.
[0430] The aqueous solution typically contains the active ingredient in an amount of 0.1 to 10 wt%, and particularly in an amount of 0.2 to 5 wt%. The amount of surfactant is typically in the range of 0.5 to 50 wt%, and particularly in the range of 3 to 30 wt%, based on the active ingredient. The active ingredient can be applied from the aqueous solution using standard methods, e.g., by means of a foulard. Alternatively, the application of the active ingredient and the amylose-containing substance can be carried out in a single step. In principle, the procedure for application with the amylose-containing substance can be the same, except that the aqueous solution now additionally contains at least one active ingredient. The active ingredient can be added to the solution separately or in the form of an inclusion compound, i.e., as a host-guest complex with the amylose-containing substance.
[0431] The cooling agents or cooling agent mixtures according to the present invention can be used for finishing any textiles, i.e., both unfinished and finished goods. Textile materials include, here and in the following, woven fabrics, knitted fabrics, and nonwovens. The textile materials can be composed of natural fiber yarns, synthetic fiber yarns, and / or blended yarns. In principle, all fiber materials commonly used in the manufacture of textiles are suitable. These include cotton, wool, hemp fiber, sisal fiber, flax, ramie, polyacrylonitrile fiber, polyester fiber, polyamide fiber, viscose fiber, silk, acetate fiber, triacetate fiber, aramid fiber, and the like, as well as mixtures of these fiber materials. Glass fibers and mixtures of the aforementioned fiber materials with glass fibers, e.g., glass fiber / Kevlar mixtures, are also suitable.The type of textile material depends primarily on the intended application. The textiles to be finished can include ready-made products such as clothing, including underwear and outerwear (e.g., shirts, trousers, jackets), outdoor, trekking, and military equipment, roofing, tents, nets (e.g., insect screens and curtains), hand and bath towels, bed linen, and the like. Finishing can also be carried out on raw materials in bale or roll form.
[0432] With an amylose-based active ingredient finish, the active ingredients remain in the treated textiles even after several washes. Furthermore, these treated textiles are characterized by a pleasant feel, which is particularly advantageous for the wearing comfort of clothing made from them.
[0433] Textiles treated with active ingredients against parasitic organisms such as insects and mites are not only suitable for protecting humans, but also particularly for animal protection against ticks, mites, fleas and the like.
[0434] The present invention also relates to cooling tobacco products.
[0435] The active ingredients according to the invention, i.e., the cooling agent, the cooling mixture, or the flavor preparation, can advantageously also be used for the manufacture of tobacco products. Examples of such tobacco products include cigars, cigarettes, pipe tobacco, chewing tobacco, and snuff. The manufacture of tobacco products supplemented with cooling additives is known per se.
[0436] In principle, the active ingredient content, i.e., the content of the refrigerant or refrigerant mixture according to the invention, can vary over a wide range, such as 0.05 ppm to 10 wt.%, preferably 0.1 ppm to 10 wt.%.
[0437] The active ingredients according to the invention are also advantageously suitable for the production of packaging materials.
[0438] The manufacturing process is also known per se. The active ingredients can be incorporated into the packaging material, either in free or encapsulated form, or applied to the packaging material, either in free or encapsulated form. Thus, appropriately equipped plastic packaging materials can be produced according to the literature on the production of polymer films. The production of suitably coated papers is also known to those skilled in the art.
[0439] Ultimately, the present invention relates to a method for modulating, in particular in vitro and / or in v / o modulation, the cold menthol receptor TRPM8, comprising the following steps: (i) Providing at least one physiological cooling agent or a physiological cooling agent mixture according to the invention or providing a cosmetic or pharmaceutical preparation according to the invention; and (ii) Bringing the cooling agent or cooling agent mixture or the cosmetic or pharmaceutical preparation from step (i) into contact with the receptor; or producing a physiological cooling effect on skin or mucous membrane, comprising the following steps: (iii) Providing at least one physiological cooling agent or a physiological cooling agent mixture according to the invention or providing a cosmetic or pharmaceutical preparation according to the invention; and (iv) the coolant or coolant mixture or the cosmetic or pharmaceutical preparation from step (iii) with human skin or mucous membrane; or to improve the taste properties of flavorings comprising the following steps: (v) Providing at least one physiological cooling agent or a physiological cooling agent mixture according to the invention or providing a cosmetic or pharmaceutical preparation according to the invention and at least one flavoring agent; (vi) Mixing the two components; and, if necessary, (vii) Incorporation of the mixture into an oral preparation.
[0440] Further aspects of the present invention will become apparent from the following examples and the attached patent claims. Examples
[0441] The following examples serve to illustrate the invention without limiting it. Unless otherwise stated, all specifications refer to weight.
[0442] Active ingredient production: The active ingredients / cooling agents used according to the invention can be produced by a person skilled in the art in the field of organic synthesis in accordance with known synthesis methods, as described in more detail below.
[0443] Cloning of human TRPM8
[0444] The starting point for cloning the human TRPM8 receptor is an LnCaP cDNA library. This is commercially available, for example (e.g., from BioChain, Hayward, USA), or can be produced from the androgen-sensitive human prostate adenocarcinoma cell line LnCaP (e.g., ATCC, CRL1740 or ECACC, 891 1021 1) using standard kits.
[0445] The coding TRPM8 sequence (see, for example, http: / / www.ncbi.nlm.nih.gov / entrez / viewer.fcgi?db=nuccore&id=109689694) can be PCR-amplified and cloned using standard methods. The human TRPM8 gene isolated in this way was used to produce the plnd_M8 plasmid. Alternatively, the TRPM8 gene can also be synthesized.
[0446] Generation of HEK293 test cells
[0447] A stably transfected HEK293 cell line was generated using human TRPM8 DNA as a test cell system. HEK293 is preferred because the introduced plasmid allows for the induction of TRPM8 expression via tetracycline.
[0448] Methods for producing suitable test cell systems are known to those skilled in the art and can be found in the relevant technical literature.
[0449] Assay on TRPM8 modulators
[0450] A test is performed, similar to the one already described in the literature by Behrendt HJ et al., Br. J. Pharmacol. 141, 2004, 737-745. Agonization or antagonism of the receptor can be measured using a Ca 2+ -sensitive dye (e.g., FURA, Fluo-4, etc.) can be quantified. Agonists alone cause an increase in Ca. 2+ - Signals; antagonists cause a reduction in Ca in the presence of, for example, menthol. 2+ - Signals (each detected via the dye Fluo-4, which is produced by Ca 2+ -ions have different fluorescence properties).
[0451] First, a fresh culture of transformed HEK cells is prepared in cell culture flasks using standard procedures. The HEK293-TRPM8 test cells are detached from the cell culture flasks using trypsin, and 40,000 cells / well are seeded with 100 pl of medium in 96-well plates (Greiner # 655948 poly-D-lysine-coated). To induce the TRPM8 receptor, tetracycline is added to the growth medium (DMEM / HG, 10% FCS tetracycline-free, 4 mM L-glutamine, 15 pg / ml blistidine, 100 pg / ml hygromycin B, 1 pg / ml tetracycline).
[0452] The following day, the cells are loaded with Fluo-4AM dye and the test is performed. The procedure is as follows: 100 pl / well of Ca-4 Kit staining solution (RB 141, Molecular Devices) is added to 100 pl of medium (DMEM / HG, 10% FCS tetracycline-free, 4 mM L-glutamine, 15 pg / ml blistidin, 100 pg / ml hygromycin B, 1 pg / ml tetracycline).
[0453] Incubation in an incubator, 30 minutes / 37 °C / 5 % CO2, 30 minutes / RT.
[0454] Preparation of the test substances (different concentrations in 200 pl HBSS buffer), as well as positive controls (different concentrations of menthol, icilin or lonomycin in 200 pl HBSS buffer) and negative controls (only 200 pl HBSS buffer). Addition of the test substances in amounts of 50 pl / well and measurement of the fluorescence change (e.g. in the FLIPR assay instrument, Molecular Devices or NovoStar, BMG) at 485 nm excitation, 520 nm emission, and evaluation of the potency of the different substances / concentrations and determination of the EC50 values.
[0455] The test substances are used in triplicate form at concentrations of 0.1–200 pM in the assay. Normally, the compounds are stored in DMSO solutions and diluted to a maximum DMSO concentration of 2% for the assay. Our own evaluations during the described assay surprisingly showed that the compounds to be used according to the invention (as described herein) are particularly suitable as agonists of TRPM8.
[0456] The described assay determines the activity of the active substances with respect to activation of the TRPM8 channel. This is done in a concentration-dependent manner. For each active substance, 6 to 10 concentrations are measured as standard practice. From the determined activity values, the EC50 value, as the inflection point of the sigmoidal curve, can be determined using a mathematical method (4-parameter or 5-parameter logistic curve fitting). These are standard methods in biochemistry that are well known to those skilled in the art.
[0457] The determined EC50 values of selected modulators according to the invention are shown in Table 7 and Table 8 below. An EC50 value of 1.72 pM was determined for substance WS-3, which serves as a reference.
[0458] Table ?: EC50 values of modulators according to the invention
[0459] Table 8: EC50 values of modulators according to the invention
[0460] The EC50 value describes the concentration of cooling agent required for half-maximal effect and is thus a measure of the potency of an agonistic drug (the strength of a drug depending on the dose or concentration), with the potency being the inverse of the EC50 value. Consequently, a low EC50 value corresponds to a high drug potency.
[0461] Thus, it can be seen from Tables 7 and 8 above that the compounds described herein according to the invention have excellent cooling properties and can produce intensive cooling effects even at low concentrations, and are generally well below the EC50 reference value of 1.72 pM for the substance WS-3.
[0462] As Table 7 above shows, those structures of the general formulas (I), (II), (V) and (VI) have proven particularly advantageous in which R1 and R2 each represent a phenyl group, X represents a sulfur atom, Y represents a methylene group or a methylene group substituted with a methyl or ethyl group, and Z represents -NH-cyclopropyl, -NH-CH3, -N(CHs)2 or an azetidine. Furthermore, it was observed that in these structures m and n each represent 1.
[0463] As Table 8 above shows, those structures of the general formulas (III), (IV), (VII) and (VIII) have proven particularly advantageous in which R1 and R2 each represent a phenyl group, X represents a sulfur atom or a cyclopropyl group or a CH2 group or piperidine, Y represents a methylene group or a methylene group substituted with a methyl group, and Z represents -NH-CH3, -NH-CH2-CH3, -NH-cyclopropyl or -CS-CH3. Furthermore, it was observed that in these structures, m represents 0 or 1, and n represents 1.
[0464] Particularly preferred with regard to the EC50 values are therefore the compounds B-01, B-02, B-03, B-04, B-05, B-06 and B-07 with an EC50 value < 1.0 pM, as well as the compounds A-01, A-02, A-03, A-04, A-06, A-07 and A-08 with an EC50 value < 1.0 pM.
[0465] Particularly efficient cooling effects with regard to the TRPM8 activity as well as the EC50 values can be observed for compounds B-01 , B-02, B-03, B-04, B-05, B-06, and B-07 as well as for compounds A-01 , A-02, A-03, A-04, A-06, A-07 and A-08 (TRPM8 activity > 100 % and EC value of < 1 ,0 pM).
[0466] In addition to the TRPM8 activity and active ingredient potency (EC50 value) described above, the compounds according to the invention also exhibit an intensive cooling effect.
[0467] To quantify the cooling effect, comparative tests are conducted using menthane-3-carboxylic acid N-ethylamide as a reference. For these comparative tests, the The person skilled in the art selects the compound or compounds to be used according to the invention by means of menthane-3-carboxylic acid-N-ethylamide (also referred to as WS-3). Then, the intensities of the cooling effects of the respective compounds or active ingredients, as described below, are sensorially evaluated and compared by trained panelists (n = 10 to 11).
[0468] The cooling intensity was investigated as follows: Test solutions containing 5 ppm of the compounds according to the invention were each tasted in a 5% sugar solution, as was a corresponding solution containing 30 ppm of the reference substance WS-3. This concentration of WS-3 was chosen because it has been shown to exhibit good cooling effects at such concentrations. The respective test solutions were tasted by the panelists for exactly 40 seconds, during which time the entire oral cavity was rinsed with the test solution, and the sample or reference solution was then spat out. Following the tasting, the test subjects rated the respective cooling intensity after one minute on a scale from 1 (very weak) to 9 (very strong).
[0469] The results of the sensory tasting of exemplary selected compounds according to the invention are shown in Table 9 and Table 10 below.
[0470] Table 9: Results of the sensory tasting of exemplary cooling agents
[0471] Table 10: Results of the sensory tasting of exemplary cooling agents
[0472] It has surprisingly been found that the compounds described herein produce a noticeably more intense or comparable cooling effect compared to the WS-3 reference sample. In particular, it has been shown that the WS-3-containing reference sample exhibited a cooling intensity of approximately 5.4 in the sensory evaluation, while the cooling intensity of the substances according to the invention, such as compound B-01 (4.2), compound B-02 (4.1), compound B-11 (5.3), compound A-02 (5.4), compound A-09 (4.66), and compound A-10 (5.38), was evaluated.
[0473] It should also be noted that WS-3, despite a six times higher concentration, is able to produce noticeably lower cooling intensities. Conversely, significantly lower concentrations of the compounds according to the invention are necessary to produce considerably more intense cooling effects compared to conventional cooling substances (such as WS-3). This demonstrates that the compounds according to the invention produce an intense and therefore highly effective cooling effect even when used at low concentrations. and in corresponding final formulations, such as product formulations containing these cooling substances, only very small amounts need to be used to create cooling effects that are perceived as intense.
[0474] In this context, it is preferred that in the corresponding comparisons the cooling effect of the samples with the compound(s) to be used according to the invention is preferably extended by at least 10 minutes, preferably by at least 15 minutes, more preferably by at least 20 minutes, even more preferably by at least 30 minutes, particularly preferably by at least 60 minutes, most preferably by at least 90 minutes compared to the comparison samples containing WS-3.
[0475] Synthesis examples:
[0476] Preparation of the compounds according to the invention
[0477] Method A:
[0478] The 2-oxazolethiol derivative (1 eq.) and the bromocarboxylic acid or chlorocarboxylic acid (1.2 eq.) were dissolved in dry DMF, and N,N-diisopropylethylamine (1.5 eq.) was added at room temperature. The reaction solution was stirred at room temperature until complete conversion was observed by uHPLC. The reaction mixture was then diluted with water and acidified to approximately pH 3 with 1 M hydrochloric acid. It was extracted with DCM, and the combined organic phases were washed with water and filtered through a phase separator. After concentration of the organic phase, the 2-oxazolecarboxylic acid derivative was obtained in satisfactory purity for use in the next reaction step.
[0479] The 2-oxazolecarboxylic acid derivative (1 eq.) obtained from Method A and the required amine (if necessary as THF solution) (3 eq.) were dissolved in ethyl acetate, and HATU (1.5 eq.) followed by N,N-diisopropylethylamine (5 eq.) were added at room temperature. DIPEA was added dropwise until the pH was adjusted to approximately 9. The reaction solution was stirred at room temperature until uHPLC showed complete conversion. It was then diluted with saturated NaHCOs solution and extracted with DCM. The combined organic phases were filtered through a phase separator. After concentration of the organic phase, the crude product was... Purified by column chromatography, the desired product was obtained as an oil or solid.
[0480] Method B: x = Br, ci Y = >CH-(CH2) n -
[0481] The 2-oxazolethiol derivative (1 eq.) and the bromamide or chloramide (1.2 eq.) were dissolved either in dry acetone and K₂CO₃ (2 eq.) was added at room temperature, or dissolved in dry DMF and diisopropylethylamine (1.5 eq.) was added at room temperature. The reaction solution was heated to 40 °C and stirred until complete conversion was observed by uHPLC. The solution was then diluted with water and extracted with either EtOAc or DCM. The combined organic phases were washed with water and saturated NaCl solution and dried over MgSO₄. After concentration of the organic phase, the crude product was purified by column chromatography, and the desired product was obtained as an oil or solid.
[0482] Method C:
[0483] The carboxylic acid derivative (1 eq) was dissolved in dry DCE and cooled to 0–5 °C. The hydrochloride of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (1 eq) was added and stirred for 30 min. Then benzoin (1 eq) was added, followed by DMAP (1 eq). Add the equation. The reaction mixture was heated to room temperature and stirred for 24 hours. The mixture was then diluted with DCM and filtered first three times with 10 wt% citric acid solution, then with saturated NaHCO₃ solution, and finally through a phase separator. After concentration of the organic phase, the ester was obtained in satisfactory purity for use in the next reaction step. If the product was a cooling agent, it was purified by column chromatography, and the desired product was obtained as an oil or solid.
[0484] The ester (1 eq) and ammonium acetate (5 eq) were dissolved in acetic acid and stirred under reflux for 90 min. After cooling to room temperature, the reaction mixture was added to water and extracted with dichloromethane. The combined organic phase was filtered and concentrated using a phase separator. The product could be used in the next reaction step without further purification. If the product was a cooling agent, it was purified by column chromatography, and the desired product was obtained as an oil or solid.
[0485] The oxazole derivative (1 eq) was dissolved in a mixture of THF and water (1:1) and cooled to 0 °C. LiOH monohydrate (2 eq) was then added, and the mixture was slowly warmed to room temperature and stirred until complete conversion was detected. The reaction solution was then diluted with water and acidified to pH 3 with 10 wt% citric acid. The aqueous solution was extracted with DCM. The combined organic phases were dried and concentrated over MgSO₄. The carboxylic acid derivative could be used in the next reaction step without further purification. If it was a cooling agent, the product was purified by column chromatography, and the desired product was obtained as an oil or solid.
[0486] The carboxylic acid derivative (1 eq) and the required amine (if necessary as a THF solution) (1 eq) were dissolved in DMF and cooled to 0 °C. HATII (1 eq) followed by N,N-diisopropylethylamine (3 eq) was then added. The reaction solution was stirred at room temperature until complete conversion was observed by uHPLC. The mixture was then diluted with water and extracted with DCM. The combined organic phases were washed with water, three times with 10 wt% citric acid, and finally with saturated NaHCO₃, and filtered through a phase separator. The solvent was removed under vacuum. The crude product was purified by column chromatography, and the desired product was obtained as an oil or solid.
[0487] Method D: Y= -(CH2) n - Diphenyl azidophosphate (1.1 eq) and triethylamine (1.1 eq) were added to a solution of oxaprozin derivative (1 eq) in dry toluene and stirred at room temperature. The reaction was monitored by HPLC. After complete conversion, the mixture was diluted with toluene and washed with water. The organic phase was dried with MgSO₄ and concentrated under vacuum. The crude product was dissolved in MeOH and stirred at 75 °C for 24 hours, then concentrated under vacuum. The crude product was purified by reversed-phase column chromatography, and the desired product was obtained as an oil or solid. The carbamate (1 eq) was dissolved in THF / MeOH (2:1), and 2 M NaOH solution (16 eq) was added. The reaction mixture was heated to 70 °C and stirred until HPLC showed complete conversion. The mixture was then cooled to room temperature and diluted with water.It was extracted three times with a mixture of chloroform and isopropanol (7:3), and the combined organic phases were filtered and concentrated using a phase separator. The product could then be used in the next reaction step without further purification. If it was a cooling agent, the product was purified by column chromatography, and the desired product was obtained as an oil or solid.
[0488] The amine derivative (1 equ) was dissolved in dry DCM, and triethylamine (2 equ) followed by acetyl chloride (1.2 equ) were added. The reaction mixture was stirred at room temperature until complete conversion was observed by HPLC. The reaction mixture was diluted with DCM and washed with saturated NaHCO₃ solution. The organic phase was filtered through a phase separator and concentrated under vacuum. The crude product was purified by column chromatography, and the desired product was obtained as an oil or solid.
[0489] Method E: Y= -(CH2) n -
[0490] Oxazole carboxylic acid (1 eq) and N,O-dimethylhydroxylamine hydrochloride (1 eq) were dissolved in DMF. HATII (1.5 eq) and diisopropylethylamine (5 eq) were added, and the reaction mixture was stirred at room temperature until complete conversion was observed by HPLC. The reaction mixture was diluted with semisaturated NaHCO₃ solution and extracted three times with DCM. The combined organic phases were washed with water and saturated NaCl solution, filtered through a phase separator, and concentrated under vacuum. The crude product was purified by column chromatography, and the desired product was obtained as an oil or solid. Weinreb amide (1 eq) was dissolved in dry THF and cooled to 0 °C. Grignard's solution in THF was added slowly dropwise at 0 °C, and after addition, the reaction mixture was stirred at room temperature until HPLC showed complete conversion. The reaction was quenched by the addition of saturated NH4Cl solution, and the aqueous phase was extracted three times with EtOAc. The combined organic phases were dried over MgSO4 and concentrated under vacuum. The crude product was purified by column chromatography, and the desired product was obtained as an oil or solid.
[0491] Method F:
[0492] The 2-imidazolethiol derivative (1 eq) was dissolved in dry dimethylformamide, and the corresponding organohalogen compound (1.2 eq) followed by diisopropylethylamine (1.5 eq) was added. The reaction mixture was stirred at room temperature until complete conversion was observed by HPLC. The reaction mixture was diluted with water and extracted with DCM. The combined organic phases were dried over MgSO₄ and concentrated under vacuum. The crude product was purified by column chromatography, and the desired product was obtained as an oil or solid.
[0493] Method G:
[0494] The benzil derivative (1 eq), the dimethoxy ester (1.3 eq), and ammonium acetate (7 eq) were dissolved in acetic acid and stirred under reflux in a nitrogen atmosphere until complete conversion was observed by HPLC. The reaction mixture was then cooled to room temperature and dissolved in water. It was made basic with 25 wt% ammonia solution and extracted with DCM. The combined organic phases were dried over MgSC and concentrated under vacuum. The product could be used in the next reaction step without further purification. The final product was purified by column chromatography, and the desired product was obtained as an oil or solid. The corresponding carboxylic acids and amides were prepared as described in Method D.
[0495] Method H: for Y = N: X = S or O for Y = C: X = O
[0496] For pyrazines: The benzil derivative (1 eq) was dissolved in methanol, and glycinamide hydrochloride (1.1 eq) followed by NaOH (2 eq) were added and stirred at 70 °C for 4 hours. The reaction mixture was then cooled to room temperature, 2 M hydrochloric acid was added, and the mixture was stirred for 30 minutes. Saturated NaHCO3 solution was then added, the solid was filtered off, and washed with methanol. The crude product was purified by column chromatography, and the desired product was obtained as an oil or solid.
[0497] For 1,2,4-triazines: The benzil derivative (1 equ) was dissolved in acetic acid and heated to 100 °C. Thiosemicarbazide (2 equ) or, equivalently, semicarbazide hydrochloride (1 equ) was added and stirred under reflux for 6 hours. The reaction mixture was then cooled to 5 °C, and the resulting solid was filtered and washed with water. After drying under vacuum, it could be used in the next reaction step without further purification.
[0498] Method I:
[0499] A suspension of Lawesson's reagent (2 eq) and pyrazine alcohol (1 eq) in THF was stirred under reflux overnight. The reaction mixture was then cooled to room temperature and diluted with water. It was extracted with diethyl ether, and the combined organic phases were dried over Na₂SO₄, filtered, and concentrated under vacuum. The crude product was purified by column chromatography, and the desired product was obtained as an oil or solid.
[0500] Method J: X = S or O or NH Y = CH or N
[0501] The thiol, alcohol, or amine derivative (1 eq.) was dissolved in acetone, and Na₂CC>3 (1.5 to 6 eq.) was added. The bromine compound (1.1 to 1.5 eq.) was added to the suspension and stirred under reflux until reaction control by TLC showed complete conversion. The solid was filtered off and washed with acetone. The filtrate was co-evaporated with silica. After column chromatographic purification, the desired product was obtained as an oil or solid.
[0502] Method K X = S or O or NH Y = CH or N
[0503] The thiol, alcohol, or amine derivative (1 eq.) was dissolved in acetone, and Na₂CO₃ (1.5 to 6 eq.) was added. The 2-bromomethyl ester (1 eq.) was added to the suspension and stirred at 60 °C until complete conversion was observed by TLC. The reaction mixture was then cooled to room temperature, filtered, and washed with acetone. The filtrate was concentrated, and the crude product was purified by column chromatography to obtain the desired methyl ester as an oil or solid. The methyl ester (1 eq.) was stirred overnight in a 2 M solution of the amine (10 eq.) in THF at 80 °C. The reaction solution was then concentrated under vacuum. The crude product was purified by column chromatography to obtain the desired amide as an oil or solid.
[0504] Method L and L':
[0505] The thiol (1 eq) was dissolved in acetone, and Na₂CO₃ (1.5 eq) was added, followed by methyl iodide (1 eq). The reaction mixture was stirred at 60 °C until TLC showed complete conversion. The mixture was then filtered and washed with acetone. The filtrate was concentrated. The product could be used in the next reaction step without further purification. The final product was purified by column chromatography, and the desired product was obtained as an oil or solid. The methyl thioether (1 eq) and the required amine (10 eq) were stirred at elevated temperature (up to 120 °C) until TLC showed complete conversion. The reaction mixture was then concentrated under vacuum, and the crude product was purified by column chromatography. The methyl thioether (1 eq) and the required alcohol (1 eq) were dissolved in dry DMF, and CS₂CO₃ (1 eq) was added.The reaction mixture was stirred at 100 °C until a TLC test showed complete conversion. The mixture was then filtered and concentrated under vacuum. The resulting crude product was purified by column chromatography.
[0506] Method M:
[0507] The thioether (1 eq) was dissolved in dry DCM and cooled to 0 °C. 3-Chloroperbenzoic acid (3 eq) was added, and the reaction solution was warmed to room temperature and stirred overnight. The reaction was then quenched with 5 wt% aqueous sodium disulfite solution and stirred for one hour. The phases were separated, and the organic phase was washed with water, filtered through a phase separator, and concentrated under vacuum. The crude product was purified by column chromatography, and the desired product was obtained as an oil or solid.
[0050] Table 11 below lists the analytical data for identifying the synthesized compounds according to the present invention. The decimal point is represented by a period in the values.
[0508] Table 11: 1H-NMR and 13C-NMR data of cooling materials according to the invention (decimal point)
[0509] Examples of wording
[0510] Examples of formulations for cosmetic preparations
[0511] The following formulation examples F1 to F54 show a wide variety of formulations for cosmetic and pharmaceutical preparations. Cooling agent 1 here refers to compound B-11 according to the invention, cooling agent 2 refers to compound A-02, cooling agent 3 refers to compound A-09, and cooling agent 4 refers to compound A-10. The cooling agents were used in pure form.
[0512] In the following tables, the decimal point is represented as a period.
[0513] Table F1 Transparent liquid soap (amounts in wt.%)
[0514] Table F2 Liquid syndet soap (amounts in wt.%)
[0515] Table F3 Body Care Lotion (Quantities in wt.%)
[0516] Table F4 Body care lotion with triclosan (amounts in wt.%)
[0517] Table F5 Intimate Wash (Quantities in wt.%)
[0518] Table F6 Liquid soap (amounts in wt.%)
[0519] Table F7 Shampoo (amounts in wt.%)
[0520] Table F8 2-in-1 Shampoo (amounts in wt.%)
[0521] Table F9 Anti-dandruff shampoo (amounts in wt.%)
[0522] Table F10 Hair conditioner with Crinipan, rinse-off (amounts in wt.%)
[0523] Table F11 Sprayable Hair Conditioner with Zinc Pyrithrione - leave-on (amounts in wt.%)
[0524] Table F12 Hair Conditioner with UV protection (amounts in wt.%)
[0525] Table F13 Shower gel (amounts in wt.%)
[0526] Table F14 Shaving foam (amounts in wt.%)
[0527] Table F15 Depilatory cream (amounts in wt.%)
[0528] Table F16 After Shave Tonic (amounts in wt.%)
[0529] Table F17 Deodorant formulation as a roll-on gel (amounts in wt.%)
[0530] Table F18 Clear roll-on deodorant (amounts in wt.%)
[0531] Table F19 Deodorant stick (amounts in wt.%)
[0532] Table F20 Antiperspirant stick (amounts in wt.%)
[0533] Table F21 Pump spray (amounts in wt.%)
[0534] Table F22 Antiperspirant (amounts in wt.%)
[0535] Table F23 Spray deodorant with triclosan (amounts in wt.%)
[0536] Table F24 O / W Lotion (amounts in wt.%)
[0537] Table F25 Body Lotion (amounts in wt.%)
[0538] Table F26 Cream (amounts in wt.%)
[0539] Table F27 Cream (amounts in wt.%)
[0540] Table F28 Hand and body cream (amounts in wt.%)
[0541] Table F29 Face cream (amounts in wt.%)
[0542] Table F30 Moisturizing Cream (amounts in wt.%)
[0543] Table F31 Anti-wrinkle cream (amounts in wt.%) Components (INGI)
[0544] Table F32 Disinfecting skin care oil (amounts in wt.%)
[0545] Table F33 Antiseptic wound cream (amounts in wt.%)
[0546] Table F34 Moisture mask (amounts in wt.%)
[0547] Table F35 Sprayable disinfectant gel (amounts in wt.%)
[0548] Table F36 Mineral washing and cleansing gel (amounts in wt.%)
[0549] Table F37 Anti-acne washes (quantities in wt.%)
[0550] Table F38 Sunscreen formulation (amounts in wt.%)
[0551] Table F39 Sunscreen spray (amounts in wt.%)
[0552] Table F40 Sunscreen Spray O / W, SPE 15-20 (amounts in wt.%)
[0553] Table F41 Sunscreen soft cream (W / O), SPF 40 (amounts in wt.%)
[0554] Table F42 Sunscreen lotion (W / O) (amounts in wt.%)
[0555] Table F43 After Sun Gel (amounts in wt.%)
[0556] Table F44 After Sun Lotion (amounts in wt.%)
[0557] Table F45 Hair Styling Gel (amounts in wt.%)
[0558] Table F46 Silicone emulsion (amounts in wt.%)
[0559] Table F47 Microemulsion gel (amounts in wt.%)
[0560] Table F48 Gel air fresheners (amounts in wt.%)
[0561] Table F49 Textile cleaners (amounts in wt.%)
[0562] Table F50 Toothpaste (amounts in wt.%)
[0563] Table F51 Mouthwash (amounts in wt.%)
[0564] Table F52 Anti-plaque toothpaste with anti-bad breath efficacy (amounts in wt.%)
[0565] Table F53 Toothpaste and mouthwash as a 2-in-1 product (amounts in wt.%)
[6566] Table F54 Other toothpaste formulations (amounts in wt.%)
[0567] Examples of wording for food preparations
[0568] The following formulation examples F55 to F63 show a wide variety of formulations for food preparations. Cooling agent 1 here refers to compound B-11 according to the invention, cooling agent 2 refers to compound A-02, cooling agent 3 refers to compound A-09, and cooling agent 4 refers to compound A-10. The cooling agents were used in pure form.
[0569] Table F55 Chewing gum (amounts in wt.%)
[0570] Table F56 Other chewing gum formulations (amounts in wt.%)
[0571] Table F57 Sugar-free chewing gum (amounts in wt.%)
[0572] Table F58 Pudding, recipe (for 100 ml) (quantities in grams)
[0573] Table 59 Chewy sweets (amounts in wt.%)
[0574] Table 60 Fruit gums (amounts in wt.%)
[0575] Table 61 Gelatin capsule for direct consumption (amounts in wt.%)
[0577] Table F63 Throat lozenges with liquid-viscous center filling (centrefilled hard candy) ((Quantities in wt.%)
Claims
Patent claims Physiological cooling agent of general formula (Va) or the general formula (Via) where in formulas (Va) and (Via) the remainders R1 and R2 can be the same or different and independently have the following meanings: R1 • H; or • a group Q; or • a possibly substituted linear or branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted acyl group -R(C=O)-; or • a possibly substituted cycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heterocycloalkyl group; or a possibly substituted heteroaryl group; R2 • H; or • a group Q; or • a possibly substituted linear or branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted acyl group R-(C=O)-; or • a possibly substituted cycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heterocycloalkyl group; or • is a possibly substituted heteroaryl group; or R1 and R2 together with the C atoms to which they are bonded form a conjugated or non-conjugated ring system; Y • is a possibly substituted branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted acyl group R-(C=O)-; or • a possibly substituted alkylaryl group; or • a possibly substituted alkyl heteroaryl group; Z • NH2; or in the • an NHRa group; or generally • an NRaRb group; or in • an optionally substituted linear or branched alkyl group; formula oder (Va) , ejne optionally substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted linear or branched alkoxy group; or • OH; or • a possibly substituted cycloalkyl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heteroaryl group; or • NH is and forms a heterocyclic ring with X; Z in the • NH2; or generally • an NHRa group or an NRaRb group, excluding -NH-phenyl and -N(CH3)-phenyl; or Formula • a possibly substituted linear or branched alkyl group; (Via) or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted linear or branched alkoxy group, excluding -OC2H5 and -OC(CH3)3; or • a possibly substituted cycloalkyl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heteroaryl group; or NH is and with the X together formed a heterocyclic ring; m 1 ist; where group Q is a residue selected from the group consisting of: halogen, -OA, -SA, -NBB, -CF3, -CN, -OCN, -SCN, -NO, -NO2, -S(O)2 a , -S(O)2OA, -OS(O)2 a , - OS(O)2OA, -P(O)(OA) 2I -P(O)(OA)(OA), -C(O)A, -C(S)A, -C(NA)A, -C(O)OA, -C(S)OA, -C(O)NBB, -C(NA)NBB, -OC(O)A, -OC(S)A, -OC(O)OA, -O -NAC(O)OA, -NAC(S)OA, -NAC(O)NBB, -NAC(NA)A or -NAC(NA)NBB; where A selected is from the Group consisting of: hydrogen, optionally substituted linear or branched alkyl group, in particular optionally substituted Ci to Cw alkyl group, in particular optionally substituted Ci to Ce alkyl group, especially optionally substituted Ci, C2, C3 or C4 alkyl group, optionally substituted linear or branched alkoxy group, in particular optionally substituted Ci-Ce alkoxy group, especially optionally substituted Ci, C2, C3 or C4 alkoxy group, optionally substituted linear or branched alkylthio group, in particular optionally substituted Ci to Ce alkylthio group, especially optionally substituted Ci, C2, C3 or C4 alkylthio group, optionally substituted cycloalkyl group, optionally substituted aryl group, optionally substituted heterocycloalkyl group, optionally substituted heteroaryl group; and / or B means A or alternatively, two Bs together with the nitrogen atom to which they are bonded, meaning a four-, five-, six- or seven-membered heterocycloalkyl ring or heteroaryl ring, wherein the heterocycloalkyl ring or heteroaryl ring may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; the optionally substituted linear or branched alkyl group is an optionally substituted Ci to Cw alkyl group, in particular an optionally substituted Ci to Ce alkyl group, especially an optionally substituted Ci, C2, C3 or C4 alkyl group;the optionally substituted linear or branched alkenyl group is an optionally substituted Ci to Cw alkenyl group, in particular an optionally substituted Ci to Ce alkenyl group, especially an optionally substituted Ci, C2, C3 or C4 alkenyl group; the optionally substituted linear or branched alkynyl group is an optionally substituted Ci to Cw alkynyl group, in particular an optionally substituted Ci to Ce alkynyl group, especially an optionally substituted Ci, C2, C3 or C4 alkynyl group; the optionally substituted linear or branched alkoxy group is an optionally substituted Ci to Cw alkoxy group, in particular an optionally substituted Ci to Ce alkoxy group, especially an optionally substituted Ci, C2, C3 or C4 alkoxy group;the optionally substituted linear or branched alkylthio group is an optionally substituted Ci to Cw alkylthio group, in particular an optionally substituted Ci to Ce alkylthio group, especially an optionally substituted Ci, C2, C3 or C4 alkylthio group; in the acyl group R-(C=O)- the residue R stands for hydrogen or an optionally substituted linear or branched Ci to Cw alkyl group, in particular an optionally substituted Ci to Ce alkyl group, especially an optionally substituted Ci, C2, C3 or C4 acyl group; the optionally substituted cycloalkyl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered, monocyclic cycloalkyl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, cycloalkyl group;the optionally substituted aryl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered, monocyclic aryl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic aryl group; the optionally substituted heterocycloalkyl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered monocyclic heterocycloalkyl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, heterocycloalkyl group, wherein the heterocycloalkyl group may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;the optionally substituted heteroaryl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered monocyclic heteroaryl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, heteroaryl group, wherein the heteroaryl group may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; Ra • an optionally substituted linear or branched alkyl group, and / preferably an O1 to C3 alkyl group, preferably a methyl or group; or Rb • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted acyl group R-(C=O)-; or • a possibly substituted cycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted heteroaryl group is / are; or • Ra and Rb, as defined above, are linked together and form a saturated or unsaturated ring; wherein the substituents are each selected independently of one another; and their salts, in particular acid addition salts, with inorganic or organic acids, wherein the cooling agents may be in stereoisomerically pure form or as mixtures of different stereoisomers; or of the general formula (Vila) or the general formula (villa) (Villa) where in the formulas (Vila) and (Villa) the remainders R1 and R2 can be the same or different and independently have the following meanings: R1 • H; or • a group Q; or • a possibly substituted linear or branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted acyl group -R(C=O)-; or • a possibly substituted cycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heterocycloalkyl group; or a possibly substituted heteroaryl group; R2 • H; or • a group Q; or • a possibly substituted linear or branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted acyl group R-(C=O)-; or • a possibly substituted cycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heterocycloalkyl group; or • is a possibly substituted heteroaryl group; or R1 and R2 together with the C atoms to which they are bonded form a conjugated or non-conjugated ring system; V • S; or • SO2; or • a possibly substituted linear or branched alkyl group; or • a possibly substituted cycloalkyl group; or • Piperidinyl is; Y • is a possibly substituted branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted acyl group R-(C=O)- is; Z • NH2; or • an NHRa group; or • an NRaRb group; or • a possibly substituted linear or branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted linear or branched alkoxy group; or • OH; or • a possibly substituted cycloalkyl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heteroaryl group; or • NH is and forms a heterocyclic ring with X; m is 1; where the group Q is a residue selected from the group consisting of: halogen, -OA, -SA, -NBB, -CF3, -CN, -OCN, -SCN, -NO, -NO2, -S(O)2A, -S(O)2OA, -OS(O)2A, -OS(O)2OA, -P(O)(OA) 2I-P(O)(OA)(OA), -C(O)A, -C(S)A, -C(NA)A, -C(O)OA, -C(S)OA, -C(O)NBB, -C(NA)NBB, -OC(O)A, -OC(S)A, -OC(O)OA, -O -NAC(O)OA, -NAC(S)OA, -NAC(O)NBB, -NAC(NA)A or -NAC(NA)NBB; where A selected is from the Group consisting of: hydrogen, optionally substituted linear or branched alkyl group, in particular optionally substituted Ci to Cw alkyl group, in particular optionally substituted Ci to Ce alkyl group, especially optionally substituted Ci, C2, C3 or C4 alkyl group, optionally substituted linear or branched alkoxy group, in particular optionally substituted Ci-Ce alkoxy group, especially optionally substituted Ci, C2, C3 or C4 alkoxy group, optionally substituted linear or branched alkylthio group, in particular optionally substituted Ci to Ce alkylthio group, especially optionally substituted Ci, C2, C3 or C4 alkylthio group, optionally substituted cycloalkyl group, optionally substituted aryl group, optionally substituted heterocycloalkyl group, optionally substituted heteroaryl group; and / or B means A or alternatively, two Bs together with the nitrogen atom to which they are bonded, meaning a four-, five-, six- or seven-membered heterocycloalkyl ring or heteroaryl ring, wherein the heterocycloalkyl ring or heteroaryl ring may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; the optionally substituted linear or branched alkyl group is an optionally substituted Ci to Cw alkyl group, in particular an optionally substituted Ci to Ce alkyl group, especially an optionally substituted Ci, C2, C3 or C4 alkyl group;the optionally substituted linear or branched alkenyl group is an optionally substituted Ci to Cw alkenyl group, in particular an optionally substituted Ci to Ce alkenyl group, especially an optionally substituted Ci, C2, C3 or C4 alkenyl group; the optionally substituted linear or branched alkynyl group is an optionally substituted Ci to Cw alkynyl group, in particular an optionally substituted Ci to Ce alkynyl group, especially an optionally substituted Ci, C2, C3 or C4 alkynyl group; the optionally substituted linear or branched alkoxy group is an optionally substituted Ci to Cw alkoxy group, in particular an optionally substituted Ci to Ce alkoxy group, especially an optionally substituted Ci, C2, C3 or C4 alkoxy group; the optionally substituted linear or branched alkylthio group is an optionally substituted Ci to Cw alkylthio group, in particular an optionally substituted Ci to Ce alkylthio group, especially an optionally substituted Ci, C2, C3 or C4 alkylthio group;in the acyl group R-(C=O)- the residue R stands for hydrogen or an optionally substituted linear or branched Ci to Cw alkyl group, in particular an optionally substituted Ci to Ce alkyl group, especially an optionally substituted Ci, C2, C3 or C4 acyl group; the optionally substituted cycloalkyl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered, monocyclic cycloalkyl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, cycloalkyl group; the optionally substituted aryl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered, monocyclic aryl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic aryl group;the optionally substituted heterocycloalkyl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered monocyclic heterocycloalkyl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, heterocycloalkyl group, wherein the heterocycloalkyl group may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;the optionally substituted heteroaryl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered monocyclic heteroaryl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, heteroaryl group, wherein the heteroaryl group may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; Ra • an optionally substituted linear or branched alkyl group; and / preferably an O1 to C3 alkyl group, preferably a methyl or group; or Rb • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted acyl group R-(C=O)-; or • a possibly substituted cycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted heteroaryl group is / are; or • Ra and Rb, as defined above, are linked together and form a saturated or unsaturated ring; wherein the substituents are each selected independently of each other; as well as their salts, in particular acid addition salts, with inorganic or organic acids, wherein the cooling agents may be in stereoisomerically pure form or as mixtures of different stereoisomers.
2. Physiological cooling agent according to claim 1, wherein in the general formulas (Va) to (Villa) Y represents a substituted methylene group, preferably a methylene group substituted with a methyl group, an ethyl group, a linear or branched butyl group or a linear or branched propyl group.
3. Physiological coolant according to claim 1 or claim 2, wherein the physiological coolant of general formulas (Va) or (Via) is selected from the group consisting of the compounds according to Table A below: Table A: and their salts, in particular acid addition salts, with inorganic or organic acids, wherein the refrigerants may be in stereoisomerically pure form or as mixtures of different stereoisomers, preferably wherein the physiological refrigerant is selected from the group consisting of compounds B-01, B-02, B-03, B-05, B-07, B-11 and B-18; or wherein the physiological refrigerant of the general formulas (Vila) or (Villa) is selected from the group consisting of the compounds according to Table B below: Table B: as well as their salts, in particular acid addition salts, with inorganic or organic acids, wherein the cooling agents may be in stereoisomerically pure form or as mixtures of different stereoisomers, preferably wherein the physiological cooling agent is selected from the group consisting of compounds A-02, A-05, A-09, A-10, and A-12.
4. Physiological coolant of general formula (I) or the general formula (II) or the general formula (III) or the general formula (IV) where in formulas (I) to (IV) the remainders R1 and R2 can be the same or different and independently have the following meanings: R1 • H; or • a group Q; or • a possibly substituted linear or branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted acyl group -R(C=O)-; or • a possibly substituted cycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted heteroaryl group; R2 • H; or • a group Q; or • a possibly substituted linear or branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted acyl group R-(C=O)-; or • a possibly substituted cycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heterocycloalkyl group; or • is a possibly substituted heteroaryl group; or R1 and R2 together with the C atoms to which they are bonded form a conjugated or non-conjugated ring system; X • S; or • SO; or • SO2; or • NH; or • O; or • a possibly substituted linear or branched alkyl group • a possibly substituted linear or branched alkenyl group • a possibly substituted linear or branched alkylthio group; or • a possibly substituted cycloalkyl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted hetero-aryl group; Y • is a possibly substituted linear or branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted acyl group R-(C=O)-; or • a possibly substituted alkylaryl group; or • a possibly substituted alkyl heteroaryl group; Z • NH2; or • an NHRa group; or • a NraRb group; or • a possibly substituted linear or branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted linear or branched alkoxy group; or • OH; or • a possibly substituted cycloalkyl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heteroaryl group; or • NH is and forms a heterocyclic ring with X; m is 0 or 1; and / or n is 0 or 1; with the proviso that if m = 0, Y is omitted; or if m = 1, Y occurs singly; or if n = 0, -(C=O)- is omitted; or if n = 1, -(C=O)- occurs singly; or if m = 0 and n = 0, Y is omitted and -(C=O)- is omitted; or if m = 1 and n = 1, Y occurs singly and -(C=O)- occurs singly; or if m = 0 and n = 1, Y is omitted and -(C=O)- occurs singly; or if m = 1 and n = 0, Y occurs singly and -(C=O)- is omitted; where group Q is a residue selected from the group consisting of: Halogen, -OA, -SA, -NBB, -CF3, -CN, -OCN, -SON, -NO, -NO2, -S(O)2A, -S(O)2OA, -OS(O)2A, -OS(O)2OA, -P(O)(OA) 2I-P(O)(OA)(OA), -C(O)A, -C(S)A, -C(NA)A, -C(O)OA, -C(S)OA, -C(O)NBB, -C(NA)NBB, -OC(O)A, -OC(S)A, -OC(O)OA, -O -NAC(O)OA, -NAC(S)OA, -NAC(O)NBB, -NAC(NA)A or -NAC(NA)NBB; where A selected is from the Group consisting of: hydrogen, optionally substituted linear or branched alkyl group, in particular optionally substituted Ci to Cw alkyl group, in particular optionally substituted Ci to Ce alkyl group, especially optionally substituted Ci, C2, C3 or C4 alkyl group, optionally substituted linear or branched alkoxy group, in particular optionally substituted Ci-Ce alkoxy group, especially optionally substituted Ci, C2, C3 or C4 alkoxy group, optionally substituted linear or branched alkylthio group, in particular optionally substituted Ci to Ce alkylthio group, especially optionally substituted Ci, C2, C3 or C4 alkylthio group, optionally substituted cycloalkyl group, optionally substituted aryl group, optionally substituted heterocycloalkyl group, optionally substituted heteroaryl group; and / or B means A or alternatively, two Bs together with the nitrogen atom to which they are bonded, meaning a four-, five-, six- or seven-membered heterocycloalkyl ring or heteroaryl ring, wherein the heterocycloalkyl ring or heteroaryl ring may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; the optionally substituted linear or branched alkyl group is an optionally substituted Ci to Cw alkyl group, in particular an optionally substituted Ci to Ce alkyl group, especially an optionally substituted Ci, C2, C3 or C4 alkyl group;the optionally substituted linear or branched alkenyl group is an optionally substituted Ci to Cw alkenyl group, in particular an optionally substituted Ci to Ce alkenyl group, especially an optionally substituted Ci, C2, C3 or C4 alkenyl group; the optionally substituted linear or branched alkynyl group is an optionally substituted Ci to Cw alkynyl group, in particular an optionally substituted Ci to Ce alkynyl group, especially an optionally substituted Ci, C2, C3 or C4 alkynyl group; the optionally substituted linear or branched alkoxy group is an optionally substituted Ci to Cw alkoxy group, in particular an optionally substituted Ci to Ce alkoxy group; in particular an optionally substituted Ci, C2, C3 or C4 alkoxy group; the optionally substituted linear or branched alkylthio group is an optionally substituted Ci to Cw alkylthio group, in particular an optionally substituted Ci to Ce alkylthio group, in particular an optionally substituted Ci, C2, C3 or C4 alkylthio group; in the acyl group R-(C=O)- the residue R stands for hydrogen or an optionally substituted linear or branched Ci to Cw alkyl group, in particular an optionally substituted Ci to Ce alkyl group, in particular an optionally substituted Ci, C2, C3 or C4 acyl group;the optionally substituted cycloalkyl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered, monocyclic cycloalkyl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, cycloalkyl group; the optionally substituted aryl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered, monocyclic aryl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, aryl group;the optionally substituted heterocycloalkyl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered monocyclic heterocycloalkyl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, heterocycloalkyl group, wherein the heterocycloalkyl group may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;the optionally substituted heteroaryl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered monocyclic heteroaryl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, heteroaryl group, wherein the heteroaryl group may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; Ra • an optionally substituted linear or branched alkyl group; and / preferably an O1 to C3 alkyl group, preferably a methyl or group; or Rb • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted acyl group R-(C=O)-; or • a possibly substituted cycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted heteroaryl group is / are; or • Ra and Rb, as defined above, are linked together to form a saturated or unsaturated ring; wherein the substituents are each selected independently of one another; and their salts, in particular acid addition salts, with inorganic or organic acids, wherein the refrigerants may be present in stereoisomerically pure form or as mixtures of different stereoisomers. Physiological refrigerant according to claim 4, wherein in the general formulas (I) and (II) • X stands for S; and / or • Y represents a possibly substituted linear or branched alkyl group; and / or • m stands for 0 or 1; and / or or wherein in the general formulas (III) and (IV) • X represents S or SO2 or an optionally substituted linear or branched alkyl group or an optionally substituted cycloalkyl group or piperidinyl; and / or • Y represents a possibly substituted linear or branched alkyl group; and / or • m represents 0 or 1. Physiological coolant according to claim 4 or claim 5, represented by the general formula (V) or by the general formula (VI) where in formulas (V) and (VI) the remainders R1 and R2 can be the same or different and independently have the following meanings: R1 as defined in claim 4; R2 as defined in claim 4; Y • is a possibly substituted linear or branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted acyl group R-(C=O)-; or • a possibly substituted alkylaryl group; or • a possibly substituted alkyl heteroaryl group; Z • NH2; or • an NHRa group; or • a NraRb group; or • a possibly substituted linear or branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted linear or branched alkoxy group; or • OH; or • a possibly substituted cycloalkyl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heteroaryl group; or • NH is and forms a heterocyclic ring with X; m is 0 or 1; with the proviso that if m = 0, Y is omitted; or if m = 1, Y occurs singly; where the group Q is a residue selected from the group consisting of: halogen, -OA, -SA, -NBB, -CF3, -CN, -OCN, -SON, -NO, -NO2, -S(O)2 a , -S(O)2OA, -OS(O)2 a , - OS(O)2OA, -P(O)(OA) 2I-P(O)(OA)(OA), -C(O)A, -C(S)A, -C(NA)A, -C(O)OA, -C(S)OA, -C(O)NBB, -C(NA)NBB, -OC(O)A, -OC(S)A, -OC(O)OA, -O -NAC(O)OA, -NAC(S)OA, -NAC(O)NBB, -NAC(NA)A or -NAC(NA)NBB; where A selected is from the Group consisting of: hydrogen, optionally substituted linear or branched alkyl group, in particular optionally substituted Ci to Cw alkyl group, in particular optionally substituted Ci to Ce alkyl group, especially optionally substituted Ci, C2, C3 or C4 alkyl group, optionally substituted linear or branched alkoxy group, in particular optionally substituted Ci-Ce alkoxy group, especially optionally substituted Ci, C2, C3 or C4 alkoxy group, optionally substituted linear or branched alkylthio group, in particular optionally substituted Ci to Ce alkylthio group, especially optionally substituted Ci, C2, C3 or C4 alkylthio group, optionally substituted cycloalkyl group, optionally substituted aryl group, optionally substituted heterocycloalkyl group, optionally substituted heteroaryl group; and / or B means A or alternatively, two Bs together with the nitrogen atom to which they are bonded, meaning a four-, five-, six- or seven-membered heterocycloalkyl ring or heteroaryl ring, wherein the heterocycloalkyl ring or heteroaryl ring may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; the optionally substituted linear or branched alkyl group is an optionally substituted Ci to Cw alkyl group, in particular an optionally substituted Ci to Ce alkyl group, especially an optionally substituted Ci, C2, C3 or C4 alkyl group;the optionally substituted linear or branched alkenyl group is an optionally substituted Ci to Cw alkenyl group, in particular an optionally substituted Ci to Ce alkenyl group, especially an optionally substituted Ci, C2, C3 or C4 alkenyl group; the optionally substituted linear or branched alkynyl group is an optionally substituted Ci to Cw alkynyl group, in particular an optionally substituted Ci to Ce alkynyl group, especially an optionally substituted Ci, C2, C3 or C4 alkynyl group; the optionally substituted linear or branched alkoxy group is an optionally substituted Ci to Cw alkoxy group, in particular an optionally substituted Ci to Ce alkoxy group, especially an optionally substituted Ci, C2, C3 or C4 alkoxy group; the optionally substituted linear or branched alkylthio group is an optionally substituted Ci to Cw alkylthio group, in particular an optionally substituted Ci to Ce alkylthio group, especially an optionally substituted Ci, C2, C3 or C4 alkylthio group;in the acyl group R-(C=O)- the residue R stands for hydrogen or an optionally substituted linear or branched Ci to Cw alkyl group, in particular an optionally substituted Ci to Ce alkyl group, especially an optionally substituted Ci, C2, C3 or C4 acyl group; the optionally substituted cycloalkyl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered, monocyclic cycloalkyl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, cycloalkyl group; the optionally substituted aryl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered, monocyclic aryl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic aryl group;the optionally substituted heterocycloalkyl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered monocyclic heterocycloalkyl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, heterocycloalkyl group, wherein the heterocycloalkyl group may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;the optionally substituted heteroaryl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered monocyclic heteroaryl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, heteroaryl group, wherein the heteroaryl group may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; Ra • an optionally substituted linear or branched alkyl group, and / preferably an O1 to C3 alkyl group, preferably a methyl or group; or Rb • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted acyl group R-(C=O)-; or • a possibly substituted cycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted heteroaryl group is / are; or • Ra and Rb, as defined above, are linked together to form a saturated or unsaturated ring; wherein the substituents are each selected independently of one another; and their salts, in particular acid addition salts, with inorganic or organic acids, wherein the cooling agents may be in stereoisomerically pure form or as mixtures of different stereoisomers; or represented by the general formula (VII) (VIII) where in formulas (VII) and (VIII) the remainders R1 and R2 can be the same or different and independently have the following meanings: R1 as defined in claim 4; R2 as defined in claim 4; V • S; or • SO2; or • a possibly substituted linear or branched alkyl group; or • a possibly substituted cycloalkyl group; or • Piperidinyl is; Y • is a possibly substituted linear or branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted acyl group R-(C=O)- is; Z • NH2; or • an NHRa group; or • a NraRb group; or • a possibly substituted linear or branched alkyl group; or • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted linear or branched alkoxy group; or • OH; or • a possibly substituted cycloalkyl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heteroaryl group; or • NH is and forms a heterocyclic ring with X; m is 0 or 1; provided that when m = 0, Y decreases; or if m = 1, since Y simply occurs; where Group Q is a residue selected from the group consisting of: Halogen, -OA, -SA, -NBB, -CF3, -CN, -OCN, -SON, -NO, -NO2, -S(O)2A, -S(O)2OA, -OS(O)2A, -O(O)(O)(O) 2I -P(O)(OA)(OA), -C(O)A, -C(S)A, -C(NA)A, -C(O)OA, -C(S)OA, -C(O)NBB, -C(NA)NBB, -OC(O)A, -OC(S)A, -OC(O)OA, -O -NAC(O)OA, -NAC(S)OA, -NAC(O)NBB, -NAC(NA)A or -NAC(NA)NBB; where A selected is from the Group consisting of: hydrogen, optionally substituted linear or branched alkyl group, in particular optionally substituted Ci to Cw alkyl group, in particular optionally substituted Ci to Ce alkyl group, especially optionally substituted Ci, C2, C3 or C4 alkyl group, optionally substituted linear or branched alkoxy group, in particular optionally substituted Ci-Ce alkoxy group, especially optionally substituted Ci, C2, C3 or C4 alkoxy group, optionally substituted linear or branched alkylthio group, in particular optionally substituted Ci to Ce alkylthio group, especially optionally substituted Ci, C2, C3 or C4 alkylthio group, optionally substituted cycloalkyl group, optionally substituted aryl group, optionally substituted heterocycloalkyl group, optionally substituted heteroaryl group; and / or B means A or alternatively, two Bs together with the nitrogen atom to which they are bonded, meaning a four-, five-, six- or seven-membered heterocycloalkyl ring or heteroaryl ring, wherein the heterocycloalkyl ring or heteroaryl ring may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; the optionally substituted linear or branched alkyl group is an optionally substituted Ci to Cw alkyl group, in particular an optionally substituted Ci to Ce alkyl group, especially an optionally substituted Ci, C2, C3 or C4 alkyl group;the optionally substituted linear or branched alkenyl group is an optionally substituted Ci to Cw alkenyl group, in particular an optionally substituted Ci to Ce alkenyl group, especially an optionally substituted Ci, C2, C3 or C4 alkenyl group; the optionally substituted linear or branched alkynyl group is an optionally substituted Ci to Cw alkynyl group, in particular an optionally substituted Ci to Ce alkynyl group, especially an optionally substituted Ci, C2, C3 or C4 alkynyl group; the optionally substituted linear or branched alkoxy group is an optionally substituted Ci to Cw alkoxy group, in particular an optionally substituted Ci to Ce alkoxy group, especially an optionally substituted Ci, C2, C3 or C4 alkoxy group; the optionally substituted linear or branched alkylthio group is an optionally substituted Ci to Cw alkylthio group, in particular an optionally substituted Ci to Ce alkylthio group, especially an optionally substituted Ci, C2, C3 or C4 alkylthio group; in the acyl group R-(C=O)- the residue R stands for hydrogen or an optionally substituted linear or branched Ci to Cw alkyl group, in particular an optionally substituted Ci to Ce alkyl group, especially an optionally substituted Ci, C2, C3 or C4 acyl group;the optionally substituted cycloalkyl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered, monocyclic cycloalkyl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, cycloalkyl group; the optionally substituted aryl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered, monocyclic aryl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, aryl group;the optionally substituted heterocycloalkyl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered monocyclic heterocycloalkyl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, heterocycloalkyl group, wherein the heterocycloalkyl group may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;the optionally substituted heteroaryl group is an optionally substituted three- to ten-membered, in particular three-, four-, five-, six- or seven-membered monocyclic heteroaryl group or an optionally substituted nine- to twelve-membered polycyclic, in particular bicyclic, heteroaryl group, wherein the heteroaryl group may comprise one, two, three or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; Ra • an optionally substituted linear or branched alkyl group; and / preferably an O1 to C3 alkyl group, preferably a methyl or group; or Rb • a possibly substituted linear or branched alkenyl group; or • a possibly substituted linear or branched alkynyl group; or • a possibly substituted linear or branched alkoxy group; or • a possibly substituted linear or branched alkylthio group; or • a possibly substituted acyl group R-(C=O)-; or • a possibly substituted cycloalkyl group; or • a possibly substituted aryl group; or • a possibly substituted heterocycloalkyl group; or • a possibly substituted heteroaryl group is / are; or • Ra and Rb, as defined above, are linked together and form a saturated or unsaturated ring; wherein the substituents are each selected independently of one another; and their salts, in particular acid addition salts, with inorganic or organic acids, wherein the refrigerants may be present in stereoisomerically pure form or as mixtures of different stereoisomers. Physiological refrigerant according to any one of claims 1 to 6, wherein the aforementioned optionally substituted groups further comprise one or more substituents such that: (i) where in the aforementioned substituted groups the substitution takes place at a saturated carbon, the substituent at the saturated carbon is selected from the group consisting of: -X, Halogen, =0, -OY, -Si R3, -SY, =S, -NZZ, =NY, =N-OY, -CF3, -CN, -OCN, -SCN, -NO, -NO2, -S(O)2Y, -S(O)2OY, -OS(O)2Y, -OS(O)2OY, -P(O)(OY) 2I-P(O)(OY)(OY), -C(0)Y, -C(S)Y, -C(NY)Y, -C(0)0Y, -C(S)OY, -C(O)NZZ, -C(NY)NZZ, -0C(0)Y, -OC(S)Y, -0C(0)0Y, -OC(S)OY, -NYC(O)Y, - NYC(S)Y, -NYC(O)OY, -NYC(S)OY, -NYC(O)NZZ, -NYC(NY)Y and -NYC(NY)NZZ; (ii) where in the aforementioned substituted groups the substitution takes place at an unsaturated carbon, the substituent at the unsaturated carbon is selected from the group consisting of: -X, halogen, -OY, -SiRs, -SY, -NZZ, -CF3, -CN, -OCN, -SCN, -NO, -NO2, -S(O)2Y, -S(O)2OY, -OS(O)2Y, -OS(O)2OY, -P(O)(OY)2, -P(O)(OY)(OY), -C(0)Y, -C(S)Y, -C(NY)Y, -C(0)0Y, -C(S)OY, -C(O)NZZ, -C(NY)NZZ, -0C(0)Y, -OC(S)Y, -0C(0)0Y, -OC(S)OY, -NYC(O)Y, -NYC(S)Y, - NYC(O)OY, -NYC(S)OY, -NYC(O)NZZ, -NYC(NY)Y and -NYC(NY)NZZ; (iii) where in the aforementioned substituted groups the substitution takes place at a nitrogen atom, the substituent on the nitrogen atom is selected from the group consisting of: -X, -OY, -SY, -NZZ, -CF3, -CN, -OCN, -SCN, -NO, -NO2, -S(O)2Y, -S(O)2OY, -OS(O)2Y, -OS(O)2OY, -P(O)(OY)2, -P(0)(0Y)(0Y), -C(0)Y, -C(S)Y, -C(NY)Y, -C(0)0Y, -C(S)OY, -C(O)NZZ, -C(NY)NZZ, -0C(0)Y, -OC(S)Y, -0C(0)0Y, -OC(S)OY, -NYC(O)Y, -NYC(S)Y, -NYC(O)OY, -NYC(S)OY, -NYC(O)NZZ, -NYC(NY)Y and -NYC(NY)NZZ; where in cases (i), (ii) and (iii) X is selected from the group consisting of: optionally substituted alkyl group, in particular optionally substituted Ci to Cw alkyl group, in particular optionally substituted Ci to Ce alkyl group, especially optionally substituted Ci, C2, C3 or C4 alkyl group, optionally substituted alkoxy group, in particular optionally substituted Ci-Ce alkoxy group, especially optionally substituted Ci, C2, C3 or C4 alkoxy group, optionally substituted alkylthio group, in particular optionally substituted Ci to Ce alkylthio group, especially optionally substituted Ci, C2, C3 or C4 alkylthio group, optionally substituted cycloalkyl group, optionally substituted aryl group, optionally substituted heterocycloalkyl group, optionally substituted heteroaryl group; and / or Y is selected from the group consisting of: hydrogen or X; and / or Z means Y or, alternatively, two Zs together with the nitrogen atom to which they are bonded, meaning a four-, five-, six-, or seven-membered heterocycloalkyl ring or heteroaryl ring, wherein the heterocycloalkyl ring or heteroaryl ring may comprise one, two, three, or four identical or different heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. Physiological coolant according to any one of claims 1 to 7, wherein in the general formulas (I) to (VIII) and (Va) to (Villa), the substituents R1 and R2 may be identical or different and independently have the following meanings: R1 represents H or an optionally substituted C1 to C3 alkyl group or an optionally substituted phenyl group, preferably an optionally substituted phenyl group; and / or R2 represents H or an optionally substituted C1 to C3 alkyl group or an optionally substituted phenyl group, preferably an optionally substituted phenyl group. Physiological coolant according to any one of claims 4 to 8, wherein in the general formulas (I) to (VIII) Y represents a methyl group or a methyl group substituted with a methyl group, an ethyl group, a butyl group or a propyl group. Physiological coolant according to any one of claims 1 to 9, wherein in the general formulas (I) to (VIII) and (Va), (Vila) and (Villa) Z is selected from the group consisting of: -NH2, -NH-CH3, -NH-CH2-CH3, -NH-CH2-CH2-CH3, -NH-CH2-CH2-CH2-CH3, -NH-CH(CH3)-CH(CH3)2, -NH-CH(CH3)-CH2-CH2-CH3, -NH-CH2-CH(CH3)2, -NH-CH2-CH2-O-CH3, -NH-CH(CH3)-CH2-O-CH3, -NH-C(=O)-CH 3I -NH-C(=O)-O-CH 3I -NH- CH(CH3)-CH2-OH, -NH-CH2-Furanyl, -NH-CH2-Tetrahydrofuranyl, -NH-CH2-Thiophenyl, -NH-Toluolyl, -NH-CH-(CH3)2, -NH-C(CH3)3, -NH-Cyclopropyl, -NH-Cyclobutyl, -NH- Cyclopentyl, -N(CH3)2, -N(CH3)-Cyclohexyl, -N(CH2-CH3)2, Azetidinyl, Pyrrolidinyl, Piperidinyl, Azacyclobutadienyl, Pyrrolyl, Pyridinyl, -O, -OH, -O-CH3, -O-C(=O)-CH3, Oxetanyl, -CH3, -CH2-CH3, -CH(CH3)2, -C(OH)-CH2-OH, Cyclopropyl, Phenyl, und-CH2- S-CH3; und worin in der allgemeinen Formel (Via) Z ausgewählt ist aus der Gruppe, die besteht aus -NH2, -NH-CH3, -NH-CH2-CH3, -NH-CH2-CH2-CH3, -NH-CH2-CH2-CH2-CH3, -NH-CH(CH3)-CH(CH3)2, -NH-CH(CH3)-CH2-CH2-CH3, -NH-CH2-CH(CH3)2, -NH-CH2- CH2-O-CH3, -NH-CH(CH3)-CH2-O-CH3, -NH-C(=O)-CH 3I -NH-C(=O)-O-CH 3I -NH- CH(CH3)-CH2-OH, -NH-CH2-Furanyl, -NH-CH2-Tetrahydrofuranyl, -NH-CH2-Thiophenyl, -NH-Toluolyl, -NH-CH-(CH3)2, -NH-C(CH3)3, -NH-Cyclopropyl, -NH-Cyclobutyl, -NH- Cyclopentyl, -N(CH3)2, -N(CH3)-Cyclohexyl, -N(CH2-CH3)2, Azetidinyl, Pyrrolidinyl, Piperidinyl, Azacyclobutadienyl, Pyrrolyl, Pyridinyl, -O, -O-CH3, -O-C(=O)-CH3, Oxetanyl, -CH3, -CH2-CH3, -CH(CH3)2, -C(OH)-CH2-OH, Cyclopropyl, Phenyl, and-CH2-S-CH3.
11. Physiological coolant according to any one of claims 4 to 10, wherein the physiological coolant of general formulas (I), (II), (V) or (VI) is selected from the group consisting of the compounds according to Table 1 below: Table 1: and their salts, in particular acid addition salts, with inorganic or organic acids, wherein the refrigerants may be in stereoisomerically pure form or as mixtures of different stereoisomers, preferably wherein the physiological refrigerant is selected from the group consisting of compounds B-01, B-02, B-03, B-04, B-05, B-06, B-07, B-11, B-18 and B-19; or wherein the physiological refrigerant of general formulas (III), (IV), (VII) or (VIII) is selected from the group consisting of the compounds according to Table 2 below: Table 2: and their salts, in particular acid addition salts, with inorganic or organic acids, wherein the refrigerants may be present in stereoisomerically pure form or as mixtures of different stereoisomers, preferably wherein the physiological refrigerant is selected from the group consisting of compounds A-02, A-04, A-05, A-06, A-07, A-08, A-09, A-10, A-12, A-16, A-17 and A-18. Physiological refrigerant according to any one of claims 1 to 11, wherein the salt of the refrigerant is selected from the group consisting of (1) Acid addition salts formed with inorganic acids or with organic acids, preferably mono- or polyhydric carboxylic acids; or (2) Salts formed when an acidic proton present in the starting compound is replaced by a metal ion, in particular an alkali metal ion, an alkaline earth ion or an aluminum ion; or coordinated with an organic base. Physiological cooling mixture comprising or consisting of: (a) one, two, three or more refrigerant(s) according to any one of claims 1 to 12; and optionally (b) at least one other physiological coolant; and / or, if applicable (c) at least one solvent. Physiological coolant mixture according to claim 13, wherein the physiological Kühlstoff, der die Komponente (b) bildet, ausgewählt ist aus der Gruppe, bestehend aus: Menthol, Menthol Methyl Ether (FEMA GRAS 4054), Monomenthyl Glutamat (FEMA GRAS 4006), Menthoxy-1 ,2-propandiol (FEMA GRAS 3784), Dimenthylglutarat (FEMA GRAS 4604), Hydroxymethylcyclohexylethanon (FEMA GRAS 4742), 2-(4- Ethylphenoxy)-N-(1 H-pyrazol-3-yl)-N-(thiophen-2-ylmethyl)acetamid (FEMA GRAS 4880), WS-23 (2-lsopropyl-N,2,3-trimethylbutyramid, FEMA GRAS 3804), N-(4- (Cyanomethyl)phenyl)-2-isopropyl-5,5-dimethylcyclohexan carboxamid (FEMA GRAS 4882), N-(3-Hydroxy-4-methoxyphenyl)-2-isopropyl-5,5-dimethylcyclohexan- carboxamid (FEMA GRAS 4881), N-(2-Hydroxy-2-phenylethyl)-2-isopropyl-5,5- dimethylcyclohexan-1-carboxamid (FEMA GRAS 4896), 3,4-Methylenedioxy Zimtsäure, (E)-3-Benzo[1 ,3]dioxol-5-yl-N,N-diphenyl-2-propenamid (FEMA GRAS 4788), Menthol Propylen Glykol Carbonat (FEMA GRAS 3806), Menthyl-N-ethyloxamat, Monomethyl Succinat (FEMA GRAS 3810), WS-3 (N-Ethyl-p-menthan-3-carboxamide,FEMA GRAS 3455), Menthol Ethylen Glykol Carbonat (FEMA GRAS 3805), WS-5 (Ethyl-3-(p- menthan-3-carboxamido)acetat, FEMA GRAS 4309), WS-12 (1 R,2S,5R)-N-(4- Methoxyphenyl)-p-menthancarboxamid (FEMA GRAS 4681), WS-27 (N-Ethyl-2,2- diisopropylbutanamid, FEMA GRAS 4557), N-Cyclopropyl-5-methyl-2- isopropylcyclohexancarboxamid (FEMA GRAS 4693), WS-116 (N-(1 ,1-Dimethyl-2- hydroxyethyl)-2,2-diethylbutanamid, FEMA GRAS 4603), Menthoxyethanol (FEMA, GRAS 4154), N-(4-Cyanomethylphenyl)-p-menthancarboxamid (FEMA GRAS 4496), N- (2-(Pyridin-2-yl)ethyl)-3-p-menthancarboxamid (FEMA GRAS 4549), N-(2- Hydroxyethyl)-2-isopropy-1-2,3-dimethylbutanamid (FEMA GRAS 4602), (2S,5R)-N-[4- (2-Amino-2-oxoethyl)phenyl]-p-menthancarboxamid (FEMA GRAS 4684), N- Cyclopropyl-5-methyl-2-isopropylcyclohexancarboncarboxamid (FEMA GRAS 4693), 2- [(2-p-Menthoxy)ethoxy]-ethanol (FEMA GRAS 4718), (2,6-Diethyl-5-isopropyl-2- methyltetrahydropyran (FEMA GRAS 4680), trans-4-tert-Butylcyclohexanol (FEMA GRAS 4724), 2-(p-Tolyloxy)-N-(1 H-pyrazol-5-yl)-N-((thiophen-2-yl)methyl)acetamid (FEMA GRAS 4809), Menthon glycerol ketal (FEMA GRAS 3807 und 3808), (-)- Menthoxypropan-1 ,2-diol, 3-(1-Menthoxy)-2-methylpropan-1 ,2-diol (FEMA GRAS 3849), Isopulegol, (+)-cis und (-)-trans-p-Menthan-3,8-diol (62:38, FEMA GRAS 4053), 2,3- Dihydroxy-p-menthan, 3,3,5-trimethylcyclohexanon glycerol ketal, Menthyl pyrrolidon carboxylat, (1 R,3R,4S)-3-menthyl-3,6-dioxaheptanoat, (1 R,2S,5R)-3-menthyl methoxyacetat, (1 R,2S,5R)-3-Menthyl-3,6,9-trioxadecanoat, (1 R,2S,5R)-3-menthyl- 3,6,9-trioxadecanoat, (1 R,2S,5R)-3-Menthyl-(2-hydroxyethoxy)acetat, (1 R,2S,5R)- Menthyl-11-hydroxy-3,6,9-trioxaundecanoat, Cubebol (FEMA GRAS 4497), 2-lsopropyl- 5-methylcyclohexyl-4-(dimethylamino)-4-oxobutanoat (FEMA GRAS 4230), Menthyllactat (FEMA GRAS 3748), 6-lsopropyl-3,9-dimethyl-1,4-dioxaspiro[4.5]decan- 2-on (FEMA GRAS 4285), N-Benzo[1,3]-dioxol-5-yl-3-p-menthancarboxamid, N-(1- lsopropyl-1 ,2-dimethylpropyl)-1 ,3-benzodioxol-5-carboxamid, N-(R)-2-, Oxotetrahydrofuran-3-yl-(1 R,2S,5R)-p-menthan-3-carboxamid, Mischung aus 2, 2, 5,6,6- Pentamethyl-2,3,6,6a-tetrahydropentalen-3a(1 H)-ol und 5-(2-Hydroxy-2-methylpropyl)- 3,4,4-trimethylcyclopent-2-en-1-on; (2S,5R)-2-lsopropyl-5-methyl-N-(2-(pyridin-4- yl)ethyl)cyclohexancarboxamide; (1S,2S,5R)-N-(4-(cyanomethyl)phenyl)-2-isopropyl-5- methylcyclohexancarboxamid, 1 ,7-lsopropyl-4,5-methyl-bicyclo[2.2.2]oct-5-en Derivate, 4-Methoxy-N-phenyl-N-[2-(pyridin-2-yl)ethyl]benzamid, 4-Methoxy-N-phenyl-N-[2- (pyridin-2-yl)ethyl]benzensulfonamid, 4-Chloro-N-phenyl-N-[2-(pyridin-2- yl)ethyl]benzensulfonamid, 4-Cyano-N-phenyl-N-[2-(pyridin-2-yl)ethyl]- benzensulfonamid, 4-((Benzhydrylamino)methyl)-2-methoxyphenol, 4-((Bis(4- methoxyphenyl)methylamino)methyl)-2-methoxyphenol, 4-((1 ,2- diphenylethylamino)methyl)-2-methoxyphenol, 4-((Benzhydryloxy)methyl)-2- methoxyphenol, 4-((9H-Fluoren-9-ylamino)methyl)-2-methoxyphenol, 4- ((benzhydrylamino)methyl)-2-ethoxyphenol, 1-(4-Methoxyphenyl)-2-(1-methyl-1H- benzo[d]imidazol-2-yl)vinyl-4-methoxybenzoat, 2-(1-lsopropyl-6-methyl-1H- benzo[d]imidazol-2-yl)-1-(4-methoxyphenyl)vinyl-4-methoxybenzoat, (Z)-2-(1-lsopropyl- 5-methyl-1H-benzo[d]imidazol-2-yl)-1-(4-methoxyphenyl)vinyl-4-methoxybenzoate, 3-alkyl-p-methane-3-ol derivatives, derivatives of fenchyl, D-bornyl, L-bornyl, exo-norbornyl, 2-methylisobornyl, 2-ethylfenchyl, 2-methylbornyl, cis-pinan-2-yl, verbanyl and isobornyl, menthyl oxamate derivatives, menthyl 3-oxocarboxylic acid esters, N-alpha-(menthanecarbonyl)amino acid amides, p-menthane carboxamide and WS-23 analogues, (-)-(1R,2R,4S)-dihydroumbellulol, p-menthane alkyloxyamide, cyclohexane derivatives, Butanone derivatives, mixture of 3-menthoxy-1-propanol and 1-Menthoxy-2-propanol, 1-[2-hydroxyphenyl]-4-[2-nitrophenyl]-1,2,3,6-tetrahydropyrimidin-2-one, 4-Methyl-3-(1-pyrrolidinyl)-2-[5H]-furanone, and the refrigerants according to the following table: as well as the refrigerants according to the following table: and their salts, in particular acid addition salts, with inorganic or organic acids and mixtures of the aforementioned refrigerants / compounds. Physiological refrigerant mixture according to claim 13 or claim 14, wherein component (a) and component (b) are present in a weight ratio of about 0.1 : 99 to about 99 : 0.
1. Physiological refrigerant mixture according to any one of claims 13 to 15, wherein the solvent forming component (c) is selected from the group consisting of: benzyl alcohol, 2-phenylethanol, benzyl benzoate, diethyl succinate, triethyl citrate, triacetin, ethanol, peppermint oil, anethole, optamint, propylene glycol, phenoxyethanol and mixtures thereof. Flavoring preparation comprising or consisting of (d) one, two, three or more refrigerant(s) according to any one of claims 1 to 12 or a physiological refrigerant mixture according to any one of claims 13 to 16; and (e) at least one flavouring substance.Flavoring preparation according to claim 17, wherein the flavoring substance forming component (e) is selected from the group consisting of: acetophenone, allyl capronate, alpha-ionone, beta-ionone, anisaldehyde, anisyl acetate, anisyl formate, anethole, benzaldehyde, benzothiazole, benzyl acetate, benzyl alcohol, benzyl benzoate, beta-ionone, butyl butyrate, butyl capronate, butylidene phthalide, carvone, camphene, caryophyllene, cineole, cinnamyl acetate, citral, citronellol, citronellal, citronellyl acetate, cyclohexyl acetate, cymene, damascone, decalactone, dihydrocoumarin, dimethyl anthranilate, dimethyl anthranilate, dodecalactone, ethoxyethyl acetate, ethyl butyric acid, ethyl butyrate, ethyl caprinate, ethyl capronate, ethyl crotonate, ethylfuraneol Ethyl guaiacol, ethyl isobutyrate, ethyl isovalerianate, ethyl lactate, ethyl methyl butyrate, ethyl propionate, eucalyptol, eugenol, ethyl heptylate, 4-(p-hydroxyphenyl)-2-butanone, gamma-decalactone, geraniol, geranyl acetate, geranyl acetate, grapefruit aldehyde, methyl dihydrojasmonate (e.gHedion®), heliotropin, 2-heptanone, 3-heptanone, 4-. Heptanone, trans-2-heptenal, cis-4-heptenal, trans-2-hexenal, cis-3-hexenol, trans-2-hexenic acid, trans-3-hexenic acid, cis-2-hexenyl acetate, cis-3-hexenyl acetate, cis-3-hexenyl capronate, trans-2-hexenyl capronate, cis-3-hexenyl formate, cis-2-hexyl acetate, cis-3-hexyl acetate, trans-2-hexyl acetate, cis-3-hexyl formate, para-hydroxybenzylacetone, isoamyl alcohol, isoamyl isovalerate, isobutyl butyrate, isobutyraldehyde, isoeugenol methyl ether, isopropyl methylthiazole, lauric acid, leavulic acid, linalool, linalool oxide, linalyl acetate, menthol, menthofuran, methyl anthranilate Methylbutanol, Methylbutyric acid, 2-Methylbutylacetate, Methylcaproate, Methylcinnamate, 5-Methylfurfural, 3,2,2-Methylcyclopentenolone, 6,5,2-Methylheptenone, Methyl dihydrojasmonate, methyl jasmonate, 2-methylmethylbutyrate, 2-methyl-2-pentenolic acid, methylthiobutyrate, 3,1-methylthiohexanol, 3-methylthiohexyl acetate, nerol, neryl acetate, trans, trans-2,4-nonadienal, 2,4-nonadienol, 2,6-nonadienol, 2,4-nonadienol, nootkatone, delta octalactone, gamma octalactone, 2-octanol, 3-octanol, 1,3-octenol, 1-octyl acetate, 3-octyl acetate, palmitic acid, paraldehyde, phellandrene, pentanedione, phenylethyl acetate, phenylethyl alcohol, phenylethyl alcohol, phenylethyl isovalerate, Piperonal, Propionaldehyde, Propyl Butyrate, Pulegone, Pulegol, Sinensal, sulfurol, terpinene, terpineol, terpinoiene, 8,3-thiomenthanone, 4,4,2-thiomethylpentanone, thymol, delta-undecalactone, gamma-undecalactone, valencene, valeric acid, vanillin, acetoin, ethyl vanillin, ethyl vanillin isobutyrate (= 3-ethoxy-4-isobutyryloxybenzaldehyde), 2,5-dimethyl-4-hydroxy-3(2H)-furanone and its derivatives (preferably homofuraneol (= 2-ethyl-4-hydroxy-5-methyl-3(2H)-furanone)Homofuronol (= 2-ethyl-5-methyl-4-hydroxy-3(2H)-furanone and 5-ethyl-2-methyl-4-hydroxy-3(2H)-furanone), maltol and maltol derivatives (preferably ethyl maltol), coumarin and coumarin derivatives, gamma-lactones (preferably gamma-undecalactone, gamma-nonalactone, gamma-decalactone), delta-lactones (preferably 4-methyldeltadecalactone, massoilactone, deltadecalactone, tuberolactone), methyl sorbate, divanillin, 4-hydroxy-2(or 5)-ethyl-5(or 2)-methyl-3(2H)-furanone, 2-hydroxy-3-methyl-2-cyclopentenone, 3-hydroxy-4,5-dimethyl-2(5H)-furanone, isoamyl acetate, Ethyl butyrate, n-butyl butyrate, isoamyl butyrate, ethyl 3-methylbutyrate, ethyl n-hexanoate, ethyl n-hexanoate, ethyl n-hexanoate, ethyl n-octanoate, ethyl 3-methyl-3-phenylglycidate, ethyl 2-trans-4-cis-decadienoate, 4-(p-hydroxyphenyl)-2-butanone, 1,1-dimethoxy-2,2,5-trimethyl-4-hexane, 2,6-dimethyl-5-hepten-1-al and phenylacetaldehyde,2-Methyl-3-(methylthio)furan, 2-Methyl-3-furanthiol, bis(2-Methyl-3- furyl)disulfid, Furfurylmercaptan, Methional, 2-Acetyl-2-thiazolin, 3-Mercapto-2- pentanon, 2,5-Dimethyl-3-furanthiol, 2,4,5-Trimethylthiazol, 2-Acetylthiazol, 2,4- Dimethyl-5-ethylthiazol, 2-Acetyl-1-pyrrolin, 2-Methyl-3-ethylpyrazin, 2-Ethyl-3,5- dimethylpyrazin, 2-Ethyl-3,6-dimethylpyrazin, 2,3-Diethyl-5-methylpyrazin, 3-lsopropyl- 2-methoxypyrazin, 3-lsobutyl-2-methoxypyrazin, 2- Acetyl pyrazin, 2-Pentylpyridin, (E,E)- 2,4-Decadienal, (E,E)-2,4-Nonadienal, (E)-2-Octenal, (E)-2-Nonenal, 2-Undecenal, 12- Methyltridecanal, 1-Penten-3-on, 4-Hydroxy-2,5-dimethyl-3(2H)-furanon, Guajakol, 3- Hydroxy-4,5-dimethyl-2(5H)-furanon, 3-Hydroxy-4-methyl-5-ethyl-2(5H)-furanon, Zimtaldehyd, Zimtalkohol, Methylsalicylat, Isopulegol sowie (hier nicht explizit genannte), Stereoisomers, enantiomers, positional isomers, diastereomers, cis / trans isomers or epimers of these substances; and / or wherein the flavoring substance forming component(s) is selected from the group consisting of: erythritol, threitol, arabitol, ribotol, xylitol, sorbitol, mannitol, dulcitol, lactitol, miraculin, monellin, thaumatin, curculin, brazzein, magap, sodium cyclamate, acesulfame K, neohesperidin dihydrochalcone, saccharin sodium salt, aspartame, superaspartame, neotame, alitame, sucralose, steviosides, rebaudiosides, lugduname, carrelame, sucrononate, sucrooctate, Monatin, phenylodulcin, glycine, D-leucine, D-threonine, D-asparagine, D-phenylalanine, D-tryptophnine, L-proline, hernandulcin, dihydrochalcone glycosides, glycyrrhizin, glycerrhetinic acid, their Derivatives and salts, extracts of licorice (Glycyrrhizza glabra ssp.), Lippia dulcis extracts, Momordica ssp. extracts, mogrosides, Hydrangea dulcis and steviosides and mixtures thereof.Aroma preparation according to claim 17 or claim 18, wherein component (d) and component (e) are present in a weight ratio of 1:99 to 99:
1. Physiological coolant according to any one of claims 1 to 12 or physiological coolant mixture according to any one of claims 13 to 16 or aroma preparation according to any one of claims 17 to 19 in encapsulated form. Use of the physiological coolant according to any one of claims 1 to 12 and 20 or the physiological coolant mixture according to any one of claims 13 to 16 and 20 as a modulator, in particular for in vivo and / or in vitro / intravenous modulation, of the cold-menthol receptor TRPM8, in particular as a TRPM8 receptor agonist or as a TRPM8 receptor antagonist.Use of the physiological coolant according to any one of claims 1 to 12 and 20, or the physiological coolant mixture according to any one of claims 13 to 16 and 20, for generating a physiological cooling effect on skin or mucous membranes in humans or animals, or for inducing a cooling effect by packaging or textiles containing the physiological coolant or the physiological coolant mixture. Use of the physiological coolant according to any one of claims 1 to 12 and 20, or the physiological coolant mixture according to any one of claims 13 to 16 and 20, for improving the taste properties of flavorings, in particular for reducing or masking an unpleasant taste.Use of the physiological coolant according to one of claims 1 to 12 and 20 or the physiological coolant mixture according to one of claims 13 to 16 and 20 or the flavor preparation according to one of claims 17 to 19 and 20 for the manufacture of foodstuffs, food supplements, cosmetic or. Pharmaceutical preparations, animal feed, textiles, packaging or tobacco products. Foodstuffs, food supplements, cosmetic or pharmaceutical preparations, animal feed, textiles, packaging or tobacco products, comprising a physiological cooling agent according to any one of claims 1 to 12 and 207 or a physiological cooling agent mixture according to any one of claims 13 to 16 and 20 or a flavoring preparation according to any one of claims 17 to 19 and 20, in particular in an amount of 0.1 ppm to 10 wt.%, in particular 1 wt.% to 10 wt.%, based on the total weight of the final product.Pharmaceutical preparation according to claim 25, comprising further pharmaceutical active substances selected from the group consisting of: Aspirin, Minoxidil, Erythromycin, Fenistil, Betamethasone, Ibuprofen, Ketoprofen, Dicyclofenac, Metronidazole, Acyclovir, Imiquimod, Terbafine, Cyclopiroxolamine, Paracetamol, and other pharmaceutical active substances of the type of nonsteroidal anti-inflammatory drugs (NSAIDs) and mixtures thereof. Pharmaceutical preparation according to claim 25 or claim 26 for use as a medicinal product, in particular for use in the prevention or treatment of pain and inflammatory conditions of the skin and mucous membranes, in particular prevention or treatment of cough, cold, inflammation, sore throat or hoarseness symptoms, or for use in the treatment of inflammatory conditions of the skin and mucous membranes as well as the joints, or for use in the treatment of prostate or bladder cancer, or for the treatment of bladder weakness.Methods for modulating, in particular in vitro and / or in v / o modulation, the cold menthol receptor TRPM8, comprising the following steps:. (ia) Providing at least one physiological coolant according to any one of claims 1 to 12 and 20 or a physiological coolant mixture according to any one of claims 13 to 16 and 20 or providing a cosmetic or pharmaceutical preparation according to any one of claims 25 to 27; and (iia) Bringing the coolant or coolant mixture or preparation from step (ia) into contact with the receptor; or producing a physiological cooling effect on skin or mucous membrane, comprising the following steps: (ib) Providing at least one physiological coolant according to any one of claims 1 to 12 and 20 or a physiological coolant mixture according to any one of claims 13 to 16 and 20 or providing a cosmetic or pharmaceutical preparation according to any one of claims 25 to 27; and (üb) Contacting the coolant or coolant mixture or the preparation from step (ib) with human skin or mucous membrane; or to improve the taste properties of flavorings comprising the following steps: (ic) Providing at least one physiological refrigerant according to any one of claims 1 to 12 and 20 or a physiological refrigerant mixture according to any one of claims 13 to 16 and 20 and at least one flavoring agent; (iic) Mixing the two components; and if necessary (iiic) Incorporation of the mixture into an oral preparation.
